<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003193.pub4" GROUP_ID="INCONT" ID="583001050111550285" MERGED_FROM="" MODIFIED="2014-11-21 15:32:41 +0000" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;/p&gt;&lt;p&gt;Old title: Anticholinergic drugs versus non-drug active therapies for urge urinary incontinence or overactive bladder syndrome in adults&lt;br&gt;Old title: Anticholinergic drugs versus non-drug active therapies for urinary incontinence in adults&lt;/p&gt;" NOTES_MODIFIED="2014-11-21 15:31:40 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2014-11-21 15:31:40 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-10-16 22:17:15 +0100" MODIFIED_BY="[Empty name]">Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults</TITLE>
<CONTACT>
<PERSON ID="14197" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Ammar</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Alhasso</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Urological Surgeon</POSITION>
<EMAIL_1>Ammar.Alhasso@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL>www.edinburghurologyspecialists.com</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Urology</DEPARTMENT>
<ORGANISATION>Western General Hospital</ORGANISATION>
<ADDRESS_1>Crewe Road South</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edinburgh</CITY>
<ZIP>EH4 2XU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 131 5371586</PHONE_1>
<PHONE_2>+44 131 5371000</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-11-21 15:30:32 +0000" MODIFIED_BY="Muhammad Imran Omar">
<PERSON ID="41D7630782E26AA20172CC999FDED6F6" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Bhavan</FIRST_NAME>
<MIDDLE_INITIALS>Prasad</MIDDLE_INITIALS>
<LAST_NAME>Rai</LAST_NAME>
<SUFFIX/>
<POSITION>Specialty Trainee in Urology</POSITION>
<EMAIL_1>bhavan@doctors.org.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>bhavan</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Urology</DEPARTMENT>
<ORGANISATION>Aberdeen Royal Infirmary</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7298" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>June</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Cody</LAST_NAME>
<SUFFIX/>
<POSITION>Review Author</POSITION>
<EMAIL_1>djunecody@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.otago.ac.nz/cure</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Incontinence Review Group</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>2nd Floor, Health Sciences Building</ADDRESS_1>
<ADDRESS_2>Health Sciences Building</ADDRESS_2>
<CITY>Foresterhill</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION>Aberdeen</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 438126</PHONE_1>
<PHONE_2>+44 1224 438128</PHONE_2>
<FAX_1>+44 1224 438165</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14197" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Ammar</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Alhasso</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Urological Surgeon</POSITION>
<EMAIL_1>Ammar.Alhasso@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL>www.edinburghurologyspecialists.com</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Urology</DEPARTMENT>
<ORGANISATION>Western General Hospital</ORGANISATION>
<ADDRESS_1>Crewe Road South</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edinburgh</CITY>
<ZIP>EH4 2XU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 131 5371586</PHONE_1>
<PHONE_2>+44 131 5371000</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14265" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Laurence</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Stewart</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Urological Surgeon</POSITION>
<EMAIL_1>laurence.stewart@luht.scot.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Urology</DEPARTMENT>
<ORGANISATION>Western General Hospital</ORGANISATION>
<ADDRESS_1>Crewe Road South</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edinburgh</CITY>
<ZIP>EH4 2XU</ZIP>
<REGION>Scotland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 131 5371586</PHONE_1>
<PHONE_2/>
<FAX_1>+44 131 5373221</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-11-18 12:40:34 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="9" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="9" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2014-11-18 12:38:39 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-11-18 12:36:24 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="11" YEAR="2014"/>
<DESCRIPTION>
<P>Changed date under "Assessed as Up-to-date" to correspond with the "Date of Search"</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-18 12:38:39 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-11-18 12:38:38 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Nine new studies added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-18 12:38:39 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>9 new studies added: <LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-16 12:07:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-11-21 15:31:40 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-11-21 15:31:40 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-11-21 15:31:40 +0000" MODIFIED_BY="[Empty name]">
<NAME>The National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Incontinence Group</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-11-14 21:59:57 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults without neurological problems</TITLE>
<SUMMARY_BODY MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>Overactive bladder syndrome occurs in adults who have urinary urgency with or without urgency urinary incontinence (leakage of urine).  People usually empty their bladders frequently during the day and also at night (nocturia). It is a major problem affecting quality of life, in over 22 million people. It affects men and women, and is more common in women and in older people.  It is also expensive for both patients and the health service.  It is not clear exactly why it occurs, and there are many treatments including drugs and behavioural treatments such as bladder training and pelvic floor exercises.  It is not clear which treatments work best, have the fewest side effects and which are most economical.  Twenty three trials with 3685 participants were included in the review. Participants were more likely to improve if they were using an anticholinergic drug compared with bladder training alone, and also when using a combination of an anticholinergic drug plus bladder training.  More people reported an improvement in their overactive bladder symptoms when using electrical stimulation than an anticholinergic drug, but this was only significant in one trial for one type of electrical stimulation, percutaneous posterior tibial nerve stimulation.  These results have to be viewed with caution as different types and doses of the anticholinergic drugs were used in the trials. The main adverse effect reported was dry mouth, in about a third of the people taking an anticholinergic drug.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-11-14 21:59:57 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-11-13 10:43:40 +0000" MODIFIED_BY="[Empty name]">
<P>Overactive bladder syndrome is defined as urgency with or without urgency incontinence, usually with frequency and nocturia. Pharmacotherapy with anticholinergic drugs is often the first line medical therapy, either alone or as an adjunct to various non-pharmacological therapies after conservative options such as reducing intake of caffeine drinks have been tried. Non-pharmacologic therapies consist of bladder training, pelvic floor muscle training with or without biofeedback, behavioural modification, electrical stimulation and surgical interventions.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the effects of anticholinergic drugs with various non-pharmacologic therapies for non-neurogenic overactive bladder syndrome in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Incontinence Group Specialised Register (searched 4 September 2012), which includes searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE, and the reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised or quasi-randomised, controlled trials of treatment with anticholinergic drugs for overactive bladder syndrome or urgency urinary incontinence in adults in which at least one management arm involved a non-drug therapy. Trials amongst patients with neurogenic bladder dysfunction were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-10-16 22:17:18 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors evaluated the trials for appropriateness for inclusion and risk of bias. Two authors were involved in the data extraction. Data extraction was based on predetermined criteria. Data analysis was based on standard statistical approaches used in Cochrane reviews.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-11-14 21:59:57 +0000" MODIFIED_BY="[Empty name]">
<P>Twenty three trials were included with a total of 3685 participants, one was a cross-over trial and the other 22 were parallel group trials. The duration of follow up varied from two to 52 weeks. The trials were generally small and of poor methodological quality. </P>
<P>During treatment, symptomatic improvement was more common amongst those participants on anticholinergic drugs compared with bladder training in seven small trials (73/174, 42% versus 98/172, 57% not improved: risk ratio 0.74, 95% confidence interval 0.61 to 0.91). Augmentation of bladder training with anticholinergics was also associated with more improvements than bladder training alone in three small trials (23/85, 27% versus 37/79, 47% not improved: risk ratio 0.57, 95% confidence interval 0.38 to 0.88). However, it was less clear whether an anticholinergic combined with bladder training was better than the anticholinergic alone, in three trials (for example 74/296, 25% versus 95/306, 31% not improved: risk ratio 0.80, 95% confidence interval 0.62 to 1.04). The other information on whether combining behavioural modification strategies with an anticholinergic was better than the anticholinergic alone was scanty and inconclusive. Similarly, it was unclear whether these complex strategies alone were better than anticholinergics alone.</P>
<P>In this review, seven small trials comparing an anticholinergic to various types of electrical stimulation modalities such as Intravaginal Electrical Stimulation (IES), transcutaneous electrical nerve stimulation (TENS), the Stoller Afferent Nerve Stimulation System (SANS) neuromodulation and percutaneous posterior tibial nerve stimulation (PTNS) were identified. Subjective improvement rates tended to favour the electrical stimulation group in three small trials (54% not improved with the anticholinergic versus 28/86, 33% with electrical stimulation: risk ratio 0.64, 95% confidence interval 1.15 to 2.34). However, this was statistically significant only for one type of stimulation, percutaneous posterior tibial nerve stimulation (risk ratio 2.21, 95% confidence interval 1.13 to 4.33), and was not supported by significant differences in improvement, urinary frequency, urgency, nocturia, incontinence episodes or quality of life.</P>
<P>The most commonly reported adverse effect among anticholinergics was dry mouth, although this did not necessarily result in withdrawal from treatment. For all comparisons there were too few data to compare symptoms or side effects after treatment had ended. However, it is unlikely that the effects of anticholinergics persist after stopping treatment. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>The use of anticholinergic drugs in the management of overactive bladder syndrome is well established when compared to placebo treatment. During initial treatment of overactive bladder syndrome there was more symptomatic improvement when (a) anticholinergics were compared with bladder training alone, and (b) anticholinergics combined with bladder training were compared with bladder training alone. Limited evidence from small trials might suggest electrical stimulation is a better option in patients who are refractory to anticholinergic therapy, but more evidence comparing individual types of electrostimulation to the most effective types of anticholinergics is required to establish this. These results should be viewed with caution in view of the different classes and varying doses of individual anticholinergics used in this review. Anticholinergics had well recognised side effects, such as dry mouth.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>Overactive bladder syndrome is a symptom triad defined as "urgency, with or without urgency incontinence, usually with frequency and nocturia" (<LINK REF="REF-Abrams-2002" TYPE="REFERENCE">Abrams 2002</LINK>). Alternative terminologies for overactive bladder syndrome are urge syndrome or urge-frequency syndrome.</P>
<P>In a survey of 16,776 adults that was performed in Europe (France, Germany, Italy, Spain, Sweden, and the United Kingdom), 16.6% had overactive bladder syndrome. Urge incontinence was reported by 36% of those with overactive bladder symptoms (<LINK REF="REF-Milsom-2001" TYPE="REFERENCE">Milsom 2001</LINK>). In a similar study in the United States, the National Overactive Bladder Evaluation (NOBLE) program estimated that 33 (16.5%) million people had overactive bladder syndrome. Of these, 12 million (37%) were incontinent (<LINK REF="REF-Stewart-2001" TYPE="REFERENCE">Stewart 2001</LINK>). The estimated prevalence of an overactive bladder amongst people aged 40 years and above is 15.6% and 17.4% in men and women respectively, and the prevalence increases with age in both sexes. The symptoms of urgency or frequency, or both, are equally common in men and women but urgency incontinence is more prevalent in women (<LINK REF="REF-Milsom-2001" TYPE="REFERENCE">Milsom 2001</LINK>). Patients with symptoms of overactive bladder syndrome who have demonstrated detrusor contractions during the filling phase of urodynamic assessment are termed as having detrusor overactivity. If detrusor overactivity is associated with a neurological condition it is termed as neurogenic detrusor overactivity. In the absence of a relevant neurological condition it is termed 'idiopathic detrusor overactivity'. In this review only idiopathic detrusor overactivity was considered.</P>
<P>Overactive bladder syndrome has economic and quality of life implications. It has been estimated that the economic cost of overactive bladder was USD 12.02 billion in 2000 in the United States (<LINK REF="REF-Hu-2003" TYPE="REFERENCE">Hu 2003</LINK>). It is also associated with poorer quality of life indices as shown by the Short Form (SF)-36 questionnaire, King's Health Questionnaire, a higher depression score and a poorer quality of sleep (<LINK REF="REF-Stewart-2001" TYPE="REFERENCE">Stewart 2001</LINK>).</P>
<P>The current European Association of Urology (EAU) guidelines suggest following a stepwise management pattern for the treatment of patients with overactive bladder and urgency urinary incontinence. The first step is conservative measures, which may include reducing the intake of caffeine drinks, optimising fluid intake, weight loss, usage of intravaginal oestrogens in postmenopausal women (<LINK REF="REF-Cody-2012" TYPE="REFERENCE">Cody 2012</LINK>), and short term usage of desmopressin in young adults with enuresis. The next option is bladder training (<LINK REF="REF-Wallace-2004" TYPE="REFERENCE">Wallace 2004</LINK>), which can be combined with pelvic floor exercises in the presence of concomitant stress incontinence. The next step is the administration of anticholinergic medications. The options for patients refractory to conservative measures and anticholinergic treatment and with detrusor overactivity are intravesical botulinum toxin A injection (<LINK REF="REF-Duthie-2011" TYPE="REFERENCE">Duthie 2011</LINK>), electrical stimulation, neuromodulation with implanted electrodes (<LINK REF="REF-Herbison-2009" TYPE="REFERENCE">Herbison 2009)</LINK> and surgical interventions with high morbidity, such as clam ileocystoplasty and urinary diversion (<LINK REF="REF-Cody-2012a" TYPE="REFERENCE">Cody 2012a</LINK>). In view of the complications associated with surgical intervention, it is commonly the last treatment option in patients with detrusor overactivity.</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>Pharmacotherapy is one of the main treatment options in the management of overactive bladder syndrome. Anticholinergics are classified based on pharmacokinetics (lipophilicity and molecular size) into tertiary and quaternary amines, or based on muscarinic receptor selectivity into non-selective antagonists, M2-M3 selective antagonists and M3 selective antagonists.</P>
<UL>
<LI>Tertiary amines are solifenacin, darifenacin, tolterodine, oxybutynin.</LI>
<LI>Qaternary amines are trospium and propantheline.</LI>
<LI>Non-selective anticholinergics are tolterodine, trospium, oxybutynin, propiverine hydrochloride (HCl) and propantheline.</LI>
<LI>Solfenacin and darifenacin are M2-M3 selective and M3 selective antagonists, respectively.</LI>
</UL>
<P>Quaternary amines do not cross the blood brain barrier and hence are thought to have fewer cognitive side effects in comparison with tertiary amines. In view of their receptor selectivity, M2-M3 selective and M3 selective antagonists are thought to have fewer adverse effects. The number of anticholinergic drugs available on the market is increasing and their effectiveness has been assessed in both observational and randomised controlled trials (<LINK REF="REF-Madhuvrata-2012" TYPE="REFERENCE">Madhuvrata 2012</LINK>; <LINK REF="REF-Thuroff-1991" TYPE="REFERENCE">Thuroff 1991</LINK>; <LINK REF="REF-Van-Kerrebroeck-1998" TYPE="REFERENCE">Van Kerrebroeck 1998</LINK>). Anticholinergics are increasingly being used in primary and secondary care settings, particularly for the treatment of urgency urinary incontinence, and this has considerable resource implications (<LINK REF="REF-Kobelt-1997" TYPE="REFERENCE">Kobelt 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparators</HEADING>
<P>Bladder training is often used as first line therapy in patients with overactive bladder syndrome whether or not they are incontinent. This modality involves encouraging patients to gradually increase the interval between voiding episodes. Employed in conjunction with a bladder chart, patients and clinicians can chart progress through both the volumes voided and the time interval between each void. It has been claimed that up to 50% of patients will achieve long term benefit with this approach (<LINK REF="REF-Holmes-1983" TYPE="REFERENCE">Holmes 1983</LINK>).</P>
<P>Pelvic floor muscle training (PFMT) has been advocated as a means of improving pelvic floor control and reducing symptoms of overactive bladder and urgency urinary incontinence. PFMT is more commonly recommended for stress urinary incontinence than for symptoms of overactive bladder syndrome (<LINK REF="REF-Dumoulin-2010" TYPE="REFERENCE">Dumoulin 2010</LINK>).</P>
<P>A combination of bladder training with biofeedback-assisted PFMT, sometimes referred to as behavioural therapy, has been shown to improve bladder control by teaching patients new skills or habits and is a recognised form of non-drug active therapy in the management of overactive bladder syndrome (<LINK REF="REF-Cardozo-1978" TYPE="REFERENCE">Cardozo 1978</LINK>).</P>
<P>Electrical stimulation involves the use of either implanted or external electrodes to stimulate reflex inhibition of pelvic efferents or activation of hypogastric efferents to down regulate detrusor muscle activity. This is mediated through stimulation of afferent input in the sacral root, S2 to S4 (<LINK REF="REF-Fall-1985" TYPE="REFERENCE">Fall 1985</LINK>; <LINK REF="REF-Shaker-1998" TYPE="REFERENCE">Shaker 1998</LINK>).</P>
<P>External electrodes are broadly classified into endocavitary and percutaneous electrodes (<LINK REF="REF-Gameiro-2012" TYPE="REFERENCE">Gameiro 2012</LINK>). Endocavitary electrodes can be placed intravaginally or rectally. Percutanous approaches include transcutaneous electrical nerve stimulation (TENS) and posterior tibial nerve stimulation (PTNS).</P>
<UL>
<LI>When the electrodes are placed on the perineal skin surface it is termed TENS.</LI>
<LI>PTNS involves non-invasive electrical stimulation of S2 to S4 sacral nerves via a 34-G needle placed on the medial malleolus of the ankle. It was first described by Dr Marshall Stoller and the protocol was termed the Stoller Afferent Nerve Stimulation (SANS) protocol.</LI>
</UL>
<P>Sacral nerve stimulation is a technique which involves implanted electrodes. It is a two stage invasive procedure where an electrode is placed percutaneously alongside S3 in the sacral foramina (<LINK REF="REF-Herbison-2009" TYPE="REFERENCE">Herbison 2009)</LINK>.</P>
<P>Surgical management of overactive bladder and urgency urinary incontinence is uncommon and is generally reserved for the most severe cases that have not responded to conservative management (<LINK REF="REF-Cody-2012" TYPE="REFERENCE">Cody 2012</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>The pathophysiology of the overactive bladder remains to be fully elucidated. However, the involvement of the autonomic nervous system in bladder and detrusor function is recognised (<LINK REF="REF-de-Groat-1997" TYPE="REFERENCE">de Groat 1997</LINK>). The motor nerve supply to the bladder is via the parasympathetic nervous system (via sacral nerves S2, S3, S4) (<LINK REF="REF-Abrams-1988" TYPE="REFERENCE">Abrams 1988</LINK>; <LINK REF="REF-Ouslander-1982" TYPE="REFERENCE">Ouslander 1982</LINK>; <LINK REF="REF-Ouslander-1986" TYPE="REFERENCE">Ouslander 1986</LINK>), which stimulates detrusor muscle contraction. This is mediated by acetylcholine acting on muscarinic (M) receptors at the level of the bladder. The bladder contains both M2 and M3 muscarinic receptor subtypes. Although the M2 subtype is more abundant, it is the M3 subtype which is mainly responsible for bladder contraction (<LINK REF="REF-Andersson-2002" TYPE="REFERENCE">Andersson 2002</LINK>). The rationale for using anticholinergic drugs in the treatment of overactive bladder syndrome is to block the parasympathetic acetylcholine pathway and thus abolish or reduce the intensity of detrusor muscle contraction. For the purpose of this review, the term 'anticholinergic' refers to both anticholinergic and antimuscarinic drugs.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>There are numerous drug and non-drug treatments for overactive bladder. While anticholinergics are well established in practice, based on their efficacy versus no treatment or placebo (<LINK REF="REF-Nabi-2006" TYPE="REFERENCE">Nabi 2006</LINK>), it is less certain how they compare to other established treatments such as bladder training and electrical stimulation.</P>
<P>This review compares anticholinergic drugs with other active (non-drug) therapies which include bladder training (BT) and pelvic floor muscle training (PFMT). Anticholinergic drugs are also compared with various combinations of bladder training and PFMT with and without anticholinergics to assess if any particular combination shows superior efficacy. The review also compares anticholinergics with various forms of electrical stimulation including neuromodulation.</P>
<P>Other Cochrane reviews covering treatments for overactive bladder syndrome and urinary incontinence that might be of interest to the reader include:</P>
<UL>
<LI>anticholinergic drugs versus placebo (<LINK REF="REF-Nabi-2006" TYPE="REFERENCE">Nabi 2006</LINK>);</LI>
<LI>which anticholinergic? (<LINK REF="REF-Madhuvrata-2012" TYPE="REFERENCE">Madhuvrata 2012</LINK>);</LI>
<LI>anticholinergic drugs versus other medications (<LINK REF="REF-Dublin-2004" TYPE="REFERENCE">Dublin 2004</LINK>);</LI>
<LI>PFMT versus no treatment (<LINK REF="REF-Dumoulin-2010" TYPE="REFERENCE">Dumoulin 2010</LINK>);</LI>
<LI>bladder training (<LINK REF="REF-Wallace-2004" TYPE="REFERENCE">Wallace 2004</LINK>);</LI>
<LI>botulinum toxin injections (<LINK REF="REF-Duthie-2011" TYPE="REFERENCE">Duthie 2011</LINK>); and</LI>
<LI>sacral neuromodulation with implanted devices (<LINK REF="REF-Herbison-2009" TYPE="REFERENCE">Herbison 2009</LINK>).</LI>
</UL>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>The following comparisons were made (for people with overactive bladder syndrome with or without urgency urinary incontinence).</P>
<P>1. Anticholinergic drugs versus bladder training (BT) alone.</P>
<P>2. Anticholinergic drugs versus pelvic floor muscle training (PFMT) alone.</P>
<P>3. Anticholinergic drugs versus external electrostimulation (endocavitary, percutaneous or sacral nerve modulation).</P>
<P>4. Anticholinergic drugs versus surgery.</P>
<P>5. Anticholinergic drugs in combination with non-drug therapies versus non-drug therapies alone.</P>
<P>6. Anticholinergic drugs in combination with non-drug therapies versus anticholinergic drugs alone.</P>
<P>7. Anticholinergic drugs versus combination non-drug therapies.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>All randomised or quasi-randomised controlled trials of anticholinergic drugs for the treatment of overactive bladder syndrome and urgency urinary incontinence.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>All adult men and women with idiopathic overactive bladder syndrome or urgency urinary incontinence (symptomatic or urodynamic diagnosis), or both. Participants with likely neurogenic causes for their symptoms were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-31 11:57:21 +0000" MODIFIED_BY="[Empty name]">
<P>At least one arm of the trial used an anticholinergic drug and at least one other arm used a non-drug treatment (such as bladder training, PFMT or surgery).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>The primary measure of outcome was the number of participants whose symptoms were 'not cured' while on treatment. Data for the following outcome measures were sought.</P>
<SUBSECTION>
<HEADING LEVEL="4">A. Participants' observations</HEADING>
<P>1. Number not cured during treatment (self-reported, subjective)*<BR/>2. Number not cured after treatment (self-reported, subjective)*<BR/>3. Number not improved (worse or unchanged) during treatment (self-reported, subjective)*<BR/>4. Number not improved (worse or unchanged) after treatment (self-reported, subjective)*<BR/>5. Number with nocturia during treatment<BR/>6. Number with nocturia after treatment</P>
<P>* Definitions based on criteria as reported by trialists for each trial</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">B. Quantification of symptoms</HEADING>
<P>7. Number of pad changes over 24 hours (from self-reported number of pads used)<BR/>8. Number of incontinent episodes over 24 hours (from self-completed urinary diary)<BR/>9. Mean volume or weight of urine loss on pad test<BR/>10. Number of micturitions over 24 hours (from self-completed urinary diary)<BR/>11. Frequency of sensation of urgency</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">C. Clinician's observations</HEADING>
<P>12. Number not cured (worse, unchanged or improved) versus cured within first year (objective test)<BR/>13. Number not cured (worse, unchanged or improved) versus cured after first year (objective test)<BR/>14. Number not cured (worse, unchanged or improved) versus cured after 5 years (objective test)<BR/>15. Urodynamic-diagnosed detrusor overactivity</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">D. Quality of life</HEADING>
<P>16. General health status measures e.g. Short Form-36 (Ware 1993)<BR/>17. Condition-specific health measures (specific instruments designed to assess impact of urinary voiding problems)<BR/>18. Measures of psychological health</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">E. Socioeconomic measures</HEADING>
<P>19. Health economic measures: costs of treatments; differential costs of treatment effect differences; formal cost effectiveness measures</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">F. Adverse events</HEADING>
<P>20. Number experiencing adverse effects<BR/>21. Number withdrawing from treatment or trial arm<BR/>22. Number changing dose of treatment</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">G. Other outcomes</HEADING>
<P>Non-prespecified outcomes judged important when performing the review</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>We did not impose any language or other limits on any of the searches.</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>This review has drawn on the search strategy developed for the Incontinence Group. Relevant trials were identified from the Incontinence Group Specialised Register, which is described under the Incontinence Group's <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/INCONT/frame.html">module</A> in T<I>he Cochrane Library</I>. The register contains trials identified from MEDLINE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL) and handsearching of journals and conference proceedings. The date of the most recent search of the register was 4 September 2012. The trials in the Incontinence Group Specialised Trials Register are also contained in CENTRAL.</P>
<P>The Incontinence Group Specialised Register was searched using the Group's own keyword system. The search terms used were:</P>
<P>{design.rct* or design.cct*}<BR/>AND<BR/>{TOPIC.URINE.INCON*} OR {TOPIC.URINE.overactivebladder*}<BR/>AND<BR/>{{INTVENT.CHEM.DRUG.ANTICHOLINERGIC} AND {INTVENT.*}} OR {relevant.review.anticholinergicVSnondrug}<BR/>(All searches were of the keyword field of Reference Manager 12, Thomson Reuters).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-05-08 10:07:55 +0100" MODIFIED_BY="[Empty name]">
<P>We checked all reference lists of identified trials and other relevant articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-10-11 10:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>Reports of studies identified as possibly eligible for the review were evaluated for appropriateness for inclusion by the review authors working independently and without prior consideration of the results. Studies were excluded from the review if they were neither randomised nor quasi-randomised trials.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Data extraction was undertaken independently by two review authors and cross-checked. Where data may have been collected but were not reported, further clarification was sought from the researchers. Included trial data were processed as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Trial data were considered in relation to the seven main hypotheses. Any difference of opinion related to the data extracted was discussed and resolved with a third review author.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>At least two review authors assessed risk of bias using the Cochrane Collaboration assessment criteria:</P>
<UL>
<LI>quality of random allocation and concealment;</LI>
<LI>description of drop-outs and withdrawals;</LI>
<LI>'blinding' at treatment and outcome assessment.</LI>
</UL>
<P>Any disagreements were resolved by discussion with a third review author.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>For categorical outcomes we related the number of participants reporting an outcome to the numbers at risk in each group to derive a risk ratio (RR). For continuous variables we used means and standard deviations to derive a mean difference. For cross-over trials and trials where continuous data were reported without measures of dispersion (for example, standard deviations) the data were entered into 'Other data' tables and comparisons made only on the direction of effect. Cross-over trials were identified by the suffix '#'.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Differences between trials were further investigated when significant statistical heterogeneity was found at the 10% level, or from consideration of the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) or appeared obvious from visual inspection of the results.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>When appropriate, meta-analysis was undertaken. A fixed-effect model was used for calculation of summary statistics (pooled estimates) and 95% confidence intervals (CIs).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-10-31 14:55:05 +0000" MODIFIED_BY="[Empty name]">
<P>Subcategories were identified according to the type(s) of drugs being compared or the different types of other interventions.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-10-12 10:22:04 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty studies were identified, of which 27 were excluded (see table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' for details). Of the 23 included trials, with 3685 participants, one was a cross-over trial (<LINK REF="STD-Soomro-2001-_x0023_" TYPE="STUDY">Soomro 2001 #</LINK>) and the other 22 were parallel group trials. The flow of literature through the assessment process is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>A detailed description of the 23 trials is given in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Four trials were in abstract form (<LINK REF="STD-Collas-1994" TYPE="STUDY">Collas 1994</LINK>; <LINK REF="STD-Milani-1987" TYPE="STUDY">Milani 1987</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Wise-1993" TYPE="STUDY">Wise 1993</LINK>), 18 were full publications (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Burgio-2011" TYPE="STUDY">Burgio 2011</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>; <LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>; <LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>; <LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Soomro-2001-_x0023_" TYPE="STUDY">Soomro 2001 #</LINK>; <LINK REF="STD-Svihra-2002" TYPE="STUDY">Svihra 2002</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) and one was a doctor of medicine (MD) thesis (<LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<P>The trials made the following comparisons.</P>
<P>1. Seven trials assessed various anticholinergics versus bladder training (<LINK REF="STD-Collas-1994" TYPE="STUDY">Collas 1994</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>; <LINK REF="STD-Milani-1987" TYPE="STUDY">Milani 1987</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</P>
<P>2. Seven trials assessed various electrical stimulation modalities versus an anticholinergic drug:</P>
<UL>
<LI>two trials used probantheline (dose range 7.5 mg to 45 mg twice daily or three times daily) and one trial oxybutynin 5 mg bd daily (<LINK REF="STD-Wise-1993" TYPE="STUDY">Wise 1993</LINK>) versus intravaginal electrical stimulation (<LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>);</LI>
<LI>one trial used oxybutynin (dose range 2.5 mg twice daily to 5 mg three times daily) versus transcutaneous electrical nerve stimulation (TENS) (<LINK REF="STD-Soomro-2001-_x0023_" TYPE="STUDY">Soomro 2001 #</LINK>), this was a cross-over trial;</LI>
<LI>one trial used oxybutynin 5 mg three times daily versus Stoller Afferent Nerve Stimulation System neuromodulation (<LINK REF="STD-Svihra-2002" TYPE="STUDY">Svihra 2002</LINK>);</LI>
<LI>one trial used trospium hydrochloride versus intravaginal electrical stimulation (<LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>);</LI>
<LI>one trial used oxybutynin 2 mg twice a day without dose titration versus intravaginal electrical stimulation (<LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>);</LI>
<LI>one trial used extended-release tolterodine 4mg versus percutaneous tibial nerve stimulation (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>).</LI>
</UL>
<P>3. Two trials assessed a combination of an anticholinergic drug with bladder training versus bladder training alone (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</P>
<P>4. Four trials assessed a combination of an anticholinergic drug with bladder training versus the drug alone (<LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>).</P>
<P>5. One trial assessed an anticholinergic drug (tolterodine) versus PFMT plus the anticholinergic drug (tolterodine) (<LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>).</P>
<P>6. One trial assessed an anticholinergic drug (oxybutynin) versus bladder training plus biofeedback-assisted PFMT (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>).</P>
<P>7. Four trials assessed anticholinergics versus anticholinergics and behavioural modification therapy (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Burgio-2011" TYPE="STUDY">Burgio 2011</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>).</P>
<P>8. One trial compared anticholinergics versus physiotherapy (inferential current therapy plus pelvic floor exercises plus bladder training) versus combination therapy (<LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Six trials had both male and female participants (<LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>; <LINK REF="STD-Soomro-2001-_x0023_" TYPE="STUDY">Soomro 2001 #</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>) and 15 had female participants only (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>; <LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>; <LINK REF="STD-Milani-1987" TYPE="STUDY">Milani 1987</LINK>; <LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>; <LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Svihra-2002" TYPE="STUDY">Svihra 2002</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>; <LINK REF="STD-Wise-1993" TYPE="STUDY">Wise 1993</LINK>), one trial included men only (<LINK REF="STD-Burgio-2011" TYPE="STUDY">Burgio 2011</LINK>), while one did not specify the gender of the participants (<LINK REF="STD-Collas-1994" TYPE="STUDY">Collas 1994</LINK>). The trials all included participants with non-neurogenic overactive bladder symptoms or did not specify the cause of the overactive bladder symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow up</HEADING>
<P>The duration of follow up varied from two to 52 weeks.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the excluded studies are given in the table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>The methodology and risk of bias of individual trials is summarised in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
<P>The risk of bias for individual trials have also been summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>In one trial, outcome data were estimated manually from graphs (<LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>); in another, data were reported in a way that could not be interpreted for the purpose of the review (<LINK REF="STD-Wise-1993" TYPE="STUDY">Wise 1993</LINK>); and in two trials outcomes were reported as median percentage change and interquartile ranges, which could not be analysed in RevMan (<LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>). Standard deviations were not reported in two trials (<LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>).</P>
<ALLOCATION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>In eight trials (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>; <LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>) the random sequence generation was deemed at low risk of bias. In the remaining studies the authors were unable to judge the level of risk for selection bias as the reporting was inadequate. In three trials (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) the allocation concealment was deemed low risk. In the remaining trials the authors were unable to judge the level of risk for allocation concealment as the reporting was inadequate.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>In four trials (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) the blinding was deemed at low risk of bias. There was high risk of performance bias and detection bias in five trials (<LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Drop-outs and withdrawals were described in six trials (<LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>). In one trial (<LINK REF="STD-Svihra-2002" TYPE="STUDY">Svihra 2002</LINK>) no actual numbers were provided for one group, and the trialists referred to "comparable therapeutic results" in their reporting. Similarly, no data were reported in another trial (<LINK REF="STD-Wise-1993" TYPE="STUDY">Wise 1993</LINK>).</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;changed data for Burgio 2008 number if micturitions wrong sd transcribed comp 6&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;removed data on freq of urgency, Burgio 2008 data urgency score comp 6&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;composite measure outcome at 8 month 70% reduction in freq, not taking drugs remove?&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;rewriting results after correction of data&lt;/p&gt;&lt;p&gt;comp 3 q o l text along with adverse effects text&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Removing p values where RRs MD should be reported&lt;/p&gt;" NOTES_MODIFIED="2012-11-13 10:43:41 +0000" NOTES_MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: anticholinergic drugs versus bladder training (BT)</HEADING>
<P>Seven trials addressed this comparison (<LINK REF="STD-Collas-1994" TYPE="STUDY">Collas 1994</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>; <LINK REF="STD-Milani-1987" TYPE="STUDY">Milani 1987</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</P>
<UL>
<LI>One trial compared tolterodine 4 mg daily versus bladder training (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>).</LI>
<LI>Two trials compared oxybutynin 5 mg daily versus bladder training (<LINK REF="STD-Collas-1994" TYPE="STUDY">Collas 1994</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</LI>
<LI>One trial compared oxybutynin 15 mg daily versus bladder training (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>).</LI>
<LI>One trial compared oxybutynin 45 mg daily versus bladder training (<LINK REF="STD-Milani-1987" TYPE="STUDY">Milani 1987</LINK>).</LI>
<LI>One trial compared probantheline 45 mg daily versus bladder training (<LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>).</LI>
<LI>One trial compared tolterodine 2mg twice daily versus bladder training (<LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Participants' observations</HEADING>
<P>Data describing cure rates during and after treatment were only available from two small trials (56 people). They tended to favour the anticholinergic groups but the differences were not statistically significant: not cured during treatment 7/28 (25%) versus 14/28 (50%) (RR 0.52, 95% CI 0.26 to 1.04; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>); not cured after treatment 9/28 (32%) versus 16 out of 28 (57%) (RR 0.58, 95% CI 0.16 to 2.21; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>). In the latter comparison there was statistical heterogeneity (I<SUP>2 </SUP>= 73%) as one trial suggested no difference whereas the other favoured the anticholinergic. However, in one trial oxybutynin 15 mg daily was used (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>) and in the other probantheline 45 mg daily was used (<LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>). Variation in anticholinergic efficacy could have contributed to this finding.</P>
<P>Data describing subjective improvement during treatment were available for all seven trials (346 participants), including three different anticholinergics. The trials favoured the anticholinergics in terms of number of participants not improved: 73/174 (42%) versus 98/172 (57%); this result was statistically significant (RR for number of people not improved 0.74, 95% CI 0.61 to 0.91; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (<LINK REF="STD-Collas-1994" TYPE="STUDY">Collas 1994</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>; <LINK REF="STD-Milani-1987" TYPE="STUDY">Milani 1987</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</P>
<P>There were no useable data regarding whether this improvement continued after stopping treatment. Song et al (<LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>) reported no change in nocturia between an anticholinergic and bladder training after treatment stopped.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quantification of symptoms</HEADING>
<P>Two trials (<LINK REF="STD-Macaulay-1988" TYPE="STUDY">Macaulay 1988</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>) reported  frequency of micturition. There was no statistical difference between the two groups for number of micturitions per 24 hours (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>), but the trials were small.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life and economic outcome</HEADING>
<P>There were no data describing quality of life or economic outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events and withdrawals</HEADING>
<P>Four trials (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Milani-1987" TYPE="STUDY">Milani 1987</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>) reported this outcome and found more adverse events in the anticholinergic groups: overall 51/132 (39%) versus 2/126 (2%) (RR 14.50, 95% CI 5.02 to 41.87; <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>). Data on withdrawals from treatment were available from two trials (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>): 5/74 in the anticholinergic group compared with 2/65 in the bladder training group withdrew from treatment (RR 1.98, 95% CI 0.46 to 8.50. <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long term outcome</HEADING>
<P>No data were reported describing the long term outcome, although bladder training might be expected to continue to be effective after stopping instruction sessions.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: anticholinergic drugs versus pelvic floor muscle training (PFMT) alone</HEADING>
<P>No eligible trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: anticholinergic drugs versus external electrostimulation</HEADING>
<P>Seven trials addressed this comparison (<LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>; <LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>; <LINK REF="STD-Soomro-2001-_x0023_" TYPE="STUDY">Soomro 2001 #</LINK>; <LINK REF="STD-Svihra-2002" TYPE="STUDY">Svihra 2002</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>; <LINK REF="STD-Wise-1993" TYPE="STUDY">Wise 1993</LINK>) but the Wise trial did not report usable data.</P>
<UL>
<LI>Four trials used different classes or doses of anticholinergics versus intravaginal electrical stimulation (<LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>; <LINK REF="STD-Wise-1993" TYPE="STUDY">Wise 1993</LINK>).</LI>
<LI>One trial used oxybutynin (dose range 2.5 mg twice daily to 5 mg three times a day) versus transcutaneous electrical nerve stimulation (TENS) (<LINK REF="STD-Soomro-2001-_x0023_" TYPE="STUDY">Soomro 2001 #</LINK>). This was a cross-over trial and the data could not be entered into the analysis.</LI>
<LI>One trial used oxybutynin 5 mg three times daily versus Stoller Afferent Nerve Stimulation System neuromodulation (<LINK REF="STD-Svihra-2002" TYPE="STUDY">Svihra 2002</LINK>).</LI>
<LI>One trial used extended release tolterodine 4mg versus percutaneous tibial nerve stimulation (PTNS) (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Participants' observations</HEADING>
<P>Data from three trials compared the number of people subjectively not cured at the end of the treatment period (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>; <LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>). There was no statistical difference between anticholinergic drugs and electrostimulation (RR 0.94, 95% CI 0.84 to 1.05; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). One trial (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>) compared the number of people objectively not cured, showing no statistically significant difference between the two groups (RR 1.00, 95% CI 0.91 to 1.1; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>The combined data from three trials for number of people not improved at the end of the treatment period favoured the electrical stimulation group (RR 1.64, 95% CI 1.15 to 2.34; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The three trials compared different types of anticholinergic drugs (oxybutynin, probantheline and extended release tolterodine) with different types of electrostimulation: intravaginal (<LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) or PTNS (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>). This result is driven mainly by the result of the slightly larger Peters trial comparing extended release tolterodine against PTNS and demonstrating a statistically significant difference favouring PTNS.</P>
<P>However, the Peters trial (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>) did not find a statistically significant difference between the groups for number of people objectively not improved (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) or for for nocturia (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quantification of symptoms</HEADING>
<P>The Peters trial (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>) found no statistically significant differences between extended release tolterodine and PTNS for number of micturitions per day (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>), sensation of urgency (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>) and the number of incontinence episodes per day (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>). One study reported there were no statistically significant differences between the groups in terms of number of pad changes per day comparing propantheline and intravaginal electrical stimulation ('Other data' <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) (<LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>).</P>
<P>One small trial comparing trospium hydrochloride and intravaginal electrical stimulation reported that there were statistically significant differences from baseline to end of treatment for the number of micturitions per day, urgency and incontinence. The data were reported as medians (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>) and hence were not suitable for meta-analysis to compare the groups at the end of treatment (<LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life assessment</HEADING>
<P>The data from the <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK> trial reported mean change from baseline for quality of life but there was no significant difference between the groups and the CI was wide. In the cross-over trial of oxybutynin versus TENS, the trialists stated that there were no statistical differences in any of the parameters of the SF-36 but they did not provide data (<LINK REF="STD-Soomro-2001-_x0023_" TYPE="STUDY">Soomro 2001 #</LINK>). One trial (<LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>) reported no statistical difference between the two groups for the Beck Depression Inventory (BDI) and Incontinence Impact Questionnaire (IIQ-7) scores. Health related quality of life scores were statistically similar for the two groups in the <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009 </LINK>trial (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>) (<LINK REF="CMP-003.15" TYPE="ANALYSIS">Analysis 3.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events and withdrawals</HEADING>
<P>Two trials reported few adverse effects for the two groups (<LINK REF="STD-Ozdedeli-2010" TYPE="STUDY">Ozdedeli 2010</LINK>; <LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>) (<LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>). Two trials (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) reported on withdrawal rates and showed very few withdrawals from either group, and this was not statistically significant (<LINK REF="CMP-003.14" TYPE="ANALYSIS">Analysis 3.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: anticholinergic drugs versus surgery</HEADING>
<P>No eligible trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 5: anticholinergic drugs in combination with non-drug therapies versus non-drug therapies alone</HEADING>
<P>Three trials addressed this comparison (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</P>
<UL>
<LI>Tolterodine plus bladder training versus bladder training alone (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>).</LI>
<LI>Oxybutynin plus bladder training versus bladder training plus placebo (<LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Participants' observations</HEADING>
<P>In one small trial, the data were too few to assess differences in cure rates (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>) (<LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>). However, for subjective improvement at the end of treatment, the overall effect in the three small trials was in favour of a combination of an anticholinergic with bladder training compared with bladder training alone (RR 0.57, 95% CI 0.38 to 0.88; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Szonyi-1995" TYPE="STUDY">Szonyi 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quantification of symptoms</HEADING>
<P>The percentage decrease from baseline in the number of voids per day for the anticholinergic plus bladder training versus bladder training alone arms were similar, at 30.3% and 32.6%, respectively, but statistical analysis was not possible ('Other data' <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>.1) (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>). Similarly, the percentage reduction in the sensation of urgency from baseline for the same groups was reported as 63.2% and 62.5%, respectively ('Other data' <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>.1) (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life assessment</HEADING>
<P>Quality of life and socioeconomic measures were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events and withdrawals</HEADING>
<P>Two trials (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>) reported that 19/57 (33%) participants had adverse events in the combination (anticholinergic plus bladder training) group compared to 0/50 with bladder training alone (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>) (<LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>). Adverse events were mainly dry mouth, blurred vision, heartburn, constipation and dry skin.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 6: anticholinergic drugs in combination with non-drug therapies versus anticholinergic drugs alone</HEADING>
<P>Nine trials compared anticholinergic drugs plus a non-drug treatment versus the anticholinergic on its own (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>; <LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>). However, the non-drug treatments were considered too different to combine in meta-analysis:</P>
<UL>
<LI>bladder training (<LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>);</LI>
<LI>behavioural modification therapy (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>);</LI>
<LI>PFMT (<LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>);</LI>
<LI>interferential therapy plus PFMT plus bladder training (<LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>).</LI>
</UL>
<P>Five of these trials included over 100 participants in each arm (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>; <LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Anticholinergics in combination with bladder training (BT) versus anticholinergic alone</HEADING>
<P>Three trials compared tolterodine 4mg daily in combination with bladder training with tolterodine alone (<LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>). One of these trials compared flexible dosing of solifenacin 5 or 10mg with a combination of bladder training and flexible dosing of solifenacin 5 or 10mg (<LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Participants' observations</HEADING>
<P>The three trials comparing the combination treatment of tolterodine and bladder training versus tolterodine alone all favoured the combination group, with higher improvement rates (RR 0.80, 95% CI 0.62 to 1.04; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.1) (<LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>) but the combined meta-analysis was not statistically significant. The flexible dosing solifenacin trial (<LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>) did not report any data from which overall cure or improvement rates could be calculated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quantification of symptoms</HEADING>
<P>The flexible dosing solifenacin trial (<LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>) showed a higher mean reduction in the frequency of micturition from baseline at eight and 16 weeks in the combination group, which was statistically significant at eight weeks favouring bladder training plus anticholinergic (MD -0.69, 95% CI -1.11 to -0.27; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.1). However, there was no statistically significant difference in mean change in urgency (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.1), number of pads used (<LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>.1) and number of incontinence episodes at the end of the treatment period (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.1).</P>
<P>In one trial (<LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>) the percentage change in incontinence episodes per day from baseline was reported as 87% for the combined anticholinergic plus bladder training arm and 81% for the anticholinergic arm ('Other data' <LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life assessment</HEADING>
<P>One large trial (<LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>) did not find a statistically significant difference in incontinence quality of life (I-QoL) scores between the two groups at eight and 16 weeks (MD -0.97, 95% CI -3.57 to 1.63; <LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events and withdrawals</HEADING>
<P>The proportion of people experiencing adverse events was similar in the four trials (<LINK REF="STD-Mattiasson-2003" TYPE="STUDY">Mattiasson 2003</LINK>; <LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Park-2002" TYPE="STUDY">Park 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>) comparing bladder training and an anticholinergic versus anticholinergic alone (52.5% versus 54.4%; RR 0.97, 95% CI 0.88 to 1.07; <LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>.1). Two trials (<LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>) compared the number of participants who withdrew from the study. There was no statistically significant difference between the two groups (4.8% versus 5.9%; RR 0.82, 95% CI 0.44 to 1.53; <LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>.1). One study (<LINK REF="STD-Mattiasson-2009" TYPE="STUDY">Mattiasson 2009</LINK>) comparing the number of people changing doses between the two groups reported no statistical difference (<LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>.1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anticholinergics in combination with pelvic floor muscle training (PFMT) versus anticholinergic alone</HEADING>
<P>One relatively large trial, which had a total study population of 475 patients, addressed this comparison (<LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>), tolterodine 4 mg daily plus PFMT compared with tolterodine alone.</P>
<SUBSECTION>
<HEADING LEVEL="5">Participants' observations</HEADING>
<P>There was no statistically significant difference between the groups in terms of subjective improvement when PFMT was added to anticholinergic treatment (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.2). No data were provided for cure rates or nocturia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quantification of symptoms</HEADING>
<P>There were no statistically significant differences in the number of micturitions per day (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.2) or incontinence episodes per day (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.2), but there were fewer reports of the sensation of urgency with tolterodine alone (MD 0.6, 95% CI 0.10 to 1.10; <LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.2) (<LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>) compared with the drug supplemented with PFMT. There were no data on pad changes or pad tests, quality of life, socioeconomic outcome measures or adverse events and withdrawals.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Combination of anticholinergics and behavioural modification therapy</HEADING>
<P>Three trials addressed this comparison (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>). Behavioural modification therapy included various combinations of PFMT, BT, urge suppression techniques, fluid management, timed or delayed voiding and lifestyle modification. </P>
<SUBSECTION>
<HEADING LEVEL="5">Participants' observation</HEADING>
<P>Data from two trials (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>) reported on subjective improvement: the result was statistically significant favouring the combined treatment group (RR 0.59, 95% CI 0.36 to 0.95; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>). However, there was statistical heterogeneity (P = 0.03) between the two studies with one trial favouring the combination group (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>) and one trial showing no statistical difference between the two groups (<LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>). When a random-effects model was used the result was no longer statistically significant.</P>
<P>One trial (<LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>) reported on the frequency of nocturia for the two groups but found no statistical difference (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quantification of symptoms</HEADING>
<P>The meta-analysis of the three trials (<LINK REF="STD-Burgio-2008" TYPE="STUDY">Burgio 2008</LINK>; <LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>) reporting micturitions per day showed no statistical significant difference between the two groups (MD -0.24, 95% CI -0.98 to 0.50; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.3). There were also no statistically significant differences in the one trial that reported urgency (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.3) and number of pad changes per day (<LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>.2) (<LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>). Meta-analysis of two trials (<LINK REF="STD-Burgio-2010" TYPE="STUDY">Burgio 2010</LINK>; <LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>) showed no statistically significant difference between the two groups in terms of the number of incontinence episodes per day (MD -0.06, 95% CI -0.47 to 0.35; <LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events and withdrawals</HEADING>
<P>One trial (<LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>) stated that the adverse effects in the two groups were similar although exact figures were not reported. One trial (<LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>) compared the withdrawal rate for the two groups. This was higher in the combination group but the difference was not statistically significant (14.6% versus 8.9%; <LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>.2). This trial (<LINK REF="STD-Chancellor-2008" TYPE="STUDY">Chancellor 2008</LINK>) also reported improvement in health related quality of life in both groups, but there was no statistical difference between the groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Combination of anticholinergics plus electrical stimulation plus PFMT plus bladder training versus anticholinergic alone</HEADING>
<P>One small trial compared trospium chloride and physiotherapy consisting of interferential current therapy, PFMT and bladder training versus trospium chloride alone (<LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Participants' observations</HEADING>
<P>No data were available on cure or improvement. There was no statistically significant difference between the two groups for nocturia in this trial (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quantification of symptoms</HEADING>
<P>This trial favoured the combination group in terms of two fewer micturitions per day (MD -2, 95% CI -3.88 to -0.12; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.4); but not quite for incontinence episodes (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life assessment</HEADING>
<P>In this trial the combination group had statistically significantly better quality of life scores (<LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events and withdrawals</HEADING>
<P>In both arms, 7/31 (23%) of participants experienced adverse effects, mainly dry mouth. The trial did not give individual figures for each group. One patient in the anticholinergic group had blurred vision, however it was not clear if this was before or after administration of the anticholinergic.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 7: anticholinergic drugs versus combination non-drug therapies</HEADING>
<P>One small trial (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>) compared oxybutynin 7.5 mg daily with behavioural treatment.</P>
<P>Another trial (<LINK REF="STD-Burgio-2011" TYPE="STUDY">Burgio 2011</LINK>) compared oxybutynin (5 to 30 mg) with behavioural treatment for men who continued to have overactive bladder symptoms with alpha-blocker therapy.</P>
<P>One small trial compared trospium chloride with a combination of inferential current therapy plus pelvic floor exercises plus bladder training (<LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants' observations</HEADING>
<P>The Burgio trial (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>), which compared anticholinergics with behavioural treatment, showed no statistically significant difference in subjective cure rates between the two groups (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.1). However, for subjective improvement the result favoured the behavioural treatment therapy (RR 2.42, 95% CI 1.00 to 5.85; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>.1).</P>
<P>There were no data available for cure and improvement rates in the trial comparing an anticholinergic with the non-drug combination of inferential current therapy plus pelvic floor exercises plus bladder training (<LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quantification of symptoms</HEADING>
<P>The Kaya trial (<LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>) comparing an anticholinergic and a combination of inferential current therapy plus pelvic floor exercises plus bladder training showed no statistically significant difference between scores for nocturia (<LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>.1). For the number of micturitions per day there was no statistically significant difference between the two groups in either of the two trials (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>.1; <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>.2). The combined result of three trials (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burgio-2011" TYPE="STUDY">Burgio 2011</LINK>; <LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>) for incontinence episodes per day showed fewer incontinence episodes in the combination therapy group compared with the anticholinergic drug alone (MD 0.41, 95% CI 0.11 to 0.70) (<LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>). However there was heterogeneity in the result, and when a random-effects model was used the result was no longer statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life assessment</HEADING>
<P>The quality of life score in the combination group was higher (better) in the non-drug group in one small trial (13.70, 95% CI 0.94 to 26.46; <LINK REF="CMP-007.06" TYPE="ANALYSIS">Analysis 7.6</LINK>.1).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>Pharmacotherapy is one of the main treatment modalities in the management of overactive bladder syndrome, with or without the use of non-drug active therapies such as bladder training (BT) or urge suppression techniques, pelvic floor muscle training (PFMT) (with or without biofeedback), lifestyle modification, fluid management and the various forms of electrical stimulation. All these recognised therapeutic modalities differ with respect to efficacy, tolerability and side effect profile.</P>
<SUMMARY_OF_RESULTS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Bladder training (BT)</HEADING>
<P>The current review suggests that patients are more likely to improve when treated with anticholinergics alone rather than bladder training alone. In the seven small trials comparing anticholinergics alone and bladder training alone, more people improved with drugs than with bladder training (RR for lack of improvement 0.74, 95% CI 0.61 to 0.91; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Interestingly, although the overall meta-analysis favoured the anticholinergic group, with statistical significance, none of the individual trials reported a statistically significant difference in subjective improvement. The trials also used different anticholinergics, formulations and variations in dose. These results therefore have to be viewed with caution. The combination of an anticholinergic with bladder training versus bladder training alone favoured the combination group over bladder training alone, which was statistically significant (RR 0.57, 95% CI 0.38 to 0.88; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). However, it was less clear whether an anticholinergic combined with bladder training was better than the anticholinergic alone, in three trials (for example RR for no improvement 0.80, 95% CI 0.62 to 1.04; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.1). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">External electrostimulation</HEADING>
<P>In this review various types of electrical stimulation modalities such as Intravaginal Electrical Stimulation (IES), transcutaneous electrical nerve stimulation (TENS), the Stoller Afferent Nerve Stimulation System (SANS) neuromodulation and percutaneous posterior tibial nerve stimulation (PTNS) were identified. Cure rates between anticholinergic drug and electrical stimulation were similar for both therapies. Improvement rates tended to favour the electrostimulation group (RR for no improvement 0.64, 95% CI 1.15 to 2.34; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). However, this was statistically significant only for one outcome in the PTNS trial (<LINK REF="STD-Peters-2009" TYPE="STUDY">Peters 2009</LINK>), not supported by the other outcomes, and needs to be confirmed in future research.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pelvic floor muscle training (PFMT)</HEADING>
<P>This review identified only one large study which compared anticholinergics individually against a combination of anticholinergic and PFMT (<LINK REF="STD-Millard-2004" TYPE="STUDY">Millard 2004</LINK>). Pelvic floor exercises alone did not appear to add any significant advantage to the overall improvement rates or individual symptoms of overactive bladder syndrome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Behavioural modification therapy</HEADING>
<P>The overall meta-analysis of three trials in the review showed better subjective improvement rates with behaviour modification therapy, which could include behavioural strategies, urge suppression, bladder training and PFMT combined with anticholinergic therapy versus the anticholinergic therapy alone (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.3). However, there was significant statistical heterogeneity between the three trials and the finding should therefore be interpreted with caution.  The other information on whether combining these behavioural modification strategies with an anticholinergic was better than the anticholinergic alone was scanty and inconclusive. Similalry, it was unclear whether these complex strategies alone were better than anticholingerics alone. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Others</HEADING>
<P>One small trial (<LINK REF="STD-Kaya-2011" TYPE="STUDY">Kaya 2011</LINK>) compared three treatment protocols: anticholinergic alone, physiotherapy (Inferential current therapy plus pelvic floor exercises plus bladder training) and a combination of anticholinergic drug and physiotherapy. The physiotherapy protocol both individually and in combination with an anticholinergic reported significant reduction in the frequency of micturition per day and improvement in quality of life compared to the anticholinergic alone. However, this was a single small trial and definitive conclusion based on this are difficult to draw.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Anticholinergics have well recognised adverse effects during treatment. Dry mouth was the most common followed by headache, constipation, dizziness, decreased visual acuity and tachycardia. There were too few data to assess withdrawal rates. The Cochrane review of anticholinergics (<LINK REF="REF-Nabi-2006" TYPE="REFERENCE">Nabi 2006</LINK>) versus placebo found broadly similar rates of dry mouth but only a small difference in withdrawal rates, which was not statistically significant. As there were no data addressing long term performance, it is not possible to say if anticholinergics would continue to be effective even if the adverse effects were tolerable.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-11-09 10:45:19 +0000" MODIFIED_BY="[Empty name]">
<P>The most common anticholinergic used in this review is oxybutynin followed by tolterodine at varying doses. A recent Cochrane review comparing various anticholinergics has shown oxybutynin and tolterodine to be similarly efficacious (<LINK REF="REF-Madhuvrata-2012" TYPE="REFERENCE">Madhuvrata 2012</LINK>). Newer generation long-acting anticholinergics such as solifenacin and fesoterodine are becoming increasing popular in clinical practice and have been shown to have better efficacy than tolterodine (<LINK REF="REF-Madhuvrata-2012" TYPE="REFERENCE">Madhuvrata 2012</LINK>). This review identified only one study that used solifenacin and none using fesoterodine. It would be interesting to see how these compare to non-drug therapies.</P>
<P>The length of follow up was also significantly variable between studies, ranging between two to 52 weeks. The authors would suggest viewing some of the evidence with caution due to potential variability between the different types of anticholinergics, formulation and dose differences between individual anticholinergics, and lack of evidence about long term use.</P>
<P>In contrast, it is possible that conservative physical therapies such as bladder training might continue to be effective even after the end of the period of intensive teaching. In the context of management of overactive bladder symptoms, it is appealing, to both the clinician and the patient, to avoid any form of pharmacotherapy, if possible, and to rely on alternatives such as bladder training, PFMT, biofeedback-assisted therapies or electrostimulation. The latter are expensive in terms of resources needed to teach them and they may have limited availability in some healthcare settings. On the other hand, adverse effects resulting in poor patient compliance with drugs may compromise their effectiveness.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>The review was characterised by studies of varying size and having trials of moderate quality in each comparison. Some comparisons were only addressed by single trials. Different classes and types of anticholinergic drugs and varying doses of individual anticholinergics were used by the various trials making the meta-analysis difficult and potentially causing clinical and statistical heterogeneity.</P>
<P>Some of the trials included patients with idiopathic overactive bladder syndrome, with clear exclusion of those with neurological diseases, but others did not clearly report such exclusions although we assumed that this was the case. This in itself could result in interpretation difficulties, given that it is known that people with neurogenic bladder problems respond differently to anticholinergic drugs. Therefore, a clearer identification of inclusion criteria to address selected subgroups could perhaps clarify this point.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>The use of anticholinergic drugs in the management of overactive bladder syndrome is well established. The evidence that is available suggests that anticholinergics are more effective than bladder training. However this should be viewed with caution as no individual study showed statistical significance although the overall meta-analysis was statistically significant. Furthermore, the effect of bladder training might be expected to persist, which is not the case with anticholinergics, but this could not be assessed as there was little information about outcomes after active treatment stops. A combination of bladder training or behavioural modification therapy with anticholinergics may also be a useful strategy compared with such non-drug treatments alone, or anticholinergic treatment alone, but more research is required to establish this as the evidence was limited.</P>
<P>The evidence suggesting that electrical stimulation may be better than anticholinergics was based on three small studies and needs to be confirmed. The limited evidence did suggest that non-implantable electrical stimulation might be an option in patients who are refractory to anticholinergic therapy. There was, however, no evidence comparing sacral neuromodulation with anticholinergics.</P>
<P>The anticholinergics used in individual studies were of different types, formulations and doses, with varying lengths of follow up. It is currently unclear if there are certain anticholinergics that may more efficacious with a more acceptable side effect profile compared to bladder training. Newer generation drugs such as solifenacin and fesoterodine have been shown to be more efficacious than tolterodine in a recent Cochrane review (<LINK REF="REF-Madhuvrata-2012" TYPE="REFERENCE">Madhuvrata 2012</LINK>). In the current review only one study used solifenacin, and fesoterodine was not used at all. It is therefore possible that these anticholinergics will be more effective than bladder training, but there is currently no evidence to support this hypothesis.</P>
<P>There was not enough evidence to assess whether symptomatic improvement is sustained after stopping either treatment. This is important because the aim of bladder training is to achieve long-term improvement. Anticholinergic treatment has well recognised side effects, such as dry mouth. These side effects are not uncommon and may lead to failure of treatment due to people stopping the use of the drugs.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>The most important clinical issue is whether to start treatment with anticholinergics, bladder training, electrostimulation or a combination of these treatments. There is a need for larger trials with longer study periods comparing these alternatives, particularly including follow up after treatment has ended. There is also a need for more trials comparing anticholinergics with various forms of implantable and non-implantable electrostimulation modalities. The anticholinergic drugs tested should be those that are in current use and that have been shown to be the most effective with the least adverse effects.</P>
<P>The reporting of the constituent parts of non-drug active therapies in trials need to be standardised to allow better interpretation of data and meta-analyses. Assessment of cost effectiveness should be incorporated. Trials should use standardised terminology and outcome measures, and report outcomes in accordance with International Continence Society (ICS) standards and the CONSORT statement. In addition, more studies comparing anticholinergic drugs with various modalities of electrostimulation and botulinum toxin therapy are required to enable analysis and draw out meaningful conclusions.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-10-12 14:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Jonathan Cook for statistical advice.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Mr L Stewart has been on consultation committees for tolterodine and oxybutynin. The remaining authors have no conflicts of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Bhavan Rai, June Cody and Ammar Alhasso conducted the review, including data abstraction, interpretation and writing the review.<BR/>Ammar Alhasso and Laurence Stewart, the supervising consultant, reviewed and scrutinised the data collection, and were involved in the interpretation and the writing up of the original version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-04-01 22:41:12 +0100" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES MODIFIED="2012-04-01 22:41:12 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-31 11:39:26 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-10-31 11:06:02 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-10-31 11:06:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Burgio-1998" NAME="Burgio 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;(ID 14585)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Candib D</AU>
<TI>Behaviour vs drug therapy for urge incontinence in older women</TI>
<SO>Proceedings of the 15th Annual Scientific Meeting of the American Urogynecology Society</SO>
<YR>1994</YR>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 5719)&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Locher JL, Goode PS</AU>
<TI>Behavioural vs drug treatment for urge urinary incontinence in older women: A randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>280</VL>
<NO>23</NO>
<PG>1995-2000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 9006)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Locher JL, Goode PS</AU>
<TI>Combined behavioural and drug therapy for urge urinary incontinence in older women</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>4</NO>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 11923)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Locher JL, Roth DL, Goode PS</AU>
<TI>Psychological improvements associated with behavioural and drug treatment of urge incontinence in older women</TI>
<SO>The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences</SO>
<YR>2001</YR>
<VL>56B</VL>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 14678)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goode PS, Burgio KL, Locher JL, Umlauf MG, LLoyd KL, Roth DL</AU>
<TI>Urodynamic changes associated with behavioural and drug treatment of urge incontinence in older women</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2002</YR>
<VL>50</VL>
<PG>808-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgio-2008" MODIFIED="2012-10-31 10:38:08 +0000" MODIFIED_BY="[Empty name]" NAME="Burgio 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-31 10:38:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Kraus SR, Borello-France D, Chai TC, Kenton K, Goode PS et al</AU>
<TI>The effects of drug and behavior therapy on urgency and voiding frequency</TI>
<SO>International Urogynecology Journal</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>6</NO>
<PG>711-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="39603"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-25 13:03:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW et al</AU>
<TI>Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>149</VL>
<NO>3</NO>
<PG>161-9</PG>
<IDENTIFIERS MODIFIED="2012-08-06 13:24:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-06 13:23:56 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
<IDENTIFIER MODIFIED="2012-08-06 13:24:22 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="27584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgio-2010" MODIFIED="2012-08-07 11:19:54 +0100" MODIFIED_BY="[Empty name]" NAME="Burgio 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-06 13:27:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM, Redden DT</AU>
<TI>Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women</TI>
<SO>Journal of Urology</SO>
<YR>2010</YR>
<VL>184</VL>
<NO>2</NO>
<PG>598-603</PG>
<IDENTIFIERS MODIFIED="2012-08-06 13:27:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-06 13:27:09 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="39902"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgio-2011" MODIFIED="2012-10-11 16:30:36 +0100" MODIFIED_BY="[Empty name]" NAME="Burgio 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-11 16:28:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Goode PS, Johnson II TM, Hammontree LN, Ouslander JG, Markland AD et al</AU>
<TI>Behavioral vs. drug treatment for overactive bladder in men: The Motive Trial (Abstract number 1516)</TI>
<SO>Journal of Urology</SO>
<YR>2010</YR>
<VL>183</VL>
<NO>4 Suppl 1</NO>
<PG>e585</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="42519"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-11 16:30:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD et al</AU>
<TI>Behavioral versus drug treatment for overactive bladder in men: the male overactive bladder treatment in veterans (MOTIVE) trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2011</YR>
<VL>59</VL>
<NO>12</NO>
<PG>2209-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="42742"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chancellor-2008" MODIFIED="2012-10-31 10:39:07 +0000" MODIFIED_BY="[Empty name]" NAME="Chancellor 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-31 10:39:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G et al</AU>
<TI>A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2008</YR>
<VL>62</VL>
<NO>4</NO>
<PG>606-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collas-1994" NAME="Collas 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;(ID 7039)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collas DM, Szonyi G, Ding YY, Malone LJ</AU>
<TI>Oxybutynin with bladder retraining for detrusor instability in the elderly - placebo controlled trial</TI>
<SO>Age and Ageing</SO>
<YR>1994</YR>
<VL>23S</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colombo-1995" NAME="Colombo 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;(ID 6056)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colombo M, Zanetta G, Scalambrino S, Milani R</AU>
<TI>Oxybutynin and bladder training in the management of female urinary urge incontinence: A randomized study</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaya-2011" MODIFIED="2012-10-31 10:53:37 +0000" MODIFIED_BY="[Empty name]" NAME="Kaya 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-31 10:53:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaya S, Akbayrak T, Beksac S</AU>
<TI>Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial.</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>4</NO>
<PG>327-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macaulay-1988" MODIFIED="2012-10-31 10:40:52 +0000" MODIFIED_BY="[Empty name]" NAME="Macaulay 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;(ID 10920)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Macaulay AJ, Holmes D, Stanton SL, Stern RS</AU>
<TI>A prospective randomised controlled trial of bladder retraining and brief psychotherapy for urinary frequency and urgency</TI>
<SO>Proceedings of the 15th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1985</YR>
<PG>184-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 515)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macaulay AJ, Stern RS, Holmes DS, Stanton SL</AU>
<TI>Micturition and the mind: psychological factors in the aetiology and the treatment of urinary symptoms in women</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>1987</YR>
<VL>294</VL>
<NO>6571</NO>
<PG>540-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-31 10:40:52 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 16286)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 10:40:52 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Macaulay AJ</AU>
<TI>Psychological factors in the aetiology and treatment of urinary symptoms in women</TI>
<SO>MD Thesis Charing Cross and Westminster Medical School</SO>
<YR>1988</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattiasson-2003" MODIFIED="2012-10-31 10:54:31 +0000" MODIFIED_BY="[Empty name]" NAME="Mattiasson 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;(ID 15701)&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mattiasson A, Blaakaer J, Hoye K, Wein AJ</AU>
<TI>Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder</TI>
<SO>BJU International</SO>
<YR>2003</YR>
<VL>91</VL>
<NO>1</NO>
<PG>54-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 15389)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mattiasson A</AU>
<TI>Effect of simplified bladder training and tolterodine treatment in overactive bladder patients</TI>
<SO>Proceedings of 2nd International Consultation on Incontinence, 1-3 July 2001 (Poster presentations)</SO>
<YR>2001</YR>
<PG>Abstract 59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-31 10:54:31 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 14380)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 10:54:31 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattiasson A</AU>
<TI>Simplified bladder training augments tolterodine treatment in overactive bladder patients</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>4</NO>
<PG>403-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattiasson-2009" MODIFIED="2012-10-31 10:56:28 +0000" MODIFIED_BY="[Empty name]" NAME="Mattiasson 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-31 10:56:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattiasson A, Masala A, Morton R, Bolodeoku J</AU>
<TI>Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study</TI>
<SO>BJU International</SO>
<YR>2009</YR>
<VL>105</VL>
<NO>8</NO>
<PG>1126-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milani-1987" MODIFIED="2012-10-11 16:52:21 +0100" MODIFIED_BY="[Empty name]" NAME="Milani 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;(ID 12030)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Milani R, Scalambrino S, Carrera S Quadri G Riva D, Casolati E</AU>
<TI>A randomized trail of bladder retraining versus oxybutynin in the treatment of idiopathic urge syndrome, early results</TI>
<SO>Proceedings of 16th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1986</YR>
<PG>488-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-11 16:52:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 9033)&lt;/p&gt;" NOTES_MODIFIED="2012-10-11 16:52:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Milani R, Scalambrino S, Quadri G, Carrera S, Riva D, Castolati E</AU>
<TI>Randomized drug therapy and bladder retraining in urge syndrome: late results</TI>
<SO>Proceedings of the 17th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1987</YR>
<VL>2</VL>
<PG>133-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millard-2004" MODIFIED="2012-10-31 10:57:32 +0000" MODIFIED_BY="[Empty name]" NAME="Millard 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-10-31 10:57:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 16646)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 10:57:32 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millard RJ</AU>
<TI>Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>48-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozdedeli-2010" MODIFIED="2011-09-16 13:01:49 +0100" MODIFIED_BY="[Empty name]" NAME="Ozdedeli 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-09-16 13:01:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozdedeli S, Karapolat H, Akkoc Y</AU>
<TI>Comparison of intravaginal electrical stimulation and trospium hydrochloride in women with overactive bladder syndrome: a randomized controlled study</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>4</NO>
<PG>342-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2002" MODIFIED="2012-10-31 10:58:47 +0000" MODIFIED_BY="[Empty name]" NAME="Park 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 10:58:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 14557)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 10:58:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park TJ, Song C, Choo M</AU>
<TI>The effects of bladder retraining, tolterodine and bladder retraining and tolterodine in female patients with overactive bladder, a prospective randomised study</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>4</NO>
<PG>434-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-2009" MODIFIED="2012-10-31 11:06:02 +0000" MODIFIED_BY="[Empty name]" NAME="Peters 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-31 11:06:02 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19616802&lt;br&gt;IN - William Beaumont Hospital, Royal Oak, Michigan, USA. kmpeters@beaumont.edu&lt;br&gt;AS - J Urol. 182(3):1055-61, 2009 Sep&lt;br&gt;JC - kc7, 0376374&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:06:02 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES et al</AU>
<TI>Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>182</VL>
<NO>3</NO>
<PG>1055-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1996" MODIFIED="2012-10-31 10:59:06 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;(ID 15469)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaronson PS, Loehner D, Bingham W, Smith JJ</AU>
<TI>Intravaginal electrical stimulation in the treatment of genuine stress urinary incontinence and detrusor instability: a controlled study</TI>
<SO>Journal of Urology</SO>
<YR>1995</YR>
<VL>153(4 Suppl)</VL>
<PG>491A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 14584)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Smith JJ, Loehner D, Bignham W</AU>
<TI>Intravaginal electrical stimulation in the treatment of GSUI and DI: a controlled study</TI>
<SO>Proceedings of the 15th Annual Scientific Meeting of the American Urogynecological Society</SO>
<YR>1994</YR>
<PG>Abstract 25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-31 10:59:06 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 2900)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 10:59:06 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith JJ</AU>
<TI>Intravaginal stimulation randomized trial</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>1</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2006" MODIFIED="2011-09-16 13:00:51 +0100" MODIFIED_BY="[Empty name]" NAME="Song 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-09-16 13:00:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song C, Park JT, Heo KO, Lee KS, Choo MS</AU>
<TI>Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study</TI>
<SO>Journal of Korean Medical Science</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1060-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soomro-2001-_x0023_" NAME="Soomro 2001 #" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;(ID 12329)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soomro NA, Khadra MH, Robson W, Neal DE</AU>
<TI>A crossover randomized crossover trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>1</NO>
<PG>146-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svihra-2002" MODIFIED="2012-10-31 11:00:07 +0000" MODIFIED_BY="[Empty name]" NAME="Svihra 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 11:00:07 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 15769)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:00:07 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svihra J, Kurca E, Luptak J, Kliment J</AU>
<TI>Neuromodulative treatment of overactive bladder - non-invasive tibial nerve stimulation</TI>
<SO>Bratislavske Lekarske Listy</SO>
<YR>2002</YR>
<VL>103</VL>
<NO>12</NO>
<PG>480-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szonyi-1995" NAME="Szonyi 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;(ID 2906)&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Szonyi G, Collas DM, Ding YY, Malone-Lee JG</AU>
<TI>Oxybutynin with bladder retraining for detrusor instability in elderly people: A randomized controlled trial</TI>
<SO>Age and Ageing</SO>
<YR>1995</YR>
<VL>24</VL>
<PG>287-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 10948)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Szonyi G, Ding YY, Malone-Lee JG</AU>
<TI>Oxybutynin with bladder retraining for detrusor instability in elderly people</TI>
<SO>Proceedings of the 24th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1994</YR>
<PG>353-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2011-09-16 13:02:19 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-09-16 13:02:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang AC, Chih SY, Chen MC</AU>
<TI>Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial</TI>
<SO>Urology</SO>
<YR>2006</YR>
<VL>68</VL>
<NO>5</NO>
<PG>999-1004</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wise-1993" NAME="Wise 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;(ID 12049)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wise BG, Cardozo LD, Plevnik S, Kelleher C, Abbott D</AU>
<TI>A comparative study of oxybutynin and maximal electrical stimulation in the treatment of detrusor instability</TI>
<SO>Proceedings of 23rd Meeting of ICS</SO>
<YR>1993</YR>
<VL>8</VL>
<PG>236</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-10-31 11:05:01 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Castleden-1986-_x0023_" NAME="Castleden 1986 #" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;(ID12080)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Castleden CM, Duffin HM, Millar AW</AU>
<TI>A controlled clinical pilot study of dicyclomine in detrusor instability</TI>
<SO>Proceedings of the 16th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1986</YR>
<PG>373-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enzelsberger-1991" NAME="Enzelsberger 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;(ID 272)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enzelsberger H, Schatten C, Kurz C</AU>
<TI>Vergleich von Emeproniumbromid mit intravesikal appliziertem Lidocain-Gel bei Frauen mit Urge-Inkontinenz</TI>
<SO>Geburtsh u Frauenheilk</SO>
<YR>1991</YR>
<VL>51</VL>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelber-1997" NAME="Gelber 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;(ID 10197)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelber DA, Swords L</AU>
<TI>Treatment of post-stroke urinary incontinence</TI>
<SO>Journal of Neurologic Rehabilitation</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>2</NO>
<PG>131</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-2011" MODIFIED="2012-10-31 11:01:33 +0000" MODIFIED_BY="[Empty name]" NAME="Goode 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-31 11:01:33 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 20945064&lt;br&gt;ST - In-Process&lt;br&gt;AS - Int Urogynecol J Pelvic Floor Dysfunct. 22(3):327-34, 2011 Mar&lt;br&gt;JC - cl5, 9514583&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SI - ClinicalTrials.gov&lt;br&gt;SA - ClinicalTrials.gov/NCT00090584&lt;br&gt;NO - U01 DK 58225 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK58229 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK58231 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK58234 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK60379 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK60380 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK60393 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK60395 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK60397 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01 DK60401 (United States NIDDK NIH HHS)&lt;br&gt;LG - English&lt;br&gt;DC - 20110210&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:01:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goode PS, Burgio KL, Kraus SR, Kenton K, Litman HJ, Richter HE et al</AU>
<TI>Correlates and predictors of patient satisfaction with drug therapy and combined drug therapy and behavioral training for urgency urinary incontinence in women</TI>
<SO>International Urogynecology Journal</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>3</NO>
<PG>327-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT41557"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henalla-1989" NAME="Henalla 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;(ID 12039)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henalla SM, Millar DR, Moon PV</AU>
<TI>The effects of terodiline and cystodistention combined with bladder drill for the treatment on the unstable bladder (preliminary results)</TI>
<SO>Proceedings 19th Annual ICS meeting</SO>
<YR>1989</YR>
<VL>95</VL>
<PG>198-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henalla-1991" NAME="Henalla 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;(ID 6283)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henalla SM, Millar DR, Moon PV</AU>
<TI>Medical or surgical augmentation of bladder drill for detrusor instability</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>2</NO>
<PG>128-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarvis-1981" NAME="Jarvis 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;(ID 741)&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jarvis GJ</AU>
<TI>A controlled trial of bladder drill and drug therapy in the management of detrusor instability</TI>
<SO>British Journal of Urology</SO>
<YR>1981</YR>
<VL>53</VL>
<PG>565-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;(ID 10972) International Continence Society&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jarvis GJ.</AU>
<TI>The unstable bladder - A psychosomatic disease?</TI>
<SO>Proceedings of 11th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1981</YR>
<PG>45-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelleher-1994" NAME="Kelleher 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;(ID 6997)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelleher CJ, Filschie J, Burton G, Khullar V, Cardozo LD</AU>
<TI>Acupuncture and the treatment of irritative bladder symptoms</TI>
<SO>Acupuncture in Medicine</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2008" MODIFIED="2012-10-31 11:01:53 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-31 11:01:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SW, Song SH, Ku JH</AU>
<TI>Bladder training versus combination of propiverine with bladder training for female urinary frequency. A prospective, randomized, comparative study</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>2</NO>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klarskov-1981" NAME="Klarskov 1981" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;(ID 10957)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Klarskov P, Gerstenberg T, Hald T</AU>
<TI>Bladder retraining and terodiline on urge incontinence in females with stable detrusor function</TI>
<SO>Proceedings of the 14th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1984</YR>
<PG>404-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klarskov-1986" NAME="Klarskov 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;(ID 595)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klarskov P, Gerstenberg TC, Hald T</AU>
<TI>Bladder training and terodiline in females with idiopathic urge incontinence and stable detrusor function</TI>
<SO>Scandinavian Journal of Urology and Nephrology</SO>
<YR>1986</YR>
<VL>20</VL>
<PG>41-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koonings-1987" NAME="Koonings 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;(ID 14564)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Koonings PP, Bergman A</AU>
<TI>Urethral relaxation: Bladder instability and stress urinary incontinence. Where is the primary pathology?</TI>
<SO>Proceedings of the 8th Annual Meeting of the American Urogynecology Society</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koonings-1988" MODIFIED="2012-10-31 11:02:06 +0000" MODIFIED_BY="[Empty name]" NAME="Koonings 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-10-31 11:02:06 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 487)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:02:06 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koonings P, Bergman A, Ballard CA</AU>
<TI>Combined detrusor instability and stress urinary incontinence: Where is the primary pathology?</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1988</YR>
<VL>26</VL>
<PG>250-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locher-2002" NAME="Locher 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;(ID 14415)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locher JL, Burgio KL, Goode PS, Roth DL, Rodriguez E</AU>
<TI>Effects of age and causal attribution to ageing on health related behaviours associated with urinary incontinence in older women</TI>
<SO>Gerentologist</SO>
<YR>2002</YR>
<VL>42</VL>
<NO>4</NO>
<PG>515-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacDiarmid-2010a" MODIFIED="2011-09-26 15:56:02 +0100" MODIFIED_BY="[Empty name]" NAME="MacDiarmid 2010a" YEAR="2010">
<REFERENCE MODIFIED="2011-09-26 15:56:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC et al</AU>
<TI>Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder</TI>
<SO>Journal of Urology</SO>
<YR>2010</YR>
<VL>183</VL>
<NO>1</NO>
<PG>234-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONTID35420"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osman-2003" NAME="Osman 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;(ID 16660)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osman T</AU>
<TI>Stress incontinence surgery for patients presenting with mixed incontinence and a normal cystogram</TI>
<SO>BJU International</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>9</NO>
<PG>964-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouslander-1987" NAME="Ouslander 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;(ID 9036)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ouslander JG, Blaustein J, Connor A, Pitt A</AU>
<TI>Habit training and oxybutynin for incontinence in functionally disabled nursing home patients with detrusor hyperreflexia: A placebo controlled trial</TI>
<SO>Proceedings of the 17th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1987</YR>
<PG>153-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouslander-1988" MODIFIED="2012-10-31 11:02:22 +0000" MODIFIED_BY="[Empty name]" NAME="Ouslander 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-10-31 11:02:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID509)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:02:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>OuslanderJG, Blaustein J, Connor A, Pitt A</AU>
<TI>Habit training and oxybutynin for incontinence in nursing home patients</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1988</YR>
<VL>36</VL>
<PG>40-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouslander-1995-_x0023_" MODIFIED="2012-10-31 11:02:42 +0000" MODIFIED_BY="[Empty name]" NAME="Ouslander 1995 #" YEAR="1995">
<REFERENCE MODIFIED="2012-10-31 11:02:42 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 3019)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:02:42 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouslander JG, Schnelle JF, Uman G, Fingold S, Glatler Nigam J, Thico E et al</AU>
<TI>Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo controlled trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>6</NO>
<PG>610-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pennisi-1994" MODIFIED="2012-10-31 11:04:30 +0000" MODIFIED_BY="[Empty name]" NAME="Pennisi 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-10-31 11:04:30 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 3098)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:04:30 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pennisi M, Grasso-Leanza Panella P, Pepe P</AU>
<TI>[Rehabilitation therapy in the treatment of female urinary incontinence. Our experience with 121 patients] [Italian]</TI>
<TO>La teapia riabilitativa nel trattamento dell'incontinenza urinaria femminile</TO>
<SO>Minerav Urologica e Nefrologica</SO>
<YR>1994</YR>
<VL>46</VL>
<NO>4</NO>
<PG>245-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-2010" MODIFIED="2012-10-31 11:04:10 +0000" MODIFIED_BY="[Empty name]" NAME="Peters 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-31 11:04:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, Macdiarmid SA</AU>
<TI>Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial</TI>
<SO>Journal of Urology</SO>
<YR>20/02/2010</YR>
<VL>183</VL>
<NO>4</NO>
<PG>1438-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visco-2011" MODIFIED="2012-05-08 10:10:28 +0100" MODIFIED_BY="[Empty name]" NAME="Visco 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-05-08 10:10:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Visco A, Meikle S</AU>
<TI>Efficacy and impact of botulinum toxin A versus anticholinergic therapy for the treatment of bothersome urge urinary incontinence</TI>
<SO>www.ClinicalTrials.gov [accessed 23 June 2011]</SO>
<YR>2011</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT41587"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weil-1995" NAME="Weil 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;(ID 10897)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Weil EHJ, Eerdmans PHA, Janknegt RA</AU>
<TI>A new randomized study on neuromodulation versus conventional treatment for incontinence or dysfunctional voiding patterns: a preliminary study</TI>
<SO>Proceedings of the 25th Annual Meeting of the International Continence Society (ICS)</SO>
<YR>1995</YR>
<PG>382-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weil-2000" NAME="Weil 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;(ID 9010)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weil EHJ, Ruiz-Cerda JL, Eerdmans PHA, Janknegt RA, Bemelmans BLH, van Kerrebroeck PhEV</AU>
<TI>Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: A Prospective randomized clinical trial</TI>
<SO>European Urology</SO>
<YR>2000</YR>
<VL>37</VL>
<PG>161-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wise-1992" NAME="Wise 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;(ID 14580)&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wise BG, Cardozo LD, Cutner A, Kelleher C, Burton G</AU>
<TI>Maximal electrical stimulation: An acceptable alternative to anticholinergic therapy</TI>
<SO>Proceedings of the 13th Annual Meeting of the American Urogynecolgy Society</SO>
<YR>1992</YR>
<PG>Abstract 32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiseman-1990" MODIFIED="2012-10-31 11:05:01 +0000" MODIFIED_BY="[Empty name]" NAME="Wiseman 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-10-31 11:05:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(ID 5115)&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:05:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiseman P, Malone-Lee JG, Rai G</AU>
<TI>A Study of terodiline with bladder retraining in the treatment of detrusor instability in the frail elderly</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>4</NO>
<PG>410-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiseman-1991" NAME="Wiseman 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;{ref ID 270}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiseman PA, Malone-Lee J, Rai GS</AU>
<TI>Terodoline with bladder retraining for treating detrusor instability in elderly people</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>302</VL>
<NO>6783</NO>
<PG>994-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-10-16 23:06:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-10-31 11:39:26 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-10-31 11:39:26 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abrams-1988" MODIFIED="2012-10-31 10:45:32 +0000" MODIFIED_BY="[Empty name]" NAME="Abrams 1988" TYPE="JOURNAL_ARTICLE">
<AU>Abrams PH, Blaivas JG, Stanton SL, Andersen JT</AU>
<TI>Standardisation of terminology of lower urinary tract function</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>5</NO>
<PG>403-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abrams-2002" NAME="Abrams 2002" TYPE="JOURNAL_ARTICLE">
<AU>Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al</AU>
<TI>The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>167</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andersson-2002" NAME="Andersson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Waldeck K, Larsson B, Sandberg B, Andersson KE, Larsson B, Sandberg B et al</AU>
<TI>Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>1</NO>
<PG>92-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cardozo-1978" NAME="Cardozo 1978" TYPE="JOURNAL_ARTICLE">
<AU>Cardozo L, Stanton SL, Hafner J, Alan V</AU>
<TI>Biofeedback in the treatment of detrusor instability</TI>
<SO>British Journal of Urology</SO>
<YR>1978</YR>
<VL>50</VL>
<NO>4</NO>
<PG>250-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cody-2012" MODIFIED="2012-10-16 14:34:00 +0100" MODIFIED_BY="[Empty name]" NAME="Cody 2012" TYPE="COCHRANE_REVIEW">
<AU>Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA.</AU>
<TI>Oestrogen therapy for urinary incontinence in post-menopausal women.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-10-16 14:34:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-16 14:34:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001405.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cody-2012a" MODIFIED="2012-10-31 10:41:46 +0000" MODIFIED_BY="[Empty name]" NAME="Cody 2012a" TYPE="COCHRANE_REVIEW">
<AU>Cody JD, Nabi G, Dublin N, McClinton S, Neal DE, Pickard R, Yong SM</AU>
<TI>Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-10-31 10:41:46 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-16 14:40:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003306.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Groat-1997" MODIFIED="2012-10-31 10:48:13 +0000" MODIFIED_BY="[Empty name]" NAME="de Groat 1997" NOTES="&lt;p&gt;{108}&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 10:48:13 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>de Groat WC</AU>
<TI>A neurologic basis for the overactive bladder</TI>
<SO>Urology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6A Suppl</NO>
<PG>36-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98088155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dublin-2004" MODIFIED="2012-05-09 12:19:21 +0100" MODIFIED_BY="[Empty name]" NAME="Dublin 2004" NOTES="&lt;p&gt;Dublin N, Alhasso AA, Stewart L. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. (Protocol) &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2004, Issue 2. Art. No.: CD003190. DOI: 10.1002/14651858.CD003190.pub2.&lt;/p&gt;" NOTES_MODIFIED="2012-05-09 12:19:21 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_PROTOCOL">
<AU>Dublin N, Alhasso AA, Stewart L</AU>
<TI>Anticholinergic drugs versus other medications for overactive bladder syndrome in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-05-09 12:19:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-09 12:19:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003190.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dumoulin-2010" MODIFIED="2012-05-09 12:20:33 +0100" MODIFIED_BY="[Empty name]" NAME="Dumoulin 2010" NOTES="&lt;p&gt;Hay-Smith EJC, Dumoulin C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2006, Issue 1. Art. No.: CD005654. DOI: 10.1002/14651858.CD005654.&lt;/p&gt;" NOTES_MODIFIED="2012-05-09 12:20:33 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Dumoulin C, Hay-Smith J</AU>
<TI>Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-05-09 12:20:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-09 12:20:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005654.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duthie-2011" MODIFIED="2012-10-11 17:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Duthie 2011" TYPE="COCHRANE_REVIEW">
<AU>Duthie James B, Vincent M, Herbison GP, Wilson DI, Wilson D</AU>
<TI>Botulinum toxin injections for adults with overactive bladder syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2012-10-11 17:24:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005493.pub3"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD005493"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fall-1985" NAME="Fall 1985" TYPE="JOURNAL_ARTICLE">
<AU>Fall M</AU>
<TI>Electrical pelvic floor stimulation for control of detrusor instability</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>329-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gameiro-2012" MODIFIED="2012-10-31 11:39:26 +0000" MODIFIED_BY="[Empty name]" NAME="Gameiro 2012" TYPE="COCHRANE_PROTOCOL">
<AU>Gameiro LFO, El Dib RP, Gameiro MO, Amaro JL</AU>
<TI>Electrical stimulation with non-implanted electrodes for overactive bladder in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2012-10-31 11:39:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-31 11:39:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010098"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herbison-2009" MODIFIED="2012-10-11 17:25:22 +0100" MODIFIED_BY="[Empty name]" NAME="Herbison 2009" TYPE="COCHRANE_REVIEW">
<AU>Herbison GP, Arnold Edwin P</AU>
<TI>Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2012-10-11 17:24:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004202.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD004202"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-09 09:59:11 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmes-1983" NAME="Holmes 1983" TYPE="JOURNAL_ARTICLE">
<AU>Holmes DM, Stone AR, Bary PR et al</AU>
<TI>Bladder training - 3 years on</TI>
<SO>BJU International</SO>
<YR>1983</YR>
<VL>55</VL>
<PG>640-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hu-2003" NAME="Hu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hu Tw, Wagner TH, Bentkover JD, Leblanc K, Piancentini A, Stewart WF</AU>
<TI>Estimated economic costs of overactive bladder in the United States</TI>
<SO>Urology</SO>
<YR>2003</YR>
<VL>61</VL>
<PG>1123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kobelt-1997" NAME="Kobelt 1997" NOTES="&lt;p&gt;{5483}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kobelt G</AU>
<TI>Economic considerations and outcome measurement in urge incontinence</TI>
<SO>Urology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6A Suppl</NO>
<PG>100-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98088168"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Madhuvrata-2012" MODIFIED="2012-05-09 09:44:22 +0100" MODIFIED_BY="[Empty name]" NAME="Madhuvrata 2012" TYPE="COCHRANE_REVIEW">
<AU>Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJC</AU>
<TI>Which anticholinergic drug for overactive bladder symptoms in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-05-09 09:44:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-09 09:44:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005429.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Milsom-2001" MODIFIED="2012-10-31 10:44:45 +0000" MODIFIED_BY="[Empty name]" NAME="Milsom 2001" TYPE="JOURNAL_ARTICLE">
<AU>Milson I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ</AU>
<TI>How widespread are symptoms of an overactive bladder and how are they managed? A population based prevalence study</TI>
<SO>BJU International</SO>
<YR>2001</YR>
<VL>87</VL>
<PG>760</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nabi-2006" MODIFIED="2012-05-09 12:21:08 +0100" MODIFIED_BY="[Empty name]" NAME="Nabi 2006" NOTES="&lt;p&gt;Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2006, Issue 4. Art. No.: CD003781. DOI: 10.1002/14651858.CD003781.pub2.&lt;/p&gt;" NOTES_MODIFIED="2012-05-09 12:21:08 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Nabi G, Cody J, Ellis G, Herbison P, Hay-Smith J</AU>
<TI>Anticholinergic drugs versus placebo for overactive bladder syndrome in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-05-09 12:21:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-09 12:21:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003781.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ouslander-1982" NAME="Ouslander 1982" NOTES="&lt;p&gt;{113}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ouslander JG, Kane RL, Abrass IB</AU>
<TI>Urinary incontinence in elderly nursing home patients</TI>
<SO>JAMA</SO>
<YR>1982</YR>
<VL>248</VL>
<NO>10</NO>
<PG>1194-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82269350"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ouslander-1986" NAME="Ouslander 1986" NOTES="&lt;p&gt;{104}&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ouslander JG, Hepps K, Raz S, Su HL</AU>
<TI>Genitourinary dysfunction in a geriatric outpatient population</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1986</YR>
<VL>34</VL>
<NO>7</NO>
<PG>507-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86251890"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shaker-1998" NAME="Shaker 1998" TYPE="JOURNAL_ARTICLE">
<AU>Shaker HS, Hassouna M</AU>
<TI>Sacral nerve root neuromodulation: an effective treatment of refractory urge incontinence</TI>
<SO>Journal of Urology</SO>
<YR>1998</YR>
<VL>159</VL>
<PG>1516-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-2001" NAME="Stewart 2001" TYPE="JOURNAL_ARTICLE">
<AU>Stewart W, Herzog AR, Wein A, Abrams P, Payne C, Corey R et al</AU>
<TI>Prevalence and impact of overactive bladder in US: results from NOBLE program</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thuroff-1991" MODIFIED="2012-10-31 11:07:09 +0000" MODIFIED_BY="[Empty name]" NAME="Thuroff 1991" NOTES="&lt;p&gt;{1288}&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 11:07:09 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J et al</AU>
<TI>Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo</TI>
<SO>Journal of Urology</SO>
<YR>1991</YR>
<VL>145</VL>
<NO>4</NO>
<PG>813-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91171391"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Kerrebroeck-1998" MODIFIED="2012-10-31 10:52:18 +0000" MODIFIED_BY="[Empty name]" NAME="Van Kerrebroeck 1998" NOTES="&lt;p&gt;{8323}&lt;/p&gt;" NOTES_MODIFIED="2012-10-31 10:52:18 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Van Kerrebroeck PE, Amarenco G, Thuroff JW, Madersbacher HG, Lock MT, Messelink EJ et al</AU>
<TI>Dose-ranging study of tolterodine in patients with detrusor hyperreflexia</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>5</NO>
<PG>499-512</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98446908"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wallace-2004" MODIFIED="2012-10-16 14:32:31 +0100" MODIFIED_BY="[Empty name]" NAME="Wallace 2004" NOTES="&lt;p&gt;Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2004, Issue 1. Art. No.: CD001308. DOI: 10.1002/14651858.CD001308.pub2.&lt;/p&gt;" NOTES_MODIFIED="2012-10-16 14:32:31 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Wallace SA, Roe B, Williams K, Palmer M</AU>
<TI>Bladder training for urinary incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-10-16 14:32:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-16 14:32:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001308.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2012-05-09 12:34:16 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgio-1998">
<CHAR_METHODS MODIFIED="2012-04-15 18:09:35 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (double blinded between active drug and placebo)<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>n = 197<BR/>women<BR/>Inclusion: 55yrs of age or older, ambulatory, urge incontinence occurring at least twice per week for at least 3 months<BR/>Exclusion: continual leakage, postvoid residual urine volume more than 200mls, uterine prolapse past introitus, narrow-angle glaucoma, unstable angina, decompensated congestive heart failure, history of malignant arrhythmias or impaired mental status<BR/>mean age 67.7 (SD 7.5)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I - (65) behavioural treatment: Visit 1 - anorectal biofeedback used to help identify pelvic muscles and teach how to contract them while keeping abdominal muscles relaxed, Visit 2 - teach how to respond adaptively to the sensation of urgency ("urge strategies"), participants were encouraged to pause, sit down if possible, relax the entire body and contract pelvic muscles repeatedly to diminish urgency and inhibit detrusor contraction and prevent urine loss, when urgency subsides they proceed to the toilet at normal pace, Visit 3 - Pelvic muscle biofeedback was repeated for subjects who had not achieved at least 50% reduction in frequency of accidents as documented on bladder diaries. Combined bladder-sphincter biofeedback was used to teach patients how to contract pelvic muscles against increasing volumes of fluid and during detrusor contraction, Visit 4 - a review process "fine-tune" home practice and encourage persistence: this include 45 pelvic muscle exercises every day (15 exercises 3 times per day). Patients were advised to practice in various positions, including lying, sitting and standing and also during activities. Finally patients were instructed to practice interrupting or slowing urinary stream during voiding once per day<BR/>II - (67) oxybutynin (2.5mg tds)<BR/>III - (65) placebo<BR/>Duration: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 12:51:41 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers not cured (subjective): I: 44/63, II: 50/65<BR/>Numbers not improved (subjective): I: 6/63, II: 15/65<BR/>Incontinence episode/24hours - mean (SD): I: 0.40 (0.67), n = 63, II: 0.81 (1.40), n = 65</P>
<P>Adverse outcomes: dry mouth I: 23/63 (34.9%), II: 65/65 (96.9%), III: 36/62 (54.8%), inability to void I: 4/63 (6.3%), II: 14/65 (21.5%), III: 2/62 (3.2%), constipation I: 14/63 (22.2%), II: 25/65 (38.5%), III: 23/62 (37.1%), blurred vision I: 6/63 (9.5%), II: 10/65 (15.4%), III: 6/62 (9.7%), confusion I: 4/63 (6.3%), II: 5/65 (7.7%), III: 7/62 (11.3%)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:55:02 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID: 5719<BR/>Combination (behavioural) treatment versus anticholinergic (oxybutynin)<BR/>Full publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 12:52:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgio-2008">
<CHAR_METHODS MODIFIED="2012-10-31 11:27:44 +0000" MODIFIED_BY="[Empty name]">
<P>Two stage multicentre randomised controlled trial 9 university based clinical centres in the US</P>
<P>n = 307</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-06 11:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>Community dwelling women with urge-predominant incontinence. Most had symptoms of stress incontinence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Stage 1: drug therapy versus drug therapy + behavioural therapy for 10 weeks</P>
<P>Stage 2: discontinuation of both drug and behavioral training sessions at end of stage 1. Instructed participants receiving combination therapy to continue their behavioural program after discontinuation of drug therapy.</P>
<P>Participants were provided with a 2 month supply of the drug at no cost if they requested to resume drug therapy and did not have a urinary tract infection. Presented option of free drugs only after a patient requested to resume drug therapy. Follow-up at 8 months</P>
<P>Drug used - extended release tolterodine tartrate at a dose of 4 mg per day. If not well tolerated, the dose could be decreased to 2 mg or another antimuscarinic medication could be substituted</P>
<P>Behavioural therapy consisted of pelvic floor muscle training (using vaginal palpation); behavioural strategies to diminish urgency, suppress bladder contractions, and prevent both stress and urge incontinence; delayed voiding to increase voiding intervals for those who voided more than 8 times per day; and individualised fluid management for those with excessive urine output (&gt;70oz/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 12:52:32 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome at end of stage 2 (8 months) defined as not receiving drugs or any other therapy for urge incontinence and a 70% or greater reduction in frequency of incontinence episodes from baseline to end of stage 2 as recorded on the bladder diary</P>
<P>Numbers not cured after stage 2 (at 8 months): 75 versus 78</P>
<P>Numbers not improved after stage 2 (at 8 months): 43 versus 85<BR/>Numbers not improved end of stage 1 (10 weeks treatment): 16 versus 35</P>
<P>Secondary outcomes (urgency and voids/day) were described in a second paper</P>
<P>Improvement in score post-treatment - mean scores on the urgency severity scale decreased significantly from baseline to 10 weeks within both the drug alone and combined drug plus behavior groups, but the change between groups was not statistically significant, P = 0.30</P>
<P>Voids in 24 hours mean (SD) = 7.74 (2.45) n = 136 versus 6.94 (1.69) n = 133</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-06 11:14:51 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by grants from National Institute of Diabetes and Kidney Diseases, whose program staff were involved in the design and conduct of the study, analysis and interpretation of data, and preparation and review of manuscript. Additional support, including provision of study drugs and funding, was contributed by Pfizer, whose staff reviewed and commented on the manuscript but were not involved in other aspects of the research </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 12:54:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgio-2010">
<CHAR_METHODS MODIFIED="2011-10-28 16:37:06 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-31 15:54:44 +0000" MODIFIED_BY="[Empty name]">
<P>N = 64</P>
<P>Drug therapy = 32</P>
<P>Drug therapy plus behavioural therapy = 32</P>
<P>Community dwelling women with urge predominant incontinence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-31 11:51:52 +0000" MODIFIED_BY="[Empty name]">
<P>Drug therapy versus drug therapy plus behavioural therapy (PFMT and urge suppression techniques) for 8 weeks (4 visits). Follow up at 6 and 12 months</P>
<P>Drug used - extended-release oxybutynin (Individual dose titration between 5mg to 30mg)</P>
<P>Behavioural therapy - pelvic floor exercises and urge suppression techniques</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 12:54:18 +0000" MODIFIED_BY="[Empty name]">
<P>1) Not improved during treatment = 3/31 versus 6/28</P>
<P>2) Incontinence episode/24hours for 8 weeks - mean (SD) -0.40(0.93), N = 31 (drug therapy) versus mean (SD) -0.84 (2.14), n = 28 (drug therapy + behavioural therapy)</P>
<P>3) Number of micturitions/24hrs mean (SD) = 8.2 (1.9) versus 8.4 (3.0)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-28 16:37:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:23:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgio-2011">
<CHAR_METHODS MODIFIED="2012-11-05 13:22:36 +0000" MODIFIED_BY="[Empty name]">
<P>Two site randomised controlled trial </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:23:01 +0000" MODIFIED_BY="[Empty name]">
<P>143 community dwelling male veterans with over active bladder manifested by urgency and frequent urination, with or without urge incontinence </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 13:23:05 +0000" MODIFIED_BY="[Empty name]">
<P>Nurse practitioners implemented behavioural and drug therapies over period of 8 weeks. Behavioural consisted of pelvic floor muscle training, delayed voiding, monitoring with bladder diaries and urge suppression techniques</P>
<P>Drug group individually titrated extended release oxybutynin 5 to 30 mg/d </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Assessed at baseline and 2 weeks after the fourth and final treatment visit (8 weeks)</P>
<P>Primary outcome - post-treatment 24 hour voiding frequency measured according to 7 day bladder diary. Also measured nocturia, urgency, incontinence</P>
<P>Secondary outcomes - Global Perception of Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-10 10:12:20 +0100" MODIFIED_BY="[Empty name]">
<P>Notes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-31 15:55:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chancellor-2008">
<CHAR_METHODS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, open label, parallel-group, multicentre study</P>
<P>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-31 15:55:16 +0000" MODIFIED_BY="[Empty name]">
<P>n = 395 were randomised</P>
<P>darifenacin alone = 190<BR/>darifenacin plus behavioural modification programme (BMP) = 205</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Darifenacin treatment (with voluntary up-titration from 7.5 mg once daily to 15 mg once daily at week 2) alone versus combination with a Behavioural Modification Programme (BMP) for men and women with dry or wet OAB</P>
<P>BMP comprised a simple regimen for which training could be given in a primary physicians office, including timed voiding, dietary modifications and Kegel-type exercises, and was meant to reflect real life clinical practice. Complex regimens that would require a trained physical therapist were avoided as would not be practical in primary care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Change in the number (per day) of micturitions<BR/>Urge urinary incontinence (UUI) episodes</P>
<P>Urgency episodes</P>
<P>Pads used<BR/>Nocturnal voids</P>
<P>Health related quality of life (HRQoL)</P>
<P>Tolerability and safety assessments included adverse events and the number of discontinuations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-29 12:04:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-31 15:55:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collas-1994">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-31 15:55:34 +0000" MODIFIED_BY="[Empty name]">
<P>n = 57<BR/>mean age 82 (72-98 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I (28) - BT plus oxybutynin 2.5mg bd<BR/>II (29) - BT plus placebo<BR/>Duration: 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Numbers NOT improved during treatment: I: 6/28, II: 13/29</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Oxybutynin versus BT<BR/>Abstract form, no details on methodology<BR/>poor quality<BR/>Ref ID: {7039}</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:34:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colombo-1995">
<CHAR_METHODS>
<P>Randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:34:22 +0000" MODIFIED_BY="[Empty name]">
<P>n = 81 women, severe (socially embarrassing urge urinary incontinence)<BR/>Three patterns: detrusor instability, low compliance bladder and sensory bladder<BR/>Exclusion: stable bladder, neurological disease, detrusor hyper-reflexia, age &gt; 65yrs, coexisting GSI, genital prolapse, post-void residual &gt; 50mls, previous gynae or urogynae surgery, previous drug therapy for urge urinary incontinence, urethral diverticulae, fistulae, urinary tract neoplasm, bacterial or interstitial cystitis, calculi or previous radiotherapy<BR/>Mean age grp I 48yrs (31-65), mean age grp II 49yrs (24-65)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 12:10:48 +0100" MODIFIED_BY="[Empty name]">
<P>I - (14) oxybutynin orally 5 mgs tds<BR/>II - (13) Bladder training: bladder training consisted of 6 weeks education, by simple but full explanation of the problem. At start of programme the maximum interval between two micturitions was identified and the patients were encouraged to initially hold their urine until this interval plus 30min had elapsed. Afterwards the women were asked to progressively increase the interval by 30min every 4 or 5 days. The goal was to achieve a delay between voids by up to 3 or 4 hours<BR/>Duration: 6 weeks follow up at 6mths after end of study<BR/>Cure was defined as reporting of total disappearance of urge incontinence and did not require protective pads or further therapies<BR/>Clinical improvement was established when urge incontinence was subjectively less troublesome but the patient still wore protective pads and required further therapies<BR/>All other cases were regarded as clinical failures</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 12:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Numbers not cured during treatment: I: 1/14, II: 2/13<BR/>Numbes not cured after treatment (at 6 months follow up): I: 5/14, II: 0/13<BR/>Numbers not improved during treatment: I: 14/14, II:10/13</P>
<P>Adverse events: dry mouth, constipation, nausea, dizziness, decrease in visual acuity and tachycardia.<BR/>Numbers experiencing adverse events: I: 18/38, II: 2/39<BR/>Numbers withdrawn: I: 4/42, II: 2/39 (reasons for withdrawal: I: dry mouth x3, glaucoma x1, II: patient claimed treatment was time consuming) these cases we excluded from final analysis<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID {6056}<BR/>anticholinergic (oxybutynin) versus bladder training<BR/>not clear in cure definition what authors meant by not needing further therapies (e.g. no need for second line treatment)<BR/>Gave clinical results in subsets i.e. DI, low compliance and sensory urgency but not the same break down in cystometry results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 12:57:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaya-2011">
<CHAR_METHODS MODIFIED="2011-10-30 12:20:24 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 12:56:35 +0000" MODIFIED_BY="[Empty name]">
<P>N = 46</P>
<P>Women admitted to Dept of Obstetrics and Gynaecology with idiopathic detrusor overactivity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 12:57:02 +0000" MODIFIED_BY="[Empty name]">
<P>A: Trospium chloride 15mg three times a day (N = 14)</P>
<P>B: Physiotherapy (N = 15)</P>
<P>C: Trospium chloride 15mg three times a day + physiotherapy (N = 16)</P>
<P>Physiotherapy = bladder training + pelvic floor exercises + inferential therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Number of voids/day (mean (SD) = 8.9 (2.8) versus 6.7 (3.8) versus 6.9 (2.4)</P>
<P>Nocturia before treatment (mean (SD) = 2.9 (1.8) versus 2.7 (2.7) versus 2.8 (1.5)</P>
<P>Nocturia after treatment (mean (SD) = 2.1 (1.8) versus 0.4 (0.9) versus 1.1 (0.9)</P>
<P>Incontinence per day (mean (SD) = 1.5 (2.0) versus 0.1 (0.20) versus 0.5 (0.8)</P>
<P>QoL score (mean (SD) = 26.3 (19.5) versus 12.6 (15.1) versus 10.1 (12.2)</P>
<P>Adverse effect: dry mouth was the most reported side effect (7/31, 22.58%) in the pharmacotherapy and combined therapy groups,</P>
<P>1 patient in the pharmacotherapy group withdrew from the study because of visual impairment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-27 13:00:10 +0100" MODIFIED_BY="[Empty name]">
<P>Turkey</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:35:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macaulay-1988">
<CHAR_METHODS>
<P>Randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>n = 50<BR/>Inclusion: GSUI or DI at cystometry<BR/>Exclusion: &lt;20yrs, &gt;65yrs, previous psychiatric illness, serious medical or renal illness, patients unable to attend regular follow up</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I - 19 psychotherapy<BR/>II - 16 bladder retraining BR. participants reviewed fortnightly for three months and again after one month, reaching a total of 7 sessions: participants were asked to keep a bladder diary and then learn to urinate at predetermined intervals. The time intervals were gradually increased throughout the study period. Participants were also taught pelvic floor muscle training to enable them to control as far as possible any symptoms of urgency<BR/>III - 15 probantheline 15 mgs tds, oral<BR/>duration: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Numbers not cured during treatment: I: 13/18, II: 9/15, III: 6/14 (data obtained manually from graph)<BR/>Numbers not cured after treatment (at follow up): I: 12/18, II: 11/15, III: 3/14 (data obtained manually from graph)<BR/>Numbers not improved during treatment: I: 13/18, II: 13/15, III: 12/14 (data obtained manually from graph)<BR/>Numbers not cured after treatment (at follow up - period not less than 12 weeks and not over 20 weeks): I: 15/18, II: 12/15, III: 13/14 (data obtained manually from graph)</P>
<P>Number of micturitions/24hrs- mean (SEM): I: 9.5 (7.5-11.2), II: 6.8 (7.0-10.2), III: 8.3 (8.0-10.4). Bars represent SEM (data obtained manually from graph)<BR/>Frequency of sensation of urgency - mean (SEM): I: 1.0 (0.7-1.4), II: 0.7 (0.2-1.0), III: 0.3 (0.1-0.6), P&#8804;0.05. Bars represent SEM (data obtained manually from graph)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ref ID: 16286<BR/>MD thesis<BR/>Data estimated manually from graphs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattiasson-2003">
<CHAR_METHODS>
<P>Multicentre<BR/>RCT<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:35:53 +0000" MODIFIED_BY="[Empty name]">
<P>n = 501<BR/>Inclusion: women and men, &gt; 18yrs age,<BR/>urinary frequency &gt; 8 x day and urgency (with or without urge urinary incontinence)<BR/>Exclusion: any contraindication to antimuscarinics, electrotherapy or bladder training in last 3 months, catheterised patients or those using CISC, pregnancy or lactation, already on anticholinergic therapy or concomitant treatment for OAB (except oestrogen replacement included)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>I (244) Tolterodine 2mg bd with bladder retraining. mean age grp I 62 yrs (range 19-86)<BR/>II - (257) Tolterodine 2mg bd mean age group II 63 (range 22-86)<BR/>Duration: 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 13:36:09 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers not improved: I: 57/239, II: 73/250<BR/>Number of Incontinence episodes/day - median % change (Interqurtile range): I: -87 (-100, -20), II: -81 (-100, -41.8), P = 028<BR/>Number of micturitions/day - median % change (interquartile range): I: -33 (-42.3, 21.3), II: -25 (p38.8, -13.0), P&lt;0.001<BR/>Adverse events: I: 158/244, II: 177/257 (dry mouth, headache and constipation)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID {pending}<BR/>Tolterodine versus tolterodine + bladder training<BR/>Withdrawals not stated<BR/>No usable data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-12 12:08:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattiasson-2009">
<CHAR_METHODS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre, prospective, randomized, parallel-group, open label study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 12:59:26 +0000" MODIFIED_BY="[Empty name]">
<P>N = 643</P>
<P>Men or women over 18 with OAB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Flexible-dose solifenacin 5/10 mg (323 participants) versus solifenacin + simplified bladder training (320 participants)</P>
<P>At week 8, patients in both groups could request a dose increase to solifenacin 10 mg od for the remaining 8 weeks of the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-12 12:08:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>At 8 weeks using solifenacin 5 mg </B>
</P>
<P>Mean number of micturitions/24h after 8 weeks = 9.32 versus 8.60</P>
<P>Change from baseline in micturitions/24h from baseline = -2.18 versus -2.87</P>
<P>Change from baseline in urgency from baseline = -1.99 versus -1.98</P>
<P>Change from baseline in urge incontinence episodes from baseline = -1.01 versus -1.16</P>
<P>Change in number of pads/24 from baseline = -1.19 versus -1.07</P>
<P>Change in patient perception of bladder condition from baseline = -1.24 versus -1.23</P>
<P>Change in treatment satisfaction VAS from baseline = 3.32 versus 3.50</P>
<P>Change in I-QOL scores from baseline = 20.65 versus 19.68</P>
<P>
<B>At 16 weeks using solifenacin 5/10mg </B>
</P>
<P>Mean number of micturitions/24h after 8 weeks = 9.32 versus 8.60 (SD not given)</P>
<P>Change from baseline in micturitions/24h from baseline = -2.42 versus -3.11</P>
<P>Change from baseline in urgency from baseline = -2.20 versus -2.50</P>
<P>Change from baseline in urge incontinence episodes from baseline = -1.13 versus -1.38</P>
<P>Change in number of pads/24 from baseline = -1.29 versus -1.11</P>
<P>Change in patient perception of bladder condition from baseline = -1.58 versus -1.63</P>
<P>Change in treatment satisfaction VAS from baseline = 3.72 versus 4.18</P>
<P>Change in I-QOL scores from baseline = 24.51 versus 25.34</P>
<P>
<B>Adverse effects</B>
</P>
<P>solifenacin n = 323 versus solifenacin +simplified bladder training n = 320</P>
<P>Number experiencing adverse effects = 150 versus 149<BR/>Number withdrawing from treatment or trial arm = 19 versus 15</P>
<P>Number changing dose of treatment = 137 versus 125</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-04 10:52:17 +0100" MODIFIED_BY="[Empty name]">
<P>81 centres in 16 countries in Europe and Australia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-31 15:59:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Milani-1987">
<CHAR_METHODS>
<P>Randomised trial of idiopathic urge syndrome</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-31 15:59:06 +0000" MODIFIED_BY="[Empty name]">
<P>n = 81 women with idiopathic urge syndrome<BR/>Exclusions; women &gt;65, previous pelvic radiotherapy, pelvic masses or malignancy, urinary tract or renal pathology, central nervous system disease, 2nd or 3rd degree genital prolapse<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-31 11:52:43 +0000" MODIFIED_BY="[Empty name]">
<P>I - (37) bladder retraining BR<BR/>II - (38) oxybutynin 15mgs tds<BR/>Duration: 4 weeks for oxybutynin. 12 weeks for bladder re-training</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Numbers NOT cured during treatment: I: 10/37, II: 10/38<BR/>Numbers NOT improved during treatment: I: 30/37 II: 25/38<BR/>Numbers NOT cured after treatment: I: 13/37, II: 22/38<BR/>Adverse events: I: 0/37, II: 14/38 (dryness of mouth)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID {9033}<BR/>Oxybutynin versus bladder training<BR/>Abstract form</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:37:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Millard-2004">
<CHAR_METHODS>
<P>Multicentre<BR/>RCT<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:37:02 +0000" MODIFIED_BY="[Empty name]">
<P>n = 475<BR/>Females = 359<BR/>Males = 116<BR/>Age - mean [SD] (range): 53.4 (17.4), (18-90 years)<BR/>Inclusion: males and females<BR/>Urinary frequency &gt; 8 times per day, urgency and urge urinary incontinence occurring at least once a day and all symptoms present for at least 6 months<BR/>Exclusion: symptomatic GSI, significant residual volumes, neuropathy, glaucoma, UTI, positive urine culture</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I (252): tolterodine, 2mg bd, orally<BR/>II (223): tolterodine, 2mg bd, orally plus PFMT, 15 contractions in morning and afternoon and 20 contractions in evening<BR/>Duration of study: 24 weeks<BR/>PFMT programme consisted of a two-page instructions which included: How to identify the correct muscle, the exercise programme, how to use pelvic floor muscle contraction to avoid leakage, and having realistic expectations. Patients were expected to contract their muscles for 10sec with rest of 10sec in between in the morning and afternoon, with 20 contractions in the evening, the number of contractions to increase up to 25 as muscle strength increased</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 13:02:46 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers not improved during treatment: I: 36/252, II: 41/223<BR/>Number of incontinence episodes/day - mean (SD): I: 0.95 (1.9), II: 1.25 (2.7)<BR/>Number of micturitions/day - mean (SD): 9.20 (5.2), II: 9.29 (5.0)<BR/>Frequency of sensation of urgency/day - mean (SD): I: 1.5 (2.3), II: 2.1 (3.1)<BR/>Adverse events: 43/475 (headache, constipation, dizziness, dry mouth)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID {pending}<BR/>Tolterodine versus PFMT+tolterodine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:03:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozdedeli-2010">
<CHAR_METHODS MODIFIED="2011-10-29 15:38:35 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:03:12 +0000" MODIFIED_BY="[Empty name]">
<P>Females with OAB</P>
<P>N = 35</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Trospium hydrochloride 45mg versus intravaginal electrical stimulation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Frequency of sensation of urgency/day at 6th week - median (range) 2.7 (0-8.0) versus 1.7 (0-13.0)</P>
<P>Number of incontinence episodes/day at 6th weeks - 1 (0-5) versus 0.3 (0-9)</P>
<P>Number of micturitions/day at 6th week - 6 (3.3-14.7) versus 7 (0.6 -15)</P>
<P>IIQ-7 at 18th week - 51.2 (4.8-68.1) versus 4.8 (0-57.8)</P>
<P>BDI at 18th week - 10 (5-40) versus 9.0 (6-18)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2002">
<CHAR_METHODS>
<P>Randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 74<BR/>women with overactive bladder<BR/>No exclusion criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I (24): bladder training<BR/>II (24): tolterodine 2mg bd, orally<BR/>III (26): tolterodine 2 mg bd, orally + bladder training<BR/>Duration of study: 12 weeks</P>
<P>Bladder training consisted of explanation of pelvic anatomy and physiology, bladder inhibition by Kegal exercises whenever she feels urgency and bi-weekly phone calls from an expert nurse to confirm that patient is doing it well</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Numbers not improved during treatment: I: 12/24, II: 10/24, III: 8/26<BR/>Adverse events: I: 0/24, II: 6/24, III: 7/26</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID [pending]<BR/>tolterodine versus bladder training alone versus tolterodine + bladder training<BR/>Abstract form<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:04:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peters-2009">
<CHAR_METHODS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 100 ambulatory adults with OAB symptoms,with or without a history of previous anticholinergic drug use, with at least 8 voids per 24 hours documented by history and physical and voiding diary were randomised to 1:1 to 12 weeks of treatment with weekly percutaneous tibial nerve stimulation or to 4 mg daily extended-release tolterodine</P>
<P>Exclusion criteria<BR/>1) OAB pharmacotherapy within the previous month<BR/>2) primary complaint of stress urinary incontinence</P>
<P>3) demonstrated sensitivity to tolterodine or its ingredients<BR/>4) pacemakers or implantable defibrillators</P>
<P>5) excessive bleeding, urinary or gastric retention, nerve damage or neuropathy</P>
<P>6) uncontrolled narrow angle glaucoma</P>
<P>7) positive urinalysis for infection</P>
<P>8) pregnancy, or current pregnancy or planning to become pregnant during the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>A (44): percutaneous tibial nerve stimulation (50)</P>
<P>B (42): extended-release tolterodine 4mg (40) for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 13:04:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Participant observation </B>percutaneous tibial nerve stimulation (44) versus extended-release tolterodine 4mg (42) for 12 weeks</P>
<P>Cured total (%) - 1 (2.3) versus 2 (4.8)</P>
<P>Improved total (%) - 34 (77.3) versus 21 (50.0)</P>
<P>No improvement/worsening total (%) - 9 (20.5) versus 19 (45.2)<BR/>Cured or improved total (%) 35 (79.5) versus 23 (54.8)</P>
<P>
<B>Clinician observation </B>percutaneous tibial nerve stimulation(44) versus extended-release tolterodine 4mg (43) for 12 weeks</P>
<P>Cured total (%) - 2 (4.5) versus 2 (4.7)</P>
<P>Improved total (%) - 33 (75.0) versus 24 (55.8)</P>
<P>No improvement/worsening total (%) - 9 (20.5) versus 17 (39.5)<BR/>Cured or improved total (%) - 35 (79.5) versus 26 (60.5)</P>
<P>Voids/day No./Total No. (%) = 30/41 (73.2) versus 32/43 (74.4)<BR/>Nocturia No./Total No. (%) = 28/40 (70.0) versus 26/42 (61.0)<BR/>Urge incontinence No./Total No. (%) = 24/30 (80.0) versus 27/37 (73.0)<BR/>Moderate to severe urgency episodes/day No./Total No. (%) = 29/41 (70.7) versus 31/41 (75.6)<BR/>Voided vol (cc) No./Total No. (%) = 31/41 (75.6) versus 28/43 (65.1)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre: 11 centres in US</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:37:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1996">
<CHAR_METHODS>
<P>RCT<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:37:51 +0000" MODIFIED_BY="[Empty name]">
<P>n = 38 females<BR/>Age: 24-82 years<BR/>Inclusion: urinary incontinence<BR/>Exclusion: Type 3 stress incontinence; pregnancy suspected; history of prolonged urinary retention; vaginal vault prolapse; diminished sensory perception; cardiac pacemaker; mixed incontinence with major and minor component indistinguishable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I (20): probantheline, 7.5 mg - 45 mg bd - tds, orally<BR/>II (18): electrical stimulation, twice daily for 4 months, 12.5 and 5 MHz frequency: the intravaginal electric stimulation system was approved by FDA, electric pulse generator by a 9 volt alkaline battery with a 12.5 HZ and 50Hz frequency. Compliance monitored by a built-in digital readout on the number of hours used (patient not aware of it)<BR/>Duration of study: 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Numbers not cured during treatment: I: 10/20, II: 14/18<BR/>Numbers not improved during treatment: I: 10/20, II: 9/18<BR/>Numbers of pad changes/day - average (range): I: 8.1 (0-16), II: 6.5 (0-18)<BR/>Number of incontinence episodes/day - average (range): I: 1.7 (0-8), II: 1.4 (0-8)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID {2900}<BR/>Anticholinergic (probantheline) versus electric stimulation (intravaginal)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Song-2006">
<CHAR_METHODS MODIFIED="2011-10-29 17:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-31 15:59:31 +0000" MODIFIED_BY="[Empty name]">
<P>n = 139</P>
<P>Women with symptoms of urgency and frequency, with or without urge incontinence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Bladder training versus tolterodine 2 mg twice daily versus combination of bladder training and tolterodine 2mg twice daily treatment for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-13 10:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Bladder training (26) versus tolterodine 2 mg twice daily (32) versus combination (31)</B>
</P>
<P>Number not improved = 12 versus 12 versus 9</P>
<P>Number of voids per day N, mean (SD): 8.1 versus 8.1 versus 7.9</P>
<P>Nocturia before treatment = 1.5 versus 1.7 versus 1.2</P>
<P>Nocturia after treatment = 0.6 versus 0.6 versus 0.6</P>
<P>Number withdrawing from tolterodine versus combination treatment = 2/32 versus 2/31</P>
<P>
<B>Adverse effects: tolterodine total number (%) versus combination total number (%)</B>
<BR/>Dry mouth:7 (21.9%) versus 9 (28.9%)<BR/>Hesitancy: 3 (9.4%) versus 2 (6.5%)<BR/>Decreased appetite/constipation: 2 (6.3%) versus 2 (6.5%)<BR/>Headache: 1 (3.1%) versus 0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:38:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soomro-2001-_x0023_">
<CHAR_METHODS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, ITT, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:38:12 +0000" MODIFIED_BY="[Empty name]">
<P>n = 43<BR/>Age- mean 50 ± 15 years<BR/>Sex: F:M 30:13<BR/>Inclusion: patients with a history of frequency, urgency and urge incontinence who had not previously been treated at the department, including some who had previously received treatment from a general practitioner at least 6 months before<BR/>Exclusion: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I (43): oxybutynin, 2.5 mg BD, up to 5 mg TDS, orally<BR/>II (43): TENS, 20 HZ, 6 hours daily</P>
<P>After 6 weeks of treatment in the first arm, patients were re-assessed. Patients completed a post-treatment side effects questionnaire. After a washout period of 2 weeks, patients were started on the second arm of treatment, and the same assessment was repeated after 6 weeks of treatment<BR/>Total duration of study: 14 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Numbers not improved during treatment: I: 20/40, II: 20/38</P>
<P>Number of voids per day N, mean (SD): I 43, 9 (SD 5), II 43, 9 (SD 4), P&#8804;0.003 compared with baseline of 43, 11 (SD 5)</P>
<P>Number of incontinence episodes: "no statistical difference between treatment arms"</P>
<P>Number of micturitions per day: "statistically significant (p&lt; 0.0001)" compared with baseline</P>
<P>QoL: "No statistical difference found in any of the parameters of SF-36"</P>
<P>Adverse events: dry mouth, blurred vision, dry skin and skin irritation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID [ pending]<BR/>Oxybutynin versus electric stimulation (TENS)<BR/>Cross-over</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:38:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svihra-2002">
<CHAR_METHODS>
<P>Randomised trial<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>n = 28 females<BR/>Age, mean (range): 54 years (45-63)<BR/>Inclusion: overactive bladder<BR/>Exclusion: bladder neck obstruction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I - (9) SANS, neuromodulation: modified non-invasive SANS, using a surface electrode on the skin over the medial ankle and stimulated the tibial nerve with different values which cannot be set by the original SANS. Frequency of stimulation was 1Hz and duration of square impulse was 0.1ms. surface stimulation of 30min duration was repeated once a week for a period of 5 weeks<BR/>II - (10) oxybutynin orally 5mg tds<BR/>III - (9) control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Numbers not cured during treatment: I: 2/9, II: "comparable therapeutic results"<BR/>Numbers not improved during treatment: I: 7/9, II: "comparable therapeutic results"<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID: {15769}<BR/>Results vague: actual data for the oxybutynin arm are not available,and only mention "comparable therapeutic results"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:38:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Szonyi-1995">
<CHAR_METHODS>
<P>Randomized double blind<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:38:44 +0000" MODIFIED_BY="[Empty name]">
<P>n = 60<BR/>Mean age (SD) 82.19 (6.96), range 72-98 years<BR/>Inclusion: either sex, over 70, symptoms of urinary frequency, urgency and urge incontinence, mobile, able to attend opd, able to keep diary chart, willing to give consent<BR/>Exclusion: UTI at time of recruitment, severe hepatic or renal disease, glaucoma, uncontrolled diabetes, concomitant anticholinergics (imipramine/propantheline)<BR/>Patients in both groups well matched for age, sex (14:1 women:men), urodynamic characteristics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>I (30) placebo + BR<BR/>II (30) oxybutynin 2.5mg bd + BR<BR/>Duration: 57 days</P>
<P>Bladder training: patients were asked to delay micturition for as long as possible whenever they experience the need to pass urine and to try by this means to reduce their frequency</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 13:08:49 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers not cured during treatment: I: 25/28, II: 20/24<BR/>Numbers not improved during treatment: I: 16/28, II: 7/24<BR/>Adverse events: dry mouth, blurred vision, heartburn, constipation, dry skin.<BR/>Poor compliance: I: 20%, II: 20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID {2906}<BR/>anticholinergic (oxybutynin) + BR versus BR</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 13:09:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_METHODS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:09:08 +0000" MODIFIED_BY="[Empty name]">
<P>N = 68</P>
<P>Patients with OAB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Intravaginal electrical stimulation (24 participants) versus oxybutynin 2.5mg without dose titration (23 participants) versus placebo (21 participants). 12 weeks duration</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 13:09:30 +0000" MODIFIED_BY="[Empty name]">
<P>Number cured after treatment ES versus oxybutynin = 4 versus 2</P>
<P>Number improved after treatment ES versus oxybutynin = 10 versus 7</P>
<P>Number cured after treatment ES versus oxybutynin =10 versus 14</P>
<P>Number of micturitions/24 hrs = 7.8 versus 7.4</P>
<P>Frequency of urgency episodes after treatment = 1 versus 6</P>
<P>Mean urine volume after treatment = 355 versus 336</P>
<P>Number withdrawing due to dry mouth drug group = 3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-15 15:49:17 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-31 16:00:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wise-1993">
<CHAR_METHODS>
<P>Randomised not placebo controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-31 16:00:17 +0000" MODIFIED_BY="[Empty name]">
<P>n = 60 women with urodynamically proven detrusor instability</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-25 16:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>I - (32) oxybutynin 5mg bd<BR/>II - (28) intravaginal maximal electrical stimulation 20HZ frequency with variable current of 0-90mA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-03 19:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>Adverse events: I: 7/32, II: not specified<BR/>No usable data for interpretation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ref ID {12049}<BR/>Anticholinergic (oxybutynin) versus electric stimulation (intravaginal electric stimulation), no detailed methodology<BR/>few actual figures /data listed<BR/>no exclusion criteria<BR/>Abstract form</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BD: Bidaily, BR: Bladder retraining, BT: Bladder training; CISC: Clean Intermittent Self Catheterisation; DI: Detrusor Instability, BT: Bladder Training, CISC: Clean Intermittent Self Catheterisation, ER: Extended Relase, GSUI: Genuine Stress Urinary Incontinence, ITT: Intention to treat, OPD: Out Patient Department, PFMT: Pelvic Floor Muscle Training, PV: Prompted Voiding, QoL: Quality of Life, RCT: Randomised Controlled Trial, SANS: Sacral Afferent Nerve Stimulation, TENS: Trancutaneous Electrical Nerve Stimulation, TDS: Tridaily, UI: Urinary Incontinence, UTI: Urinary Tract Infection.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-10-31 11:59:58 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castleden-1986-_x0023_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>This is a dose escalation study and comparison against placebo only and there is no non-drug therapeutic arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Enzelsberger-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Emepronium bromide is a tricyclic antidepressant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gelber-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population: neuropathic bladder following stroke, with normal urodynamics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-03 23:23:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goode-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-03 23:23:52 +0100" MODIFIED_BY="[Empty name]">
<P>This was a part of BE-DRI study and the objective was find factors that influence patient satisfaction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henalla-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Terodiline withdrawn from worldwide market because of serious cardiotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henalla-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Terodiline withdrawn from worldwide market because of serious cardiotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jarvis-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>No good evidence of efficacy for flavoxate, and not recommended by WHO and is not in regular use anymore</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelleher-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Not electric stimulation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-31 11:59:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-31 11:59:58 +0000" MODIFIED_BY="[Empty name]">
<P>Objective of the study was to assess bladder training versus combination of propiverine + bladder training for urinary frequency not OAB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klarskov-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Terodiline withdrawn from worldwide market because of serious cardiotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klarskov-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Terodiline withdrawn from worldwide market because of serious cardiotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koonings-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Mixed urinary incontinence not relevant comparing surgery for SUI component versus surgery and anticholinergics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koonings-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Mixed urinary incontinence not relevant comparing surgery for sui component versus surgery and anticholinergics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Locher-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Not a treatment trial testing anticholinergics but "to assess the effects of age and patients' attribution of incontinence to aging on health-behaviours associated with incontinence"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-26 19:21:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacDiarmid-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-26 19:21:34 +0100" MODIFIED_BY="[Empty name]">
<P>Not compared with anticholinergics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Osman-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not OAB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ouslander-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Assessement of habit training in functionally impaired nursing home patients (dementia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ouslander-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Assessement of habit training in functionally impaired nursing home patients (dementia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ouslander-1995-_x0023_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prompted voiding is not bladder training and not part of our study protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pennisi-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Not RCT, only address urinary stress Incontinence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peters-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Not compared with anticholinergics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Visco-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing anticholinergics and Botilinum toxin. However study data is expected in mid-2012</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weil-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No anticholinergic arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weil-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No anticholinergic arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wise-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not confirmed to have been randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wiseman-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Terodiline withdrawn from worldwide market because of serious cardiotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wiseman-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Terodiline withdrawn from worldwide market because of serious cardiotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>OAB: Over Active Bladder</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-10-16 23:06:41 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-11-05 13:22:15 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-30 12:38:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>Randomization was performed with computer-generated random numbers using a block size of 6</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2008">
<DESCRIPTION>
<P>Randomisation was done at the coordinating centre through a web-based automated randomisation system. A permuted block randomisation schedule, stratified by type of incontinence (urge only versus mixed), the number of incontinence episodes per week: 7 to 13 per week versus more than 14 per week</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-27 10:54:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2010">
<DESCRIPTION>
<P>Stratified blocked randomisation, stratified by age, type of incontinence and severity of incontinence. Method of generation not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-10 10:14:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2011">
<DESCRIPTION>
<P>Stratified according to voiding frequency and presence or absence of incontinence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chancellor-2008">
<DESCRIPTION>
<P>Validated, computer-generated randomisation scheme used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:23:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collas-1994">
<DESCRIPTION>
<P>Unclear from the methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>Computer-generated random assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaya-2011">
<DESCRIPTION>
<P>Computer-generated block randomisation list created by a statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:24:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macaulay-1988">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mattiasson-2003">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattiasson-2009">
<DESCRIPTION>
<P>No mention in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:25:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milani-1987">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:25:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Millard-2004">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozdedeli-2010">
<DESCRIPTION>
<P>The researcher randomised each patient into one of the two groups by opening sealed envelopes. The randomisation list was generated by a blinded researcher (the third author) using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:25:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Park-2002">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-2009">
<DESCRIPTION>
<P>Random block design stratified, stratified by investigational site, generation sequence not mentioned. Randomised 1:1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:25:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1996">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-28 14:19:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Song-2006">
<DESCRIPTION>
<P>Paper states 'randomly assigned' no mention of how this was done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:26:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soomro-2001-_x0023_">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-30 19:40:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svihra-2002">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szonyi-1995">
<DESCRIPTION>
<P>The randomisation was achieved by allocating tablets in random permutations of blocks of four patients at a time</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>The allocation of the three groups was undertaken by sequentially opening of sealed envelope, prepared by the Biostatistics Center for Chang Gung Medical College in blocks of six</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-03 19:46:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wise-1993">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:23:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>Unclear from the methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-07 13:30:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2008">
<DESCRIPTION>
<P>Randomisation was done at the coordinating centre through a web-based automated randomisation system. Clinical site ensured concealment of the allocation sequence*</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2010">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2011">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chancellor-2008">
<DESCRIPTION>
<P>The randomisation scheme was reviewed by the sponsor's Quality Assurance group and locked after approval</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:23:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collas-1994">
<DESCRIPTION>
<P>Unclear from the methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:24:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>Unclear from the methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaya-2011">
<DESCRIPTION>
<P>No mention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:24:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macaulay-1988">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:24:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattiasson-2003">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattiasson-2009">
<DESCRIPTION>
<P>No mention in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:25:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milani-1987">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:25:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Millard-2004">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozdedeli-2010">
<DESCRIPTION>
<P>The randomisation results were kept in sealed envelopes, one for each patient</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:25:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Park-2002">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-30 19:14:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-2009">
<DESCRIPTION>
<P>Randomisation was done at investigational site, however no mention of allocation concealment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-30 19:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1996">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Song-2006">
<DESCRIPTION>
<P>No mention in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soomro-2001-_x0023_">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-30 19:40:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svihra-2002">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 20:26:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Szonyi-1995">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>The allocation of the three groups was undertaken by sequentially opening of sealed envelope, prepared by the Biostatistics Center for Chang Gung Medical College in blocks of six</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-03 19:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wise-1993">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-11-05 13:22:15 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-05 13:22:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P> Assignment to drug treatment or the placebo control condition was double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2008">
<DESCRIPTION>
<P>Open label, study staff who performed evaluations, but not participants and interventionists, were blinded to group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burgio-2010">
<DESCRIPTION>
<P>Questionnaires were completed by subjects before the visit and collected in a sealed envelope to ensure the nurse was blinded to these outcomes. Because participants were aware that behavioral treatment was provided in 1 study arm and they could potentially seek such treatment on their own, they were asked at each visit about any contact with other healthcare providers, new medications and hospitalisations</P>
<P>open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-10 10:14:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2011">
<DESCRIPTION>
<P>Research assistant blind to treatment group scored bladder diaries</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chancellor-2008">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-21 20:23:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collas-1994">
<DESCRIPTION>
<P>No mention in the publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 14:54:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>No mention in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 15:53:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaya-2011">
<DESCRIPTION>
<P>No mention in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 15:55:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macaulay-1988">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 17:55:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattiasson-2003">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mattiasson-2009">
<DESCRIPTION>
<P>Open label. Investigator or research nurse reviewed the bladder diaries with the patient to ensure accuracy of completion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 18:07:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milani-1987">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 18:18:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Millard-2004">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozdedeli-2010">
<DESCRIPTION>
<P>There was no complete blindness in the study, since stimulation was applied by a separate researcher, while examination and data collection were carried out by a different researcher</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 19:03:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Park-2002">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peters-2009">
<DESCRIPTION>
<P>Non-blinded, bladder diary analysed by a biostatistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 19:36:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1996">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Song-2006">
<DESCRIPTION>
<P>No blinding of participants or care providers, no mention of blinding of outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 19:39:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soomro-2001-_x0023_">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 20:54:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svihra-2002">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-30 21:15:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szonyi-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-09-04 10:07:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Physiotherpists conducted treatments unaware of the progress and outcome of the interventions. Patients receiving pharmacotherapy and investigators were unaware of regimen from central pharmacy whether active drug or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-07-03 19:47:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wise-1993">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-10-31 15:01:46 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-27 10:31:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>After 8 weeks 169 out of 197 participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 13:39:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burgio-2008">
<DESCRIPTION>
<P>220 out of 307 completed assessment at the end of 8 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burgio-2010">
<DESCRIPTION>
<P>31 out of 32 in drug group completed at 8 weeks compared with 27 out of 32 in the combined group</P>
<P>28 out of 32 in drug group completed at 6 months compared with 25 out of 32 in the combined group</P>
<P>28 out of 32 in drug group completed at 12 months compared with 22 out of 32 in the combined group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chancellor-2008">
<DESCRIPTION>
<P>173 out of 190 (91.1%) in drugs group completed compared with 175 out of 205 (85.4%). The proportion of patients discontinuing from the combination groups was higher (14.6% versus 8.9%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 14:50:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collas-1994">
<DESCRIPTION>
<P>No mention in the publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 15:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>The treatment was discontinued in 6 cases (4 in the drug group because of side effects and 2 in bladder training because the patient claimed it was time consuming</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 15:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaya-2011">
<DESCRIPTION>
<P>Only one patient in the pharmacotherapy group did not complete the study. All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 17:49:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macaulay-1988">
<DESCRIPTION>
<P>One patient from each group withdrew and all the outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 18:05:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mattiasson-2003">
<DESCRIPTION>
<P>391 patients (78%) completed 24 weeks of treatment, and completion rates were comparable for the two groups (tolterodine + BT, 77%; tolterodine alone, 79%). The main reasons for withdrawal were: adverse events (15%), lack of efficacy (3%), withdrawal of consent (2%), and protocol violations (1%). The two treatment groups were comparable in terms of the reasons for withdrawal, and 74% of patients in each treatment group were compliant in taking their medication throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mattiasson-2009">
<DESCRIPTION>
<P>"Full analysis set included all patients randomised at baseline who took one or more doses of study medication and who provided primary efficacy data at baseline and week 4 or 8". Safety population included all patients who took at least one dose of study medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Milani-1987">
<DESCRIPTION>
<P>6 patients discontinued from the study (4 in the drug group because of side effects and 2 in bladder training because the patient claimed it was time consuming)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Millard-2004">
<DESCRIPTION>
<P>In the Group I - 81.0 and 75.5% of subjects completed 12 and 24 weeks of treatment. The addition of pelvic floor exercises did not significantly impact continuation, with 79.7 and 71.4% completing 12 and 24 weeks (group II). Reasons for discontinuation were similar in both groups as follows; consent withdrawn and failure to take the medication 5.6%, protocol violation 5.2%, adverse event 9.4%. Only 1.9% discontinued due to lack of efficacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-31 15:01:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozdedeli-2010">
<DESCRIPTION>
<P>Two patients in Group 1 (one patient discontinued the study when all her complaints were resolved and one patient developed haematuria) and 2 patients in Group 2 (due to menorrhagia in 1 patient and vaginal pain after vaginal probe placement in 1 patient) could not complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 19:04:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Park-2002">
<DESCRIPTION>
<P>Overall discontinuation numbers not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peters-2009">
<DESCRIPTION>
<P>100 (50 in each group) adults were randomised. Of the patients who completed 12 weeks of therapy 41 receiving PTNS and 43 on tolterodine completed the voiding diary. Three patients in the drug group discontinued due to unsuccessful treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1996">
<DESCRIPTION>
<P>Only one patient did not complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-28 15:27:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Song-2006">
<DESCRIPTION>
<P>Bladder training group 26 out of 46 (56%) completed. Tolterodine 32 out of 47 (68%) completed. Combination therapy 31 out of 46 (67%) completed. Out of 139 patients 89 completed the 12 week regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-30 19:40:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soomro-2001-_x0023_">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-03 20:42:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svihra-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-23 22:00:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Szonyi-1995">
<DESCRIPTION>
<P>One patient in the placebo group and two randomised to active treatment failed to attend the first review and so no data were available for analysis. Not all patients kept the diary charts as requested, but diary data were available for analysis from 28 patients on placebo and 24 patients on active treatment. Five patients on placebo withdrew early , Eight patients on oxybutynin withdrew early</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 16:56:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>6 patients dropout from the study, however all three groups had similar number of patients. All pre-stated objectives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-03 19:47:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wise-1993">
<DESCRIPTION>
<P>No mention in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-06-28 14:10:08 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-04-15 17:17:12 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-11-06 13:03:45 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-10-17 00:11:38 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Anticholinergic drugs versus bladder training</NAME>
<DICH_OUTCOME CHI2="1.7460514838024492" CI_END="1.0433540663814624" CI_START="0.25593730332844267" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5167525773195877" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="42.727920151457496" I2_Q="34.347733687967335" ID="CMP-001.01" LOG_CI_END="0.01843171301106476" LOG_CI_START="-0.5918664102870769" LOG_EFFECT_SIZE="-0.2867173486380061" METHOD="MH" MODIFIED="2012-10-16 11:58:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1863739973939299" P_Q="0.2171398214822804" P_Z="0.06553695984733951" Q="1.5231766642254074" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.8415776015708993">
<NAME>Numbers not cured at end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3859632253318146" CI_START="0.024885072913900817" DF="0" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.14175170700930176" LOG_CI_START="-1.6040610824241417" LOG_EFFECT_SIZE="-0.7311546877074201" MODIFIED="2012-10-16 11:58:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10065541576826989" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="37.371134020618555" Z="1.6416844505981967">
<NAME>Oxybutinin</NAME>
<DICH_DATA CI_END="1.3859632253318146" CI_START="0.024885072913900817" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.14175170700930176" LOG_CI_START="-1.6040610824241417" LOG_EFFECT_SIZE="-0.7311546877074201" ORDER="89595" O_E="0.0" SE="1.0254990744258874" STUDY_ID="STD-Colombo-1995" TOTAL_1="14" TOTAL_2="13" VAR="1.0516483516483517" WEIGHT="37.371134020618555"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4859394513585593" CI_START="0.3433545567191083" DF="0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.1720011132760996" LOG_CI_START="-0.4642571846325756" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2012-10-12 14:13:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3679706415446836" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="62.628865979381445" Z="0.900281184551371">
<NAME>Probantheline 45mg daily</NAME>
<DICH_DATA CI_END="1.4859394513585593" CI_START="0.3433545567191083" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.1720011132760996" LOG_CI_START="-0.4642571846325756" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="89596" O_E="0.0" SE="0.3737412737209254" STUDY_ID="STD-Macaulay-1988" TOTAL_1="14" TOTAL_2="15" VAR="0.13968253968253969" WEIGHT="62.628865979381445"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.641188822717183" CI_END="2.2054717803555928" CI_START="0.1551149553170697" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5848945688437498" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="72.53644211579874" I2_Q="71.84279886880323" ID="CMP-001.02" LOG_CI_END="0.34350150522743716" LOG_CI_START="-0.8093463279210046" LOG_EFFECT_SIZE="-0.23292241134678368" METHOD="MH" MODIFIED="2012-10-17 00:11:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.056366867679759736" P_Q="0.05949217811952778" P_Z="0.4283689825880449" Q="3.5514893520153548" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6661899679544224" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="0.7919857665606383">
<NAME>Numbers not cured at follow up after treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7842845145282853" CI_START="0.4459431665774223" DF="0" EFFECT_SIZE="1.1142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.44471361196447273" LOG_CI_START="-0.3507204866120256" LOG_EFFECT_SIZE="0.04699656267622358" MODIFIED="2012-10-17 00:11:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.816848118596296" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="51.84643433263311" Z="0.2316007583970051">
<NAME>Oxybutinin</NAME>
<DICH_DATA CI_END="2.7842845145282853" CI_START="0.4459431665774223" EFFECT_SIZE="1.1142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.44471361196447273" LOG_CI_START="-0.3507204866120256" LOG_EFFECT_SIZE="0.04699656267622358" ORDER="89597" O_E="0.0" SE="0.4672419269661257" STUDY_ID="STD-Colombo-1995" TOTAL_1="14" TOTAL_2="13" VAR="0.21831501831501837" WEIGHT="51.84643433263311"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.833724784649333" CI_START="0.10241436430712042" DF="0" EFFECT_SIZE="0.29220779220779225" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.07897728777194966" LOG_CI_START="-0.989639126350289" LOG_EFFECT_SIZE="-0.5343082070611194" MODIFIED="2012-10-12 14:13:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.021452733547584802" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="48.153565667366884" Z="2.2999203395166243">
<NAME>Probantheline 45mg daily</NAME>
<DICH_DATA CI_END="0.8337247846493328" CI_START="0.10241436430712036" EFFECT_SIZE="0.2922077922077922" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.07897728777194978" LOG_CI_START="-0.9896391263502892" LOG_EFFECT_SIZE="-0.5343082070611194" ORDER="89598" O_E="0.0" SE="0.5349272718297191" STUDY_ID="STD-Macaulay-1988" TOTAL_1="14" TOTAL_2="15" VAR="0.28614718614718615" WEIGHT="48.153565667366884"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.765926270758353" CI_END="0.905833763722786" CI_START="0.6056556583840316" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7406911262827504" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="98" I2="11.320346100556971" I2_Q="23.984965740575106" ID="CMP-001.03" LOG_CI_END="-0.04295149561462932" LOG_CI_START="-0.21777422099421126" LOG_EFFECT_SIZE="-0.1303628583044203" METHOD="MH" MODIFIED="2012-10-12 14:14:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34303790000071865" P_Q="0.2614443645625394" P_Z="0.003466371081359154" Q="5.262116946956517" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="172" WEIGHT="100.00000000000003" Z="2.923035396497754">
<NAME>Numbers not improved at end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.014322552095962686" CI_END="0.8440072427620972" CI_START="0.29077378284575817" DF="1" EFFECT_SIZE="0.49539396315170525" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="29" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.0736538265045391" LOG_CI_START="-0.5364447535169259" LOG_EFFECT_SIZE="-0.3050492900107325" NO="1" P_CHI2="0.9047391300689575" P_Z="0.009771106708418553" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="57" WEIGHT="28.158295217211993" Z="2.583826030429275">
<NAME>Oxybutynin 5mg daily</NAME>
<DICH_DATA CI_END="1.0811650772314143" CI_START="0.2113507144137388" EFFECT_SIZE="0.47802197802197804" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.033892009084921106" LOG_CI_START="-0.6749962798178336" LOG_EFFECT_SIZE="-0.32055213536645627" ORDER="89599" O_E="0.0" SE="0.41640448995510143" STUDY_ID="STD-Collas-1994" TOTAL_1="28" TOTAL_2="29" VAR="0.1733926992547682" WEIGHT="13.058119655806268"/>
<DICH_DATA CI_END="1.029038548881445" CI_START="0.25317338587004284" EFFECT_SIZE="0.5104166666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.012431644201609564" LOG_CI_START="-0.5965819502237192" LOG_EFFECT_SIZE="-0.2920751530110548" ORDER="89600" O_E="0.0" SE="0.35773760003135047" STUDY_ID="STD-Szonyi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.12797619047619047" WEIGHT="15.100175561405727"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.533104662549071" CI_START="0.04755266876379176" DF="0" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.6563957463789577" LOG_CI_START="-1.3228251044497223" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2012-10-12 14:14:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5092889230575157" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="2.120549345814693" Z="0.6599453211661364">
<NAME>Oxybutynin 15mg daily</NAME>
<DICH_DATA CI_END="4.533104662549071" CI_START="0.04755266876379176" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6563957463789577" LOG_CI_START="-1.3228251044497223" LOG_EFFECT_SIZE="-0.33321467903538243" ORDER="89601" O_E="0.0" SE="1.162604125077987" STUDY_ID="STD-Colombo-1995" TOTAL_1="14" TOTAL_2="13" VAR="1.3516483516483517" WEIGHT="2.120549345814693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.070499368795925" CI_START="0.615017321110545" DF="0" EFFECT_SIZE="0.8114035087719298" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.0295864155552329" LOG_CI_START="-0.21111265275011293" LOG_EFFECT_SIZE="-0.09076311859744" MODIFIED="2012-10-12 14:14:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1393725705754371" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="37" WEIGHT="31.081194697226785" Z="1.4781315509692734">
<NAME>Oxybutynin 45mg daily</NAME>
<DICH_DATA CI_END="1.070499368795925" CI_START="0.615017321110545" EFFECT_SIZE="0.8114035087719298" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.0295864155552329" LOG_CI_START="-0.21111265275011293" LOG_EFFECT_SIZE="-0.09076311859744" ORDER="89602" O_E="0.0" SE="0.14138782420216423" STUDY_ID="STD-Milani-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.019990516832622096" WEIGHT="31.081194697226785"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3240864233557095" CI_START="0.738730281597126" DF="0" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.1219163325066771" LOG_CI_START="-0.13151409827021457" LOG_EFFECT_SIZE="-0.004798882881768708" MODIFIED="2012-10-12 14:14:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9408300929998126" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="12.83297966174064" Z="0.07422658427766111">
<NAME>Probantheline 45mg daily</NAME>
<DICH_DATA CI_END="1.3240864233557095" CI_START="0.738730281597126" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.1219163325066771" LOG_CI_START="-0.13151409827021457" LOG_EFFECT_SIZE="-0.004798882881768708" ORDER="89603" O_E="0.0" SE="0.14886628953921083" STUDY_ID="STD-Macaulay-1988" TOTAL_1="14" TOTAL_2="15" VAR="0.022161172161172152" WEIGHT="12.83297966174064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.003256949405536156" CI_END="1.2706034057332598" CI_START="0.5323053183627401" DF="1" EFFECT_SIZE="0.8224043715846996" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="0.10401001508642961" LOG_CI_START="-0.27383919468756407" LOG_EFFECT_SIZE="-0.08491458980056724" MODIFIED="2012-10-12 14:14:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9544897138742102" P_Z="0.3783551864674519" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="50" WEIGHT="25.806981078005904" Z="0.8809309823389707">
<NAME>Tolterodine 4mg daily</NAME>
<DICH_DATA CI_END="1.4957784030382886" CI_START="0.4413462907734612" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.17486725832383243" LOG_CI_START="-0.35522051902200846" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2011-10-30 15:33:18 +0000" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.31137618438976383" STUDY_ID="STD-Song-2006" TOTAL_1="32" TOTAL_2="26" VAR="0.0969551282051282" WEIGHT="13.538088434363754"/>
<DICH_DATA CI_END="1.5487892172461395" CI_START="0.4483789251059079" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.18999231639329406" LOG_CI_START="-0.3483548084885437" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="89604" O_E="0.0" SE="0.316227766016838" STUDY_ID="STD-Park-2002" TOTAL_1="24" TOTAL_2="24" VAR="0.10000000000000003" WEIGHT="12.268892643642152"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-02 14:39:55 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not improved at follow up after treatment (subjective)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-02 14:41:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Numbers with nocturia at end of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-02 14:42:07 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Numbers with nocturia at follow up after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-09-23 20:40:02 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of pad changes per 24hrs</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2012-04-14 12:49:23 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinence episodes per 24 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2012-04-14 12:49:32 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean weight of urine loss on pad test</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.08225300632771224" CI_END="2.4517682093125246" CI_START="-2.8660708702612143" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20715133047434472" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2012-10-04 15:47:41 +0100" MODIFIED_BY="[Empty name]" NO="10" NOTES="&lt;p&gt;wrong sds from included in last published review Macualey&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;recalculated correct sds with Jonathan&lt;/p&gt;&lt;p&gt;entered Song data calculated by Jonathan&lt;/p&gt;" NOTES_MODIFIED="2012-10-04 15:47:41 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.7742671205726428" P_Q="0.7742671205726429" P_Z="0.8786371940620468" Q="0.08225300632771218" RANDOM="NO" SCALE="26.35085429133134" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="41" UNITS="" WEIGHT="100.0" Z="0.1526970414124734">
<NAME>Number of micturitions per 24 hours</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.446884328067579E-35" CI_END="3.4876099111759364" CI_START="-3.2876099111759336" DF="0" EFFECT_SIZE="0.10000000000000141" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.10.01" MODIFIED="2012-09-24 14:44:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.9538626636365275" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="61.606083690706804" Z="0.05785683818181188">
<NAME>Probantheline 45mg daily</NAME>
<CONT_DATA CI_END="3.4876099111759364" CI_START="-3.2876099111759336" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="8.2" MODIFIED="2012-09-24 14:44:10 +0100" MODIFIED_BY="[Empty name]" ORDER="89605" SD_1="4.3" SD_2="5.0" SE="1.7284041634932936" STUDY_ID="STD-Macaulay-1988" TOTAL_1="14" TOTAL_2="15" WEIGHT="61.606083690706804"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5713942262216807E-33" CI_END="3.591152892826174" CI_START="-4.991152892826174" DF="0" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-001.10.02" MODIFIED="2012-10-04 15:41:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.7491792927003195" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="26" WEIGHT="38.39391630929319" Z="0.3197217212818648">
<NAME>Tolterodine</NAME>
<CONT_DATA CI_END="3.591152892826174" CI_START="-4.991152892826174" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-2.8" MODIFIED="2012-10-04 15:41:10 +0100" MODIFIED_BY="[Empty name]" ORDER="90" SD_1="9.71" SD_2="6.93" SE="2.1894039516410713" STUDY_ID="STD-Song-2006" TOTAL_1="32" TOTAL_2="26" WEIGHT="38.39391630929319"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2012-10-04 15:46:38 +0100" MODIFIED_BY="[Empty name]" NO="11" NOTES="&lt;p&gt;deleted Macauley 1988 not freq of sensation data&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;deleted Song not data on sensation of urgency&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;sds still wrong for Macauley  reclculated sds with Jonathan&lt;/p&gt;" NOTES_MODIFIED="2012-10-04 15:46:38 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Frequency of sensation of urgency</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-14 12:50:10 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not cured within first year (objective)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-14 12:50:19 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not cured after first year (objective)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-14 12:50:28 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Number not cured after 5 years (objective)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-14 12:50:39 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urodynamic diagnosed detrusor overactivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2012-04-14 12:50:47 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>General health status (SF-36)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2012-04-14 12:50:54 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Condition-specific health measures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-14 12:51:01 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Socioeconomic measures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7186121043333296" CI_END="41.8674547099631" CI_START="5.022373687361653" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="14.500827662313773" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="1.621876559195071" LOG_CI_START="0.7009090230565937" LOG_EFFECT_SIZE="1.1613927911258324" METHOD="MH" MODIFIED="2012-10-05 15:10:21 +0100" MODIFIED_BY="[Empty name]" NO="19" NOTES="&lt;p&gt;changed lable on graph, wrongly labled.  Changed headings on data&lt;/p&gt;" NOTES_MODIFIED="2012-10-05 15:10:21 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.8688177314446835" P_Q="0.7314727152183892" P_Z="7.682943825451638E-7" Q="0.6253908386693169" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="126" WEIGHT="100.0" Z="4.9432535962240856">
<NAME>Numbers experiencing adverse events</NAME>
<GROUP_LABEL_1>Antichol</GROUP_LABEL_1>
<GROUP_LABEL_2>BT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="37.11727349096995" CI_START="2.2986400684392723" DF="0" EFFECT_SIZE="9.236842105263158" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="1.5695760669187044" LOG_CI_START="0.3614709727793236" LOG_EFFECT_SIZE="0.9655235198490139" MODIFIED="2012-08-08 11:10:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.001731322396580431" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="55.913187419532825" Z="3.132825669406678">
<NAME>Oxybutynin 15mg daily</NAME>
<DICH_DATA CI_END="37.11727349096995" CI_START="2.2986400684392723" EFFECT_SIZE="9.236842105263158" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="1.5695760669187044" LOG_CI_START="0.3614709727793236" LOG_EFFECT_SIZE="0.9655235198490139" ORDER="89607" O_E="0.0" SE="0.7096469125141359" STUDY_ID="STD-Colombo-1995" TOTAL_1="38" TOTAL_2="39" VAR="0.5035987404408457" WEIGHT="55.913187419532825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="457.0940883981389" CI_START="1.7467404213793332" DF="0" EFFECT_SIZE="28.256410256410255" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="2.660005604591301" LOG_CI_START="0.2422283703872333" LOG_EFFECT_SIZE="1.451116987489267" MODIFIED="2012-08-08 11:10:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.01863829480939739" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="37" WEIGHT="14.346146772116974" Z="2.352687412717337">
<NAME>Oxybutynin 45mg daily</NAME>
<DICH_DATA CI_END="457.0940883981389" CI_START="1.7467404213793332" EFFECT_SIZE="28.256410256410255" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.660005604591301" LOG_CI_START="0.2422283703872333" LOG_EFFECT_SIZE="1.451116987489267" ORDER="89608" O_E="0.0" SE="1.4202143155617992" STUDY_ID="STD-Milani-1987" TOTAL_1="38" TOTAL_2="37" VAR="2.01700870212667" WEIGHT="14.346146772116974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0706771684482361" CI_END="129.6990768914012" CI_START="2.432440294352557" DF="1" EFFECT_SIZE="17.76190476190476" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="2.112936885086414" LOG_CI_START="0.38604218906312265" LOG_EFFECT_SIZE="1.2494895370747683" MODIFIED="2012-08-08 11:10:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7903533691149947" P_Z="0.0045646376561714426" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="50" WEIGHT="29.740665808350194" Z="2.8362522594639326">
<NAME>Tolterodine 4mg daily</NAME>
<DICH_DATA CI_END="218.64841056423586" CI_START="0.7729303842817103" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.339746324645931" LOG_CI_START="-0.11185962003225755" LOG_EFFECT_SIZE="1.1139433523068367" ORDER="89609" O_E="0.0" SE="1.4400854675491153" STUDY_ID="STD-Park-2002" TOTAL_1="24" TOTAL_2="24" VAR="2.0738461538461537" WEIGHT="14.162221813500091"/>
<DICH_DATA CI_END="354.8290913686849" CI_START="1.375333298012325" EFFECT_SIZE="22.09090909090909" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.5500192191161597" LOG_CI_START="0.13840795776401474" LOG_EFFECT_SIZE="1.3442135884400872" MODIFIED="2012-04-14 19:53:25 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="1.4165923925865218" STUDY_ID="STD-Song-2006" TOTAL_1="32" TOTAL_2="26" VAR="2.0067340067340065" WEIGHT="15.578443994850101"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.023638622578464358" CI_END="8.496808789753505" CI_START="0.46249594868148175" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9823570924488354" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.9292558450990932" LOG_CI_START="-0.3348920671908579" LOG_EFFECT_SIZE="0.2971818889541176" METHOD="MH" MODIFIED="2012-10-05 15:12:17 +0100" MODIFIED_BY="[Empty name]" NO="20" NOTES="&lt;p&gt;relabled graphs&lt;/p&gt;" NOTES_MODIFIED="2012-10-05 15:12:17 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.8778080025267092" P_Q="0.8779775158874307" P_Z="0.35678148592693826" Q="0.023572564263406596" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="65" WEIGHT="99.99999999999999" Z="0.921515265017588">
<NAME>Numbers withdrawing from treatment</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bladder training</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.578357959214605" CI_START="0.36008046541200067" DF="0" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.9812910633191091" LOG_CI_START="-0.4436004387339491" LOG_EFFECT_SIZE="0.26884531229257996" NO="1" P_CHI2="1.0" P_Z="0.45954082885088343" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="79.04022582921664" Z="0.7396031610079169">
<NAME>Oxybutynin 15mg daily</NAME>
<DICH_DATA CI_END="9.578357959214602" CI_START="0.3600804654120007" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.981291063319109" LOG_CI_START="-0.44360043873394905" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="89610" O_E="0.0" SE="0.836988321632656" STUDY_ID="STD-Colombo-1995" TOTAL_1="42" TOTAL_2="39" VAR="0.7005494505494505" WEIGHT="79.04022582921664"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="57.85149323598522" CI_START="0.10414240067846972" DF="0" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="1.7623145732407337" LOG_CI_START="-0.982372415239209" LOG_EFFECT_SIZE="0.3899710790007623" MODIFIED="2012-04-14 19:56:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5775603190614631" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="26" WEIGHT="20.959774170783344" Z="0.5569518659590527">
<NAME>Tolterodine 4mg daily</NAME>
<DICH_DATA CI_END="57.85149323598522" CI_START="0.10414240067846968" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7623145732407337" LOG_CI_START="-0.9823724152392092" LOG_EFFECT_SIZE="0.3899710790007623" MODIFIED="2012-04-14 19:56:44 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="1.6122427234528303" STUDY_ID="STD-Song-2006" TOTAL_1="32" TOTAL_2="26" VAR="2.599326599326599" WEIGHT="20.959774170783344"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-14 12:51:16 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Numbers changing dose of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-14 12:51:24 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other outcomes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-04-14 13:04:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Anticholinergic drugs versus pelvic floor muscle training alone</NAME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-10-17 00:11:20 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;deleted Soomro data, cross over study so end of study data cannot be combined with parallel group data&lt;/p&gt;" NOTES_MODIFIED="2012-10-17 00:11:20 +0100" NOTES_MODIFIED_BY="[Empty name]">
<NAME>Anticholinergic drugs versus external electrostimulation</NAME>
<DICH_OUTCOME CHI2="4.74214728563371" CI_END="1.051422789293402" CI_START="0.8431543921715827" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9415475255248821" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" I2="57.82501302608248" I2_Q="46.1462756081245" ID="CMP-003.01" LOG_CI_END="0.021777385995236924" LOG_CI_START="-0.07409289331263502" LOG_EFFECT_SIZE="-0.026157753658699053" METHOD="MH" MODIFIED="2012-10-08 11:39:57 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;added subgroups.  Reversed comparison   tx appears first&lt;/p&gt;" NOTES_MODIFIED="2012-10-08 11:39:57 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.09338064059328022" P_Q="0.15615889843488628" P_Z="0.2848291946374787" Q="3.7137635745425333" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="86" WEIGHT="100.0" Z="1.0695338630000493">
<NAME>Numbers not cured at end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostim</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours electrostim</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3637707219625637" CI_START="0.8802459730715139" DF="0" EFFECT_SIZE="1.0956521739130434" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.13474136258127367" LOG_CI_START="-0.05539595305337134" LOG_EFFECT_SIZE="0.039672704763951176" MODIFIED="2012-10-05 15:27:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4134117915349451" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="25.650808558095854" Z="0.8179043892262332">
<NAME>Oxybutinin 2.5 mg tds vs Intravaginal stimulation</NAME>
<DICH_DATA CI_END="1.3637707219625637" CI_START="0.8802459730715138" EFFECT_SIZE="1.0956521739130434" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.13474136258127367" LOG_CI_START="-0.055395953053371395" LOG_EFFECT_SIZE="0.039672704763951176" MODIFIED="2012-10-05 15:27:53 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.1116876003986823" STUDY_ID="STD-Wang-2006" TOTAL_1="23" TOTAL_2="24" VAR="0.012474120082815739" WEIGHT="25.650808558095854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.063118413364541" CI_START="0.38872932772799335" DF="0" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.026581640258659084" LOG_CI_START="-0.4103526927364854" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2012-10-05 15:28:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08516221237177224" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="19.31147829659848" Z="1.7214885266842357">
<NAME>Probantheline vs Intravaginal stimulation</NAME>
<DICH_DATA CI_END="1.063118413364541" CI_START="0.38872932772799335" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.026581640258659084" LOG_CI_START="-0.4103526927364854" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2012-10-05 15:28:52 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.2566573900611784" STUDY_ID="STD-Smith-1996" TOTAL_1="20" TOTAL_2="18" VAR="0.06587301587301587" WEIGHT="19.31147829659848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0570283093477872" CI_START="0.898469264285094" DF="0" EFFECT_SIZE="0.9745293466223699" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.02408661874441001" LOG_CI_START="-0.046496775071084344" LOG_EFFECT_SIZE="-0.01120507816333716" MODIFIED="2012-10-05 15:29:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5337534423478385" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="44" WEIGHT="55.037713145305666" Z="0.6222865877349205">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<DICH_DATA CI_END="1.0570283093477875" CI_START="0.8984692642850939" EFFECT_SIZE="0.9745293466223699" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.024086618744410104" LOG_CI_START="-0.0464967750710844" LOG_EFFECT_SIZE="-0.01120507816333716" MODIFIED="2012-10-05 15:29:40 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.04146103492065577" STUDY_ID="STD-Peters-2009" TOTAL_1="42" TOTAL_2="44" VAR="0.001719017416691837" WEIGHT="55.037713145305666"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-15 13:49:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.278558177015458" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not cured at end of treatment (objective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="42" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-12 11:33:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<DICH_DATA CI_END="1.0954555341361865" CI_START="0.9108415228748414" EFFECT_SIZE="0.9988925802879292" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="42" LOG_CI_END="0.039594753716700334" LOG_CI_START="-0.04055717925982846" LOG_EFFECT_SIZE="-4.81212771564051E-4" MODIFIED="2012-10-05 15:34:12 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.04708164218888009" STUDY_ID="STD-Peters-2009" TOTAL_1="43" TOTAL_2="44" VAR="0.0022166810312017338" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5760526214466228" CI_END="2.3350840976837994" CI_START="1.154370258504482" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6418135197009898" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.3683025262307473" LOG_CI_START="0.062345128953613015" LOG_EFFECT_SIZE="0.21532382759218013" METHOD="MH" MODIFIED="2012-10-08 11:31:56 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;re labled graphs re entered data on correct side&lt;/p&gt;" NOTES_MODIFIED="2012-10-08 11:31:56 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.45474158774155626" P_Q="0.4741466717746068" P_Z="0.005802643037331479" Q="1.4924775692250167" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="86" WEIGHT="100.0" Z="2.758730142495726">
<NAME>Numbers not improved end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>electric stimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours electrostim</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5980292949563415" CI_START="0.8214456591084409" DF="0" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.41464404379865544" LOG_CI_START="-0.08542116105415308" LOG_EFFECT_SIZE="0.16461144137225117" MODIFIED="2012-10-05 15:36:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19692509990433835" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="34.890089996416485" Z="1.2903617104405578">
<NAME>Oxybutinin 2.5 mg tds vs Intravaginal stimulation</NAME>
<DICH_DATA CI_END="2.5980292949563415" CI_START="0.8214456591084409" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.41464404379865544" LOG_CI_START="-0.08542116105415308" LOG_EFFECT_SIZE="0.16461144137225117" MODIFIED="2012-10-05 15:36:39 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.29374077669322585" STUDY_ID="STD-Wang-2006" TOTAL_1="23" TOTAL_2="24" VAR="0.08628364389233956" WEIGHT="34.890089996416485"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2824470876732814" CI_START="0.7404333748313877" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.35840071838689497" LOG_CI_START="-0.13051401377322142" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2012-10-05 15:37:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.36095155351835606" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="33.77232967616515" Z="0.9135534362503995">
<NAME>Probantheline vs Intravaginal stimulation</NAME>
<DICH_DATA CI_END="2.2824470876732814" CI_START="0.7404333748313877" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.35840071838689497" LOG_CI_START="-0.13051401377322142" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2012-10-05 15:37:03 +0100" MODIFIED_BY="[Empty name]" ORDER="89613" O_E="0.0" SE="0.28719093383780847" STUDY_ID="STD-Smith-1996" TOTAL_1="20" TOTAL_2="18" VAR="0.08247863247863249" WEIGHT="33.77232967616515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.326396050849309" CI_START="1.1305836008203054" DF="0" EFFECT_SIZE="2.2116402116402116" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.6361262735000571" LOG_CI_START="0.05330268170352507" LOG_EFFECT_SIZE="0.344714477601791" MODIFIED="2012-10-08 11:31:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.020424079457851806" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="44" WEIGHT="31.337580327418365" Z="2.3184646968955103">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<DICH_DATA CI_END="4.326396050849309" CI_START="1.1305836008203054" EFFECT_SIZE="2.2116402116402116" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6361262735000571" LOG_CI_START="0.05330268170352507" LOG_EFFECT_SIZE="0.344714477601791" MODIFIED="2012-10-06 11:39:26 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.34235346284459134" STUDY_ID="STD-Peters-2009" TOTAL_1="42" TOTAL_2="44" VAR="0.11720589352168298" WEIGHT="31.337580327418365"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-15 13:55:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="39.45910215288513" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not improved end of treatment treatment (objective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="9" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-12 11:34:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<DICH_DATA CI_END="3.8536393464405068" CI_START="0.9694160329142528" EFFECT_SIZE="1.9328165374677002" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.5858710675638923" LOG_CI_START="-0.013489801872792395" LOG_EFFECT_SIZE="0.28619063284554996" MODIFIED="2012-10-08 11:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.35206754159126163" STUDY_ID="STD-Peters-2009" TOTAL_1="43" TOTAL_2="44" VAR="0.12395155384211473" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-16 11:59:12 +0100" MODIFIED_BY="[Empty name]" NO="5" NOTES="&lt;p&gt;re labled graph re entered data&lt;/p&gt;" NOTES_MODIFIED="2012-10-16 11:59:12 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Nocturia</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="28" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-12 11:35:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<DICH_DATA CI_END="1.2083568185795865" CI_START="0.6472273157016346" EFFECT_SIZE="0.8843537414965986" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" LOG_CI_END="0.0821951970814764" LOG_CI_START="-0.18894316196415503" LOG_EFFECT_SIZE="-0.05337398244133934" MODIFIED="2012-10-05 15:42:22 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.15926801425992718" STUDY_ID="STD-Peters-2009" TOTAL_1="42" TOTAL_2="40" VAR="0.025366300366300366" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2012-10-15 14:14:27 +0100" MODIFIED_BY="[Empty name]" NO="6" NOTES="&lt;p&gt;deleted Soomro data, cross over trial cannot use end of treatment data&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;re labled graph reentered data on opposite side&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 14:14:27 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="9.035468764532398" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of micturitions per day</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.01" MODIFIED="2012-10-05 15:45:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<CONT_DATA CI_END="1.5605692492796166" CI_START="-1.3605692492796173" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="9.8" MODIFIED="2012-10-05 15:45:32 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="3.8" SD_2="3.0" SE="0.7452020857527999" STUDY_ID="STD-Peters-2009" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.07" MODIFIED="2012-04-15 11:23:45 +0100" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of pad changes per day-IVS</NAME>
<TR>
<TH>
<P>Anticholinergic</P>
</TH>
<TH>
<P>Electric stimulation</P>
</TH>
</TR>
<OTHER_DATA ORDER="30" STUDY_ID="STD-Smith-1996">
<TR>
<TD>
<P>8.1, range 0-16</P>
</TD>
<TD>
<P>6.5, range 0-18</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2012-10-15 14:14:40 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.084144381106293" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Sensation of urgency</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours electrostimulatio</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.01" MODIFIED="2012-10-12 11:36:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<CONT_DATA CI_END="1.9756306565054662" CI_START="-0.775630656505466" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.9" MODIFIED="2012-10-05 15:48:47 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="3.6" SD_2="2.8" SE="0.701865272707185" STUDY_ID="STD-Peters-2009" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2012-10-15 14:14:51 +0100" MODIFIED_BY="[Empty name]" NO="9" NOTES="&lt;p&gt;re labled graphs re entered data&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 14:14:51 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.058745765915829" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinence episodes per day</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticholinergi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours electrostimulatio</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.09.01" MODIFIED="2012-10-12 11:36:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<CONT_DATA CI_END="1.493425158463062" CI_START="-0.29342515846306183" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.2" MODIFIED="2012-10-05 15:50:20 +0100" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="2.5" SD_2="1.6" SE="0.4558375386028955" STUDY_ID="STD-Peters-2009" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.10" MODIFIED="2012-10-08 11:13:51 +0100" MODIFIED_BY="[Empty name]" NO="10" NOTES="&lt;p&gt;swapped headings antich first exp group&lt;/p&gt;" NOTES_MODIFIED="2012-10-08 11:13:51 +0100" NOTES_MODIFIED_BY="[Empty name]" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of micturitions per day</NAME>
<TR>
<TH>
<P>Trospium hydrochloride 45mg Median (Range)</P>
</TH>
<TH>
<P>Intravaginal Electrical Stimulation Median (Range)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-10-08 11:07:59 +0100" MODIFIED_BY="[Empty name]" ORDER="33" STUDY_ID="STD-Ozdedeli-2010">
<TR>
<TD>
<P>6 (3.3-14.7) week 6 (17 participants)</P>
</TD>
<TD>
<P>7 (0.6-15) week 6 (18 participants)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.11" MODIFIED="2012-10-08 11:13:24 +0100" MODIFIED_BY="[Empty name]" NO="11" NOTES="&lt;p&gt;swapped headings anticol first exp group&lt;/p&gt;" NOTES_MODIFIED="2012-10-08 11:13:24 +0100" NOTES_MODIFIED_BY="[Empty name]" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Sensation of urgency</NAME>
<TR>
<TH>
<P>Trospium hydrochloride 45mg Median (Range)</P>
</TH>
<TH>
<P>Intravaginal Electrical Stimulation Median (Range)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-10-08 11:12:29 +0100" MODIFIED_BY="[Empty name]" ORDER="34" STUDY_ID="STD-Ozdedeli-2010">
<TR>
<TD>
<P>2.7 (0-8) week 6 (17 participants)</P>
</TD>
<TD>
<P>1.7 (0-13) week 6 (18 Participants)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.12" MODIFIED="2012-10-08 11:19:21 +0100" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of incontinence episodes per day</NAME>
<TR>
<TH>
<P>Trospium hydrochloride 45mg Median (Range)</P>
</TH>
<TH>
<P>Intravaginal Electrical Stimulation Median (Range)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2012-10-08 11:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="35" STUDY_ID="STD-Ozdedeli-2010">
<TR>
<TD>
<P>1 (0-5) week 6 (17 participants)</P>
</TD>
<TD>
<P>1 (0-5) 0.3 (0-9) week 6 (18 participants)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-17 00:11:20 +0100" MODIFIED_BY="[Empty name]" NO="13" NOTES="&lt;p&gt;antich first, labled graph&lt;/p&gt;" NOTES_MODIFIED="2012-10-17 00:11:20 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Numbers experiencing adverse events</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostim</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours electrostim</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-003.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-17 00:11:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Trospium HCl versus intravaginal electrical stimulation</NAME>
<DICH_DATA CI_END="4.164754037329588" CI_START="0.6891246340963683" EFFECT_SIZE="1.6941176470588235" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6195893578713166" LOG_CI_START="-0.1617022251094028" LOG_EFFECT_SIZE="0.22894356638095692" MODIFIED="2012-10-08 11:22:12 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.45893454329858385" STUDY_ID="STD-Ozdedeli-2010" TOTAL_1="17" TOTAL_2="18" VAR="0.21062091503267974" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9648710795512027E-4" CI_END="17.795338944517326" CI_START="0.47998398086724736" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9225806451612906" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="1.2503062643450165" LOG_CI_START="-0.31877325665993556" LOG_EFFECT_SIZE="0.4657665038425404" METHOD="MH" MODIFIED="2012-10-15 14:16:53 +0100" MODIFIED_BY="[Empty name]" NO="14" NOTES="&lt;p&gt;added sub groups swapped lables on data and graphs re entered data&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 14:16:53 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.9841135853351565" P_Q="0.9841172788322549" P_Z="0.2445887000005489" Q="3.96302743227818E-4" RANDOM="NO" SCALE="262.1679935185305" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="74" WEIGHT="100.0" Z="1.1635937637524427">
<NAME>Numbers withdrawing from treatment</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostim</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours electrostim</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.918681763942033" CI_START="0.3210427904067218" DF="0" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-003.14.01" LOG_CI_END="1.4136129093434457" LOG_CI_START="-0.4934370785016816" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2012-10-08 11:35:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.34429780449036695" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="67.09677419354838" Z="0.9457075060376149">
<NAME>Oxybutinin 2.5 mg tds vs Intravaginal stimulation</NAME>
<DICH_DATA CI_END="25.918681763942033" CI_START="0.3210427904067218" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4136129093434457" LOG_CI_START="-0.4934370785016816" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2012-10-08 11:35:43 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="1.1202106029099148" STUDY_ID="STD-Wang-2006" TOTAL_1="26" TOTAL_2="25" VAR="1.2548717948717947" WEIGHT="67.09677419354838"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.8891116541987" CI_START="0.12519281144120745" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.14.02" LOG_CI_END="1.8566631169949925" LOG_CI_START="-0.9024206075556673" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-10-08 11:36:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4978585246623114" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="32.903225806451616" Z="0.6778630653271643">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<DICH_DATA CI_END="71.8891116541987" CI_START="0.12519281144120745" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8566631169949925" LOG_CI_START="-0.9024206075556673" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-10-08 11:36:09 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="1.6206994374857624" STUDY_ID="STD-Peters-2009" TOTAL_1="49" TOTAL_2="49" VAR="2.6266666666666665" WEIGHT="32.903225806451616"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.15" MODIFIED="2012-10-15 14:18:22 +0100" MODIFIED_BY="[Empty name]" NO="15" NOTES="&lt;p&gt;deleted Q of l data for Ozedeli wrong number of participants cannot see where data came from in paper IIQ ranges given no sds&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Dta entered wrongly, data under Ozdedeli is data for Peters&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 14:18:22 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrostimulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours electrostimualtio</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.15.01" MODIFIED="2012-10-12 11:37:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>E R Tolterodine 4mg vs PTNS</NAME>
<CONT_DATA CI_END="5.667741231836844" CI_START="-12.067741231836843" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="25.3" MODIFIED="2012-10-08 14:44:41 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="20.7" SD_2="21.5" SE="4.5244409090087645" STUDY_ID="STD-Peters-2009" TOTAL_1="43" TOTAL_2="44" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Anticholinergic drugs versus surgery</NAME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-10-12 11:41:50 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Anticholinergic drugs in combination with non-drug therapies versus non-drug therapies alone</NAME>
<DICH_OUTCOME CHI2="1.2362289944915805E-30" CI_END="1.1632045857640545" CI_START="0.7488889931936775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9333333333333335" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="100.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.06565610566085192" LOG_CI_START="-0.12558255241573815" LOG_EFFECT_SIZE="-0.029963223377443157" METHOD="MH" MODIFIED="2012-10-02 14:46:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.5391008195941334" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.6141732981309397">
<NAME>Numbers not cured end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic + BT</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol+BT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2362289944915805E-30" CI_END="1.1632045857640545" CI_START="0.7488889931936775" DF="0" EFFECT_SIZE="0.9333333333333335" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="100.0" ID="CMP-005.01.01" LOG_CI_END="0.06565610566085192" LOG_CI_START="-0.12558255241573815" LOG_EFFECT_SIZE="-0.029963223377443157" MODIFIED="2012-04-15 12:15:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5391008195941334" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.6141732981309397">
<NAME>Oxybutynin 5mg daily +Bladder Training vs. Bladder Training</NAME>
<DICH_DATA CI_END="1.1632045857640543" CI_START="0.7488889931936773" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.06565610566085184" LOG_CI_START="-0.1255825524157383" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="89618" O_E="0.0" SE="0.1123345344008138" STUDY_ID="STD-Szonyi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.01261904761904762" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.29845075394594967" CI_END="0.8757553172730878" CI_START="0.3765263184068891" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5742342078264694" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.057617217121488644" LOG_CI_START="-0.4242046621208885" LOG_EFFECT_SIZE="-0.24091093962118856" METHOD="MH" MODIFIED="2012-10-02 14:47:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8613749724371529" P_Q="0.5873071245328014" P_Z="0.009993150860649176" Q="0.2945695236141449" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="79" WEIGHT="100.0" Z="2.5760662105599725">
<NAME>Numbers not improved end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic + BT</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol+BT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0019100424007522845" CI_END="1.0177400449242007" CI_START="0.3805822623351205" DF="1" EFFECT_SIZE="0.6223614775725594" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.0076368629987410164" LOG_CI_START="-0.41955145658890997" LOG_EFFECT_SIZE="-0.2059572967950845" MODIFIED="2012-04-15 18:52:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.96514033380596" P_Z="0.05877303811261082" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="50" WEIGHT="66.65689579363917" Z="1.889887272485535">
<NAME>Tolterodine 4mg daily +Bladder Training vs.Bladder Training</NAME>
<DICH_DATA CI_END="1.2414398373839837" CI_START="0.3050475854311881" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.0939256776358455" LOG_CI_START="-0.5156324082656318" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="89619" O_E="0.0" SE="0.35805743701971643" STUDY_ID="STD-Park-2002" TOTAL_1="26" TOTAL_2="24" VAR="0.1282051282051282" WEIGHT="32.580976110215445"/>
<DICH_DATA CI_END="1.2533696178540497" CI_START="0.31569425016317865" EFFECT_SIZE="0.6290322580645161" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.09807916303169058" LOG_CI_START="-0.5007333279752" LOG_EFFECT_SIZE="-0.20132708247175468" MODIFIED="2012-04-15 18:52:30 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.3517454213870835" STUDY_ID="STD-Song-2006" TOTAL_1="31" TOTAL_2="26" VAR="0.12372484146677692" WEIGHT="34.07591968342371"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0811650772314143" CI_START="0.21135071441373873" DF="0" EFFECT_SIZE="0.47802197802197804" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.033892009084921106" LOG_CI_START="-0.6749962798178337" LOG_EFFECT_SIZE="-0.32055213536645627" MODIFIED="2012-08-08 11:11:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07630298862914853" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="33.34310420636084" Z="1.7725518965988971">
<NAME>Oxybutynin 5mg daily + Bladder Training vs. Bladder Training</NAME>
<DICH_DATA CI_END="1.0811650772314143" CI_START="0.2113507144137388" EFFECT_SIZE="0.47802197802197804" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.033892009084921106" LOG_CI_START="-0.6749962798178336" LOG_EFFECT_SIZE="-0.32055213536645627" ORDER="89620" O_E="0.0" SE="0.41640448995510143" STUDY_ID="STD-Szonyi-1995" TOTAL_1="28" TOTAL_2="29" VAR="0.1733926992547682" WEIGHT="33.34310420636084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-005.03" MODIFIED="2012-04-15 12:16:38 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Number of micturitions per day</NAME>
<TR>
<TH>
<P>Antichol. + BT</P>
</TH>
<TH>
<P>BT ALONE</P>
</TH>
<TH>
<P>Average SD</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.03.01" NO="1" STUDIES="1">
<NAME>percentage change from baseline</NAME>
<OTHER_DATA ORDER="44" STUDY_ID="STD-Park-2002">
<TR>
<TD>
<P>30.3%</P>
</TD>
<TD>
<P>32.6%</P>
</TD>
<TD>
<P>27.1%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.04" MODIFIED="2012-10-12 11:41:50 +0100" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Sensation of urgency</NAME>
<TR>
<TH>
<P>Antichol + BT</P>
</TH>
<TH>
<P>Antichol. + BT</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.04.01" MODIFIED="2012-10-12 11:41:50 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>percentage change from baseline</NAME>
<OTHER_DATA MODIFIED="2012-10-12 11:41:50 +0100" MODIFIED_BY="[Empty name]" ORDER="45" STUDY_ID="STD-Park-2002">
<TR>
<TD>
<P>63.2%</P>
</TD>
<TD>
<P>48.4%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.043487565182893026" CI_END="127.09459907098906" CI_START="2.428896393984905" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="17.569849554805035" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="2.104127095451693" LOG_CI_START="0.385408990111722" LOG_EFFECT_SIZE="1.2447680427817074" METHOD="MH" MODIFIED="2012-04-15 12:24:58 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8348100395426237" P_Q="1.0" P_Z="0.004525842761151788" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="50" WEIGHT="100.0" Z="2.838976939125192">
<NAME>Numbers experiencing adverse events</NAME>
<GROUP_LABEL_1>Anticholinergic + BT</GROUP_LABEL_1>
<GROUP_LABEL_2>Bladder training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antichol +BT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.043487565182893026" CI_END="127.09459907098906" CI_START="2.428896393984905" DF="1" EFFECT_SIZE="17.569849554805035" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="2.104127095451693" LOG_CI_START="0.385408990111722" LOG_EFFECT_SIZE="1.2447680427817074" MODIFIED="2012-04-15 12:24:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8348100395426237" P_Z="0.004525842761151788" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="50" WEIGHT="100.0" Z="2.838976939125192">
<NAME>Tolterodine 4mg daily +Bladder Training vs.Bladder Training</NAME>
<DICH_DATA CI_END="230.81965990164778" CI_START="0.8357227224496236" EFFECT_SIZE="13.88888888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.363272796785137" LOG_CI_START="-0.07793778964767359" LOG_EFFECT_SIZE="1.1426675035687315" ORDER="89621" O_E="0.0" SE="1.433979182657927" STUDY_ID="STD-Park-2002" TOTAL_1="26" TOTAL_2="24" VAR="2.056296296296296" WEIGHT="48.91003991403132"/>
<DICH_DATA CI_END="339.9807872628986" CI_START="1.3087395103842567" EFFECT_SIZE="21.09375" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.5314543752144156" LOG_CI_START="0.11685321380782242" LOG_EFFECT_SIZE="1.324153794511119" MODIFIED="2012-04-15 12:24:58 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="1.4183486746787486" STUDY_ID="STD-Song-2006" TOTAL_1="31" TOTAL_2="26" VAR="2.011712962962963" WEIGHT="51.089960085968684"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-11-06 13:03:45 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Anticholinergic drugs in combination with non-drug therapies versus anticholinergic drugs alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="78" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-06 13:03:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="154" TOTAL_2="153" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not cured at follow up after treatment (objective)</NAME>
<GROUP_LABEL_1>Antichol. + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Antichol.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="78" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-11 14:31:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="153" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic and behavioural modification therapy vs. Anticholinergic</NAME>
<DICH_DATA CI_END="1.1957833426176503" CI_START="0.7631716728603872" EFFECT_SIZE="0.9552947052947053" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="78" LOG_CI_END="0.0776524993604117" LOG_CI_START="-0.11737775799570098" LOG_EFFECT_SIZE="-0.019862629317644626" MODIFIED="2012-04-03 21:28:09 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.11456173858632451" STUDY_ID="STD-Burgio-2008" TOTAL_1="154" TOTAL_2="153" VAR="0.013124391947921355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.391050841734053" CI_END="1.0384987907226906" CI_START="0.6991372381421357" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8520875403148491" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="169" I2="56.10589339412647" I2_Q="68.68947245934335" ID="CMP-006.02" LOG_CI_END="0.01640599515829332" LOG_CI_START="-0.1554375654307902" LOG_EFFECT_SIZE="-0.06951578513624845" METHOD="MH" MODIFIED="2012-10-12 15:02:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04415488369136389" P_Q="0.04101519443340251" P_Z="0.11280138807646749" Q="6.387627922918271" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="700" TOTAL_2="741" WEIGHT="300.0" Z="1.5857263985570267">
<NAME>Numbers not improved end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Antichol. + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Antichol.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug+behav</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours drug alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07108243597978914" CI_END="1.0387659025767917" CI_START="0.6202570079684175" DF="2" EFFECT_SIZE="0.8026841413108231" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="95" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.016517685503101693" LOG_CI_START="-0.20742832015560106" LOG_EFFECT_SIZE="-0.0954553173262497" MODIFIED="2012-10-11 14:49:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9650829550895167" P_Z="0.09475326409402762" STUDIES="3" TAU2="0.0" TOTAL_1="296" TOTAL_2="306" WEIGHT="100.0" Z="1.6708401075696633">
<NAME>Tolterodine + Bladder training vs. Tolterodine</NAME>
<DICH_DATA CI_END="1.099889268619587" CI_START="0.6065117819748449" EFFECT_SIZE="0.8167593282512753" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="73" LOG_CI_END="0.041348964750826785" LOG_CI_START="-0.21716075819895592" LOG_EFFECT_SIZE="-0.08790589672406458" ORDER="89624" O_E="0.0" SE="0.15184989090446877" STUDY_ID="STD-Mattiasson-2003" TOTAL_1="239" TOTAL_2="250" VAR="0.023058389367699064" WEIGHT="76.26360835415878"/>
<DICH_DATA CI_END="1.5570854533968455" CI_START="0.35022191145471987" EFFECT_SIZE="0.7384615384615385" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.19231244745593862" LOG_CI_START="-0.45565668599047526" LOG_EFFECT_SIZE="-0.13167211926726832" ORDER="89625" O_E="0.0" SE="0.38062027648536395" STUDY_ID="STD-Park-2002" TOTAL_1="26" TOTAL_2="24" VAR="0.14487179487179488" WEIGHT="11.114982708944517"/>
<DICH_DATA CI_END="1.5734681355336417" CI_START="0.380926462270509" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.19685795239570855" LOG_CI_START="-0.41915885664104185" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-10-30 15:32:44 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.36185132296057093" STUDY_ID="STD-Song-2006" TOTAL_1="31" TOTAL_2="32" VAR="0.1309363799283154" WEIGHT="12.621408936896705"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.938868349830952" CI_START="0.8542908328786883" DF="0" EFFECT_SIZE="1.2869955156950672" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="36" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.28754832125868507" LOG_CI_START="-0.06839425388702179" LOG_EFFECT_SIZE="0.10957703368583163" MODIFIED="2012-10-11 14:42:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.22752805160932787" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="252" WEIGHT="100.0" Z="1.2067510579145884">
<NAME>Tolterodine + PFMT vs. Tolterodine</NAME>
<DICH_DATA CI_END="1.938868349830952" CI_START="0.8542908328786882" EFFECT_SIZE="1.2869955156950672" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="36" LOG_CI_END="0.28754832125868507" LOG_CI_START="-0.06839425388702185" LOG_EFFECT_SIZE="0.10957703368583163" ORDER="89626" O_E="0.0" SE="0.20908243058475146" STUDY_ID="STD-Millard-2004" TOTAL_1="223" TOTAL_2="252" VAR="0.04371546277922741" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.967987491050381" CI_END="0.9512084775115247" CI_START="0.3617049501254457" DF="1" EFFECT_SIZE="0.5865635642598398" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="38" I2="79.87112484076384" ID="CMP-006.02.03" LOG_CI_END="-0.02172428778374149" LOG_CI_START="-0.4416455476457481" LOG_EFFECT_SIZE="-0.23168491771474475" MODIFIED="2012-09-24 15:20:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.025820833220275063" P_Z="0.03055977464329343" STUDIES="2" TAU2="0.0" TOTAL_1="181" TOTAL_2="183" WEIGHT="100.0" Z="2.162758297263868">
<NAME>Anticholinergic and behavioural modification therapy vs. Anticholinergic</NAME>
<DICH_DATA CI_END="0.7852614140157473" CI_START="0.2626824382775877" EFFECT_SIZE="0.4541743970315399" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.10498574227994578" LOG_CI_START="-0.5805689611464846" LOG_EFFECT_SIZE="-0.3427773517132151" MODIFIED="2012-04-03 21:43:52 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.27935993693710587" STUDY_ID="STD-Burgio-2008" TOTAL_1="154" TOTAL_2="153" VAR="0.07804197436550377" WEIGHT="92.51212748082638"/>
<DICH_DATA CI_END="8.030031154126434" CI_START="0.6149753979971319" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9047172302150386" LOG_CI_START="-0.211142257765726" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2012-09-24 15:20:02 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.65546138683345" STUDY_ID="STD-Burgio-2010" TOTAL_1="27" TOTAL_2="30" VAR="0.42962962962962964" WEIGHT="7.487872519173614"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2012-10-15 15:01:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.1089406376032045" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="211" TOTAL_2="199" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Numbers with nocturia end of treatment</NAME>
<GROUP_LABEL_1>Antichol. + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Anticholinergic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AcH+NDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AcH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.03.01" MODIFIED="2012-10-11 14:46:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="195" TOTAL_2="185" WEIGHT="0.0" Z="0.0">
<NAME>Darifenacin and behavioural modification therapy vs. Darifenacin</NAME>
<CONT_DATA CI_END="0.2286129660568054" CI_START="-0.2686129660568054" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="-0.65" MODIFIED="2012-04-15 14:05:26 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="1.21" SD_2="1.26" SE="0.12684568084813433" STUDY_ID="STD-Chancellor-2008" TOTAL_1="195" TOTAL_2="185" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.03.02" MODIFIED="2012-10-11 14:47:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Trospium chloride + Inferential current therapy + pelvic floor exercises + Bladder training vs. Trospium chloride</NAME>
<CONT_DATA CI_END="0.04091170608873762" CI_START="-2.0409117060887376" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.1" MODIFIED="2012-04-15 14:33:36 +0100" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="0.9" SD_2="1.8" SE="0.5310871599168742" STUDY_ID="STD-Kaya-2011" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.707113729973809" CI_END="-0.21189230497515926" CI_START="-0.8753734982279184" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5436329016015389" ESTIMABLE="YES" I2="57.29092485709382" I2_Q="40.47285898857178" ID="CMP-006.04" MODIFIED="2012-10-15 15:01:56 +0100" MODIFIED_BY="[Empty name]" NO="4" NOTES="&lt;p&gt;Burgio 2010 changed denominator to 30 one person did not provide valid bladder diart at 8 weeks&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 15:01:56 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.039029059899464036" P_Q="0.16891198721795575" P_Z="0.001318833913672704" Q="5.039717932067408" RANDOM="YES" SCALE="6.000897357573361" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.16318427672640368" TOTALS="SUB" TOTAL_1="891" TOTAL_2="921" UNITS="" WEIGHT="400.0" Z="3.211849616192847">
<NAME>Number of micturitions per 24 hours</NAME>
<GROUP_LABEL_1>Antichol. + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Antichol.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug+behav</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours drug alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.27457604096626387" CI_START="-1.105423959033736" DF="0" EFFECT_SIZE="-0.69" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.01" MODIFIED="2012-10-11 15:05:14 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;changed demoniator for Matti 2009&lt;/p&gt;" NOTES_MODIFIED="2012-10-11 15:05:14 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="1.0" P_Z="0.001132289316742553" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="305" WEIGHT="100.00000000000001" Z="3.255409612094166">
<NAME>Solifenacin + Bladder training vs. Solifenacin</NAME>
<CONT_DATA CI_END="-0.27457604096626387" CI_START="-1.105423959033736" EFFECT_SIZE="-0.69" ESTIMABLE="YES" MEAN_1="-2.87" MEAN_2="-2.18" MODIFIED="2012-09-24 15:26:17 +0100" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="2.6" SD_2="2.6" SE="0.2119548942279283" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="297" TOTAL_2="305" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9680694132132014" CI_START="-0.8680694132132" DF="0" EFFECT_SIZE="0.05000000000000071" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.02" MODIFIED="2012-10-11 14:48:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9149922498034634" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="252" WEIGHT="100.0" Z="0.10674377973667037">
<NAME>Tolterodine + PFMT vs. Tolterodine</NAME>
<CONT_DATA CI_END="0.9680694132132014" CI_START="-0.8680694132132" EFFECT_SIZE="0.05000000000000071" ESTIMABLE="YES" MEAN_1="9.25" MEAN_2="9.2" ORDER="89628" SD_1="5.0" SD_2="5.2" SE="0.46841136901229563" STUDY_ID="STD-Millard-2004" TOTAL_1="223" TOTAL_2="252" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.473160695646271" CI_END="0.5020474521087652" CI_START="-0.979347595470659" DF="2" EFFECT_SIZE="-0.2386500716809469" ESTIMABLE="YES" I2="69.10319248917823" ID="CMP-006.04.03" MODIFIED="2012-09-24 15:22:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03929811431903607" P_Z="0.5277180131060456" STUDIES="3" TAU2="0.2783048318881071" TOTAL_1="355" TOTAL_2="350" WEIGHT="100.0" Z="0.6314933294354494">
<NAME>Anticholinergic and behavioural modification therapy vs. Anticholinergic</NAME>
<CONT_DATA CI_END="-0.2979642428746052" CI_START="-1.3020357571253944" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="6.94" MEAN_2="7.74" MODIFIED="2012-08-29 11:12:14 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="1.69" SD_2="2.45" SE="0.25614539914273354" STUDY_ID="STD-Burgio-2008" TOTAL_1="133" TOTAL_2="136" WEIGHT="41.52733963355326"/>
<CONT_DATA CI_END="1.520129470287506" CI_START="-1.1201294702875038" EFFECT_SIZE="0.20000000000000107" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="8.2" MODIFIED="2012-09-24 15:22:51 +0100" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="3.0" SD_2="1.9" SE="0.6735478206235" STUDY_ID="STD-Burgio-2010" TOTAL_1="27" TOTAL_2="30" WEIGHT="19.511534790755693"/>
<CONT_DATA CI_END="0.7222867798951426" CI_START="-0.4422867798951423" EFFECT_SIZE="0.14000000000000012" ESTIMABLE="YES" MEAN_1="-2.82" MEAN_2="-2.96" MODIFIED="2012-03-04 13:56:23 +0000" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="2.87" SD_2="2.91" SE="0.2970905508918257" STUDY_ID="STD-Chancellor-2008" TOTAL_1="195" TOTAL_2="184" WEIGHT="38.96112557569105"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.12006858767704087" CI_START="-3.879931412322959" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.04" MODIFIED="2012-04-15 13:00:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.03705621856516357" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="2.0851441405707476">
<NAME>Anticholinergic and Inferential current therapy + pelvic floor exercises + Bladder training vs.Anticholinergic .</NAME>
<CONT_DATA CI_END="-0.12006858767704087" CI_START="-3.879931412322959" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="8.9" MODIFIED="2012-03-04 14:04:25 +0000" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="2.4" SD_2="2.8" SE="0.9591663046625438" STUDY_ID="STD-Kaya-2011" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.05" MODIFIED="2012-10-12 15:03:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.68" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="715" TOTAL_2="741" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Frequency of sensation of urgency</NAME>
<GROUP_LABEL_1>Antichol. + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Antichol.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug+behav</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours drug alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.01" MODIFIED="2012-10-09 10:32:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="305" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic + Bladder training vs. Anticholinergic</NAME>
<CONT_DATA CI_END="1.5758287686656207" CI_START="-1.5558287686656207" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="-1.98" MEAN_2="-1.99" MODIFIED="2012-09-24 15:39:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;changed denominators for Matt 2009&lt;/p&gt;" NOTES_MODIFIED="2012-09-24 15:39:15 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="83" SD_1="9.8" SD_2="9.8" SE="0.7989069090129606" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="297" TOTAL_2="305" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.02" MODIFIED="2012-04-15 13:03:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="252" WEIGHT="0.0" Z="0.0">
<NAME>Tolterodine 4mg + PFMT vs tolterodine alone</NAME>
<CONT_DATA CI_END="1.0961699592715335" CI_START="0.10383004072846669" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="1.5" ORDER="89629" SD_1="3.1" SD_2="2.3" SE="0.2531525901420938" STUDY_ID="STD-Millard-2004" TOTAL_1="223" TOTAL_2="252" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.03" MODIFIED="2012-08-29 12:23:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="195" TOTAL_2="184" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic and behavioural modification therapy vs. Anticholinergic</NAME>
<CONT_DATA CI_END="0.908290400029417" CI_START="-0.5282904000294171" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" MEAN_1="-2.68" MEAN_2="-2.87" MODIFIED="2012-04-15 14:18:06 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="3.54" SD_2="3.59" SE="0.3664814280748014" STUDY_ID="STD-Chancellor-2008" TOTAL_1="195" TOTAL_2="184" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2012-10-12 15:04:29 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.593565984407797" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="515" TOTAL_2="507" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of pad changes per day</NAME>
<GROUP_LABEL_1>Anticholinergic+NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Anticholinergic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AcH+NDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AcH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.06.01" MODIFIED="2012-10-09 10:32:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="320" TOTAL_2="323" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic + Bladder training vs. Anticholinergic</NAME>
<CONT_DATA CI_END="0.3673416820076246" CI_START="-0.12734168200762483" EFFECT_SIZE="0.11999999999999988" ESTIMABLE="YES" MEAN_1="-1.07" MEAN_2="-1.19" MODIFIED="2012-04-15 13:16:47 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="1.6" SD_2="1.6" SE="0.12619705461866867" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="320" TOTAL_2="323" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.06.02" MODIFIED="2012-04-15 14:21:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="195" TOTAL_2="184" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic and behavioural modification therapy vs. Anticholinergic</NAME>
<CONT_DATA CI_END="0.39598810781067983" CI_START="-0.17598810781067986" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.61" MEAN_2="-0.72" MODIFIED="2012-04-15 14:21:25 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="1.28" SD_2="1.54" SE="0.14591498112542758" STUDY_ID="STD-Chancellor-2008" TOTAL_1="195" TOTAL_2="184" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.597879714257903" CI_END="0.13676346993652094" CI_START="-0.25630375841699343" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05977014424023624" ESTIMABLE="YES" I2="47.35373353576858" I2_Q="49.0767697573741" ID="CMP-006.07" MODIFIED="2012-10-12 15:05:20 +0100" MODIFIED_BY="[Empty name]" NO="7" NOTES="&lt;p&gt;changed denoms for Matt 2009 used FAS where imputed data&lt;/p&gt;" NOTES_MODIFIED="2012-10-12 15:05:20 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.10746998012179654" P_Q="0.1170244112572626" P_Z="0.5511300357276026" Q="5.8912209333665055" RANDOM="NO" SCALE="3.6409624956315825" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="759" TOTAL_2="786" UNITS="" WEIGHT="400.0" Z="0.5960676526116695">
<NAME>Number of incontinence episodes per 24 hours</NAME>
<GROUP_LABEL_1>Antichol. + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Antichol.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AcH+NDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AcH alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12162335782975059" CI_START="-0.4216233578297504" DF="0" EFFECT_SIZE="-0.1499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.01" MODIFIED="2012-10-09 10:33:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27909205524632774" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="305" WEIGHT="100.0" Z="1.082361252102919">
<NAME>Anticholinergic + Bladder training vs. Anticholinergic</NAME>
<CONT_DATA CI_END="0.12162335782975059" CI_START="-0.4216233578297504" EFFECT_SIZE="-0.1499999999999999" ESTIMABLE="YES" MEAN_1="-1.16" MEAN_2="-1.01" MODIFIED="2012-09-24 15:34:30 +0100" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="1.7" SD_2="1.7" SE="0.13858589237979926" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="297" TOTAL_2="305" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7249822940533068" CI_START="-0.12498229405330669" DF="0" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.02" MODIFIED="2012-04-15 13:41:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.16649272410342092" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="252" WEIGHT="100.0" Z="1.3835616297187743">
<NAME>Anticholinergic + PFMT vs. Anticholinergic</NAME>
<CONT_DATA CI_END="0.7249822940533068" CI_START="-0.12498229405330669" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="0.95" ORDER="89627" SD_1="2.7" SD_2="1.9" SE="0.2168316853807074" STUDY_ID="STD-Millard-2004" TOTAL_1="223" TOTAL_2="252" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7066587808913982" CI_END="0.34556319661251106" CI_START="-0.47095400898642387" DF="1" EFFECT_SIZE="-0.06269540618695642" ESTIMABLE="YES" I2="41.40597926214085" ID="CMP-006.07.03" MODIFIED="2012-04-15 14:22:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19141954170187836" P_Z="0.7634240232155904" STUDIES="2" TAU2="0.0" TOTAL_1="223" TOTAL_2="215" WEIGHT="100.0" Z="0.3009875046843828">
<NAME>Anticholinergic vs.Anticholinergic and Behavioural modification therapy</NAME>
<CONT_DATA CI_END="1.297598233564801" CI_START="-0.4175982335648011" EFFECT_SIZE="0.43999999999999995" ESTIMABLE="YES" MEAN_1="0.84" MEAN_2="0.4" MODIFIED="2012-03-04 20:50:29 +0000" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="2.14" SD_2="0.93" SE="0.4375581593995739" STUDY_ID="STD-Burgio-2010" TOTAL_1="28" TOTAL_2="31" WEIGHT="22.66224520200673"/>
<CONT_DATA CI_END="0.25423680111105906" CI_START="-0.6742368011110594" EFFECT_SIZE="-0.2100000000000002" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-1.89" MODIFIED="2012-04-15 14:22:55 +0100" MODIFIED_BY="[Empty name]" ORDER="97" SD_1="2.32" SD_2="2.29" SE="0.23685986312651655" STUDY_ID="STD-Chancellor-2008" TOTAL_1="195" TOTAL_2="184" WEIGHT="77.33775479799327"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.11857856938313893" CI_START="-2.118578569383139" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.04" MODIFIED="2012-04-15 14:37:01 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0797408658180628" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.00000000000001" Z="1.7521916101261559">
<NAME>Anticholinergic and Inferential current therapy + pelvic floor exercises + Bladder training vs.Anticholinergic .</NAME>
<CONT_DATA CI_END="0.11857856938313893" CI_START="-2.118578569383139" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.5" MODIFIED="2012-04-15 14:37:01 +0100" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="0.8" SD_2="2.0" SE="0.5707138387268051" STUDY_ID="STD-Kaya-2011" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.4512879939051305" CI_END="1.0731357938791448" CI_START="0.8777670438066956" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9705479037102951" ESTIMABLE="YES" EVENTS_1="326" EVENTS_2="346" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.030654680773903247" LOG_CI_START="-0.05662072898384779" LOG_EFFECT_SIZE="-0.012983024104972296" METHOD="MH" MODIFIED="2012-10-12 15:07:18 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9294552451977028" P_Q="1.0" P_Z="0.5598088033749635" Q="0.0" RANDOM="NO" SCALE="5.957652493180516" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="621" TOTAL_2="636" WEIGHT="100.0" Z="0.583125527036581">
<NAME>Numbers experiencing adverse events</NAME>
<GROUP_LABEL_1>Antichol. + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Antichol.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug+behav</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours drug alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4512879939051305" CI_END="1.0731357938791448" CI_START="0.8777670438066956" DF="3" EFFECT_SIZE="0.9705479037102951" ESTIMABLE="YES" EVENTS_1="326" EVENTS_2="346" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="0.030654680773903247" LOG_CI_START="-0.05662072898384779" LOG_EFFECT_SIZE="-0.012983024104972296" MODIFIED="2012-10-09 10:33:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9294552451977028" P_Z="0.5598088033749635" STUDIES="4" TAU2="0.0" TOTAL_1="621" TOTAL_2="636" WEIGHT="100.0" Z="0.583125527036581">
<NAME>Anticholinergic + Bladder training vs. Anticholinergic</NAME>
<DICH_DATA CI_END="1.0641199561083485" CI_START="0.8307371787933413" EFFECT_SIZE="0.9402148745021766" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="177" LOG_CI_END="0.02699058786453846" LOG_CI_START="-0.08053635269417621" LOG_EFFECT_SIZE="-0.02677288241481888" ORDER="89630" O_E="0.0" SE="0.06316185715112906" STUDY_ID="STD-Mattiasson-2003" TOTAL_1="244" TOTAL_2="257" VAR="0.003989420198779632" WEIGHT="50.597723697824584"/>
<DICH_DATA CI_END="1.1834745041267511" CI_START="0.8494468310007851" EFFECT_SIZE="1.0026458333333332" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="150" LOG_CI_END="0.07315890625637023" LOG_CI_START="-0.07086379952079086" LOG_EFFECT_SIZE="0.001147553367789668" MODIFIED="2012-04-14 18:00:35 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.0845996502973959" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="320" TOTAL_2="323" VAR="0.007157100830441678" WEIGHT="43.8163176873654"/>
<DICH_DATA CI_END="2.753403662106035" CI_START="0.4212107834280944" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.43986988570283464" LOG_CI_START="-0.3755005189600322" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="89631" O_E="0.0" SE="0.4789526118475652" STUDY_ID="STD-Park-2002" TOTAL_1="26" TOTAL_2="24" VAR="0.22939560439560444" WEIGHT="1.831302997743437"/>
<DICH_DATA CI_END="1.7530216428077403" CI_START="0.5179228579264575" EFFECT_SIZE="0.9528535980148883" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.24378727792719598" LOG_CI_START="-0.28573492147435325" LOG_EFFECT_SIZE="-0.020973821773578646" MODIFIED="2011-10-30 15:01:15 +0000" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.3110439611056309" STUDY_ID="STD-Song-2006" TOTAL_1="31" TOTAL_2="32" VAR="0.09674834574028121" WEIGHT="3.754655617066571"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.676271714509582" CI_END="1.8202280512275135" CI_START="0.7907297551072242" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1997118325608163" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="38" I2="25.26917244026945" I2_Q="61.71177824163455" ID="CMP-006.09" LOG_CI_END="0.26012580292196125" LOG_CI_START="-0.1019719184230158" LOG_EFFECT_SIZE="0.07907694224947279" METHOD="MH" MODIFIED="2012-10-12 15:07:35 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.26233442351508374" P_Q="0.10607340831683243" P_Z="0.39196682776741676" Q="2.6117692441057643" RANDOM="YES" SCALE="36.67229211464778" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.057365849912993004" TOTALS="SUB" TOTAL_1="556" TOTAL_2="545" WEIGHT="200.0" Z="0.8560559742868998">
<NAME>Numbers withdrawing from treatment</NAME>
<GROUP_LABEL_1>Anticholinergics + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Anticholinergics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AcH +NDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AcH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.06381899052976485" CI_END="1.5271251233265661" CI_START="0.4396677499489046" DF="1" EFFECT_SIZE="0.8194068994482746" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="0.18387462195757695" LOG_CI_START="-0.35687538912875116" LOG_EFFECT_SIZE="-0.08650038358558712" MODIFIED="2012-10-09 10:33:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8005586247321482" P_Z="0.5306289146286176" STUDIES="2" TAU2="0.0" TOTAL_1="351" TOTAL_2="355" WEIGHT="99.99999999999999" Z="0.6270462616766715">
<NAME>Anticholinergic + Bladder training vs. Anticholinergic</NAME>
<DICH_DATA CI_END="1.540364276571505" CI_START="0.4122464895371275" EFFECT_SIZE="0.796875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.18762343810716514" LOG_CI_START="-0.38484303387906676" LOG_EFFECT_SIZE="-0.09860979788595081" MODIFIED="2012-04-15 13:27:33 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.3362696393994512" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="320" TOTAL_2="323" VAR="0.11307727038183694" WEIGHT="89.2263159256308"/>
<DICH_DATA CI_END="6.878874912437529" CI_START="0.15490276030924435" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8375174121778957" LOG_CI_START="-0.8099408432066292" LOG_EFFECT_SIZE="0.013788284485633285" MODIFIED="2012-04-15 13:28:12 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.967725134262757" STUDY_ID="STD-Song-2006" TOTAL_1="31" TOTAL_2="32" VAR="0.936491935483871" WEIGHT="10.773684074369188"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.867096884755936" CI_START="0.9330432548659495" DF="0" EFFECT_SIZE="1.63558106169297" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="17" I2="0.0" ID="CMP-006.09.02" LOG_CI_END="0.45744236884601436" LOG_CI_START="-0.030098222369087976" LOG_EFFECT_SIZE="0.2136720732384632" MODIFIED="2012-04-15 14:27:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08580245160223887" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="190" WEIGHT="100.0" Z="1.7179680034667026">
<NAME>Anticholinergic and behavioural modification therapy vs. Anticholinergic</NAME>
<DICH_DATA CI_END="2.8670968847559353" CI_START="0.9330432548659494" EFFECT_SIZE="1.6355810616929698" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="17" LOG_CI_END="0.45744236884601425" LOG_CI_START="-0.03009822236908803" LOG_EFFECT_SIZE="0.21367207323846316" MODIFIED="2012-04-15 14:27:49 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.28638375664459986" STUDY_ID="STD-Chancellor-2008" TOTAL_1="205" TOTAL_2="190" VAR="0.08201565606987339" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="125" EVENTS_2="137" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-12 15:07:41 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.756990294582066" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="320" TOTAL_2="323" WEIGHT="0.0" Z="0.0">
<NAME>Numbers changing dose of treatment</NAME>
<GROUP_LABEL_1>Anticholinergic + NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Anticholinergic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AcH +NDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AcH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="125" EVENTS_2="137" I2="0.0" ID="CMP-006.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-12 14:56:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="320" TOTAL_2="323" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic + Bladder training vs. Anticholinergic</NAME>
<DICH_DATA CI_END="1.1100551252163984" CI_START="0.7640810579562548" EFFECT_SIZE="0.9209625912408759" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="137" LOG_CI_END="0.04534454633876776" LOG_CI_START="-0.1168605666130747" LOG_EFFECT_SIZE="-0.03575801013715346" MODIFIED="2012-04-15 13:33:28 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.09528008627617082" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="320" TOTAL_2="323" VAR="0.009078294840794556" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-006.11" MODIFIED="2012-10-12 15:08:19 +0100" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Number of incontinence episodes per day</NAME>
<TR>
<TH>
<P>Anticholinergic + behavioural</P>
</TH>
<TH>
<P>Anticholinergic alone</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-006.11.01" NO="1" STUDIES="1">
<NAME>Percentage change from baseline</NAME>
<OTHER_DATA ORDER="81" STUDY_ID="STD-Mattiasson-2003">
<TR>
<TD>
<P>87%</P>
</TD>
<TD>
<P>81%<BR/>
</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.12" MODIFIED="2012-10-15 15:02:43 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="33.001989405845165" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="336" TOTAL_2="337" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life</NAME>
<GROUP_LABEL_1>Anticholinergic+ NDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Anticholinergic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AcH +NDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AcH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.12.01" MODIFIED="2012-10-09 10:33:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="320" TOTAL_2="323" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic + Bladder training vs. Anticholinergic</NAME>
<CONT_DATA CI_END="1.6270876610800609" CI_START="-3.5670876610800586" EFFECT_SIZE="-0.9699999999999989" ESTIMABLE="YES" MEAN_1="19.68" MEAN_2="20.65" MODIFIED="2012-04-15 13:38:21 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="16.8" SD_2="16.8" SE="1.325069073496021" STUDY_ID="STD-Mattiasson-2009" TOTAL_1="320" TOTAL_2="323" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.12.02" MODIFIED="2012-04-15 14:40:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Anticholinergic and Inferential current therapy + pelvic floor exercises + Bladder training vs.Anticholinergic .</NAME>
<CONT_DATA CI_END="-4.36480096708479" CI_START="-28.035199032915216" EFFECT_SIZE="-16.200000000000003" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="26.3" MODIFIED="2012-04-15 14:40:42 +0100" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="12.2" SD_2="19.5" SE="6.038477811974992" STUDY_ID="STD-Kaya-2011" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2012-10-17 00:10:58 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Anticholinergic drugs versus combination non-drug therapies</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-17 00:08:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.19" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="65" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not cured at end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT+PFMT+Bio.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="44" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-17 00:08:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Oxybutynin vs behavioural</NAME>
<DICH_DATA CI_END="1.3586423627356186" CI_START="0.892861073991737" EFFECT_SIZE="1.1013986013986015" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="44" LOG_CI_END="0.13310515185303687" LOG_CI_START="-0.04921611053192179" LOG_EFFECT_SIZE="0.04194452066055753" ORDER="89633" O_E="0.0" SE="0.10709641202972893" STUDY_ID="STD-Burgio-1998" TOTAL_1="65" TOTAL_2="63" VAR="0.011469641469641467" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-17 00:09:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.259107593531416" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="65" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Numbers not improved at end of treatment (subjective)</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT+PFMT+Bio.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="6" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-17 00:09:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Oxybutynin vs behavioural</NAME>
<DICH_DATA CI_END="5.847986928725241" CI_START="1.0039868157550362" EFFECT_SIZE="2.423076923076923" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.7670063932266776" LOG_CI_START="0.0017280097388498881" LOG_EFFECT_SIZE="0.3843672014827637" ORDER="89634" O_E="0.0" SE="0.4495283106498434" STUDY_ID="STD-Burgio-1998" TOTAL_1="65" TOTAL_2="63" VAR="0.20207570207570208" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.03" MODIFIED="2012-10-17 00:09:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.9727293471033995" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Nocturia</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.03.01" MODIFIED="2012-10-17 00:09:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Trospium vs. Inferential current therapy + pelvic floor exercises + Bladder training</NAME>
<CONT_DATA CI_END="2.7471208637938647" CI_START="0.6528791362061355" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="0.4" MODIFIED="2012-04-14 13:48:21 +0100" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="1.8" SD_2="0.9" SE="0.5342551557341974" STUDY_ID="STD-Kaya-2011" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8877566503001202" CI_END="1.4154918242347425" CI_START="-0.20929640889064982" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6030977076720463" ESTIMABLE="YES" I2="47.027070473251015" I2_Q="47.027070473251015" ID="CMP-007.04" MODIFIED="2012-10-17 00:10:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1694553841490415" P_Q="0.16945538414904138" P_Z="0.1456636910744157" Q="1.8877566503001204" RANDOM="NO" SCALE="6.9727293471033995" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="79" UNITS="" WEIGHT="100.0" Z="1.4550201215110015">
<NAME>Number of micturitions per 24 hours</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ANTICHOLINERGIC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COMBINATION</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.591215316324455E-32" CI_END="1.2625094258876521" CI_START="-0.4625094258876516" DF="0" EFFECT_SIZE="0.4000000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-007.04.01" MODIFIED="2012-10-17 00:09:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.36337184681355805" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="64" WEIGHT="88.71679401821967" Z="0.9089588708079142">
<NAME>Oxybutynin vs. behavioural</NAME>
<CONT_DATA CI_END="1.2625094258876524" CI_START="-0.46250942588765154" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="9.1" MODIFIED="2012-10-10 10:19:15 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="2.4" SD_2="2.5" SE="0.4400639158122374" STUDY_ID="STD-Burgio-2011" TOTAL_1="60" TOTAL_2="64" WEIGHT="88.71679401821967"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.618524611750641" CI_START="-0.21852461175064075" DF="0" EFFECT_SIZE="2.2" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.02" MODIFIED="2012-10-17 00:10:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07460707770571516" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="11.283205981780332" Z="1.782872394615389">
<NAME>Trospium vs. Inferential current therapy + pelvic floor exercises + Bladder training</NAME>
<CONT_DATA CI_END="4.618524611750641" CI_START="-0.21852461175064075" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="6.7" MODIFIED="2012-04-14 14:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="2.8" SD_2="3.8" SE="1.233963802818651" STUDY_ID="STD-Kaya-2011" TOTAL_1="14" TOTAL_2="15" WEIGHT="11.283205981780332"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.376220363963968" CI_END="0.7020762807903904" CI_START="0.10919265016545071" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.40563446547792054" ESTIMABLE="YES" I2="54.298462287936395" I2_Q="73.14777538171359" ID="CMP-007.05" MODIFIED="2012-10-17 00:10:40 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.11212853757700147" P_Q="0.05363321554230971" P_Z="0.007320412932649515" Q="3.724086232017432" RANDOM="NO" SCALE="3.11" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="100" UNITS="" WEIGHT="100.00000000000001" Z="2.6819055280270288">
<NAME>Number of incontinence episodes per 24 hours</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antichol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BT+PFMT+Bio.</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.652134131946536" CI_END="0.6289078395001881" CI_START="0.011010184500607423" DF="1" EFFECT_SIZE="0.3199590120003978" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" MODIFIED="2012-10-17 00:10:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4193509802340559" P_Z="0.04237561894961043" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="85" WEIGHT="92.06738869825612" Z="2.02981233210935">
<NAME>Oxybutynin vs. behavioural</NAME>
<CONT_DATA CI_END="0.7884265804240137" CI_START="0.03157341957598636" EFFECT_SIZE="0.41000000000000003" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="0.4" ORDER="89635" SD_1="1.4" SD_2="0.67" SE="0.19307833379031158" STUDY_ID="STD-Burgio-1998" TOTAL_1="65" TOTAL_2="63" WEIGHT="61.36428262072133"/>
<CONT_DATA CI_END="0.674993256128033" CI_START="-0.3949932561280331" EFFECT_SIZE="0.13999999999999996" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.34" MODIFIED="2012-10-12 11:20:53 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="1.0" SD_2="0.85" SE="0.27296075864046054" STUDY_ID="STD-Burgio-2011" TOTAL_1="24" TOTAL_2="22" WEIGHT="30.703106077534787"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4525224716099805" CI_START="0.34747752839001955" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.02" MODIFIED="2012-04-14 14:28:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.009133340588153366" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="7.932611301743885" Z="2.607022322439179">
<NAME>Trospium 15mgs TDS vs. Inferential current therapy + pelvic floor exercises + Bladder training</NAME>
<CONT_DATA CI_END="2.4525224716099805" CI_START="0.34747752839001955" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="0.1" MODIFIED="2012-04-14 13:44:20 +0100" MODIFIED_BY="[Empty name]" ORDER="173" SD_1="2.0" SD_2="0.2" SE="0.537011128731009" STUDY_ID="STD-Kaya-2011" TOTAL_1="14" TOTAL_2="15" WEIGHT="7.932611301743885"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2012-10-17 00:10:58 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="69.14821729254565" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life</NAME>
<GROUP_LABEL_1>Anticholinergic</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Anticholinergic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combination</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.06.01" MODIFIED="2012-10-17 00:10:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Trospium vs. Inferential current therapy + pelvic floor exercises + Bladder training</NAME>
<CONT_DATA CI_END="26.456547358760833" CI_START="0.943452641239169" EFFECT_SIZE="13.700000000000001" ESTIMABLE="YES" MEAN_1="26.3" MEAN_2="12.6" MODIFIED="2012-04-14 14:27:07 +0100" MODIFIED_BY="[Empty name]" ORDER="176" SD_1="19.5" SD_2="15.1" SE="6.508562126336427" STUDY_ID="STD-Kaya-2011" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-11-05 13:22:16 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-10-11 17:23:30 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAANUCAYAAACZrKt6AABWwElEQVR42u2dD4RVzf/HvyRJkkiy
kkSSJIkkSRJJ8vhJJI/k8YiVJMmSJFmJlSRJJCtJIkmSRJKsPCJJ8kgkyUoiKyvJ/PY9zzP3mTud
M3POuXd375/Xi2vvveeeP3POZz7vMzNn5/0/4/G///2PVxe9Wg2uCfEH7cn//EoMXXbxW+iaE3/E
H7S5kHBBqcwkFODaQwPXkQtJEPyvK/cNxB8gJICQAPEHCAkgJMQf8UcMICRARSaJADGAkAAVmSQC
xAAgJICQAPEHCAkgJO3Ay5cvCRqEBMoIyejoqFm8ePEv34+MjJjdu3ebadOmmTlz5piDBw+aL1++
1AVH+JoyZQpBThkL7VuxtG3bNjN9+nQzY8YMs3PnTvPp06cJLbe/3H+vmJ+s89eJ8YiQdLiQ/Pjx
w2zfvj3zQu/du9ecOnXK/Pz5077Onj1rf5vH7du3zdGjRwlyylho3ydOnDDHjx+vxdeVK1eaHj9l
hIQWHGWCikKyYcMG8/79+8wLrbsyVXCH3s+cOTNzO1q2YsUK24qJBdPTp0/N3LlzzapVq+oSyqxZ
s+xdqVo9Pt+/f7etIt21LlmyxAwNDdUt7+vrs+tpucry4cOH6P50nPv27bPl6OnpMdeuXasr+927
d83UqVNty2r58uXm0aNHVORx2vemTZvMq1ev6m5qtmzZkrudt2/f1lowukaKh1u3btXFYOzappa7
91nzRYVlSMXd5cuXzYIFC2wc6Vjv3btXuBwICbSdkDx48CD3QodCoqQeNvkdFy5cSN5Nah/79++3
2/z48WNtPVU6fadEosqtVpDj2LFj5saNG/b9nTt3zNKlS2vLTp8+bc6dO1e7o9W2JDqx/Z05c8ac
PHnSfqdulHXr1tWV3a/09+/fN4sWLaIij9O+ldD9+HLf5aEblatXr9aut669bhIcqWubWp73Pvxc
JO4kFE5cFE+Kq6LlQEig7YQkdqFVOdSdpWDXOMqBAwdyx0BUOd69e5fch3/nJlauXPlLMvGTt4Qj
XO5YtmyZFTdf6DSWE9ufWib+Os+ePasruyq0Ey4q8vju20+use9i+PGYurap5UWFpErcpc6/Xw6E
BDpKSDQYqgFQVW4NxusOPatF8vr1a7N69epK+9C2YwP2scSSJWr+7/P2F3bJ+b9TGfVZAqf+eyry
+O07df2yUFelWqm7du2yCT1sTcaubWp5USGpEnfhd7FyICTQUUISov5s9S2HqNWiPuMq+0g95RVL
LFnLUhUytY6r5OpG27x5szl8+DAVeRy7top85xgcHLQt1EuXLtkuWXVXxoQi3HeZeIkJSZW4879L
lQMhgY4Wkps3b9o7qBA9yaXEW2UfGtD++vVr7jpqCeV1bWndsIvBbzFl7W/NmjV160gc88r+4sWL
jqkArSgkEupv377VPqv7VAPXeUhk/FhRV6q/7dS1TS0vKiRV4s7/LlUOhAQ6Skh01yTxEHrSRBVf
/cohGtNwg9ll96GBSzcAqpc++8lEzX91N4mHDx/+MtjuxnD0On/+fN3/w2TtT4Oc/f39tQHXjRs3
1v1O29eTWyIcJKUiN3ffelrPv/a6Q491J+opKPd0k0RA3an+tlPXNrXcf68nqjTO4QQjHGwvG3f+
d6lyICTQUUIi0dAApRsjyRuE1vK8VkORYNLTXrpL012dnnbxRUl3qTt27LD7UF9yKGTuMUy99HDA
mzdvkvsbGBiwg6N65FhP3Pi/U7eW9uMe23SiQkVu/r51nZXMdd312rp1a90/vIY8fvzY3rToukjw
FY/htmPXNrXcf68nB91xZZWhbNz536XKgZBA2woJdHwQkESAGACEBBASIP4AIQGEBIg/QEiAikwS
AWIAIQEqMkkEiAFASAAhAeIPEBJASID4A4QEqMgkESAGEJIJoVWsS7vVQhUh6SzaLY6JgQ4Wkqru
cVWIWZc6MynNuNuM/cbWn0wL1cmsdAjJ+B9vN9YnhAQhmdCLH9tW6CA3nvuKTcaHkCAk43m8nVif
EBKEpJQNqYhZ4sbsRWPWpUVsTWP7LXLc/jFm7UsT8OXZoubZA6esVlMVSWXSMc+ePds65IVzLcWO
qVOEpNOsl7utPiEkCMkvFzdlQ5qyxE3Zi8ZaArFlqf2mjrtIi0STBcaOO7TrLWK1GtuvyiOfE3fM
a9eu/eV8xI6pk4Skk6yXu7E+ISQISSkb0pQlbspetGrgp/abOu4iQpI67nB5EavV2H7lizE8PJx7
zFWsWttVSDrJerkb6xNCgpCUtimNWeKmkmfVwC9rxRsedxEhKXPcolGr1XCgNGb52ulCknUe29V6
uRvrE0KCkJSyD01Z4o5X4Fex4h1vIWnUarWMd3i3CUk7Wy93Y31CSBCSUjakKUvc8Qr81H7LWOc2
S0jKWq2GVqpyxFP/s+P58+cIScHr3crWy91YnxAShKSUDWnKEjcV+DHr0ljgp/abOu6Q2HEUFZKU
1ao/QPv+/Xs7aBobbFd5EJJi17uVrZe7sT4hJAhJaZvSmCVuKvBj1qWpVkJsv0WO2ydloVpESETM
atUlHHUjKJEpEYXbUWXV8eoRSx1z6s65W4Qkdb1b2Xq5G+sTQoKQQIug5Dh//vxJSeaTKSTQVUmI
k4CQQDPR3Z4Gb92z/LqLjg3iIiSAkABCAnU8ePDAPq+vrgX9Z/uhQ4esoCAkgJAAQgJUZJIIEAMI
CVCRSSJADABCAggJEH+AkABCAsQfICRARSaJADGAkHQH3WC/24pC0o22x1g9A0IyiYE2nmVoB/vd
ThSSbrQ97oZYQ0gQEhIdQjJh++5G2+NuiDWEpMuEJGUjGrPkfPv2rZ2nR5PHaRuyPb1161Zd4IS2
pjGb1CKWt/77PBtS/9jzrGzDAC9rv5s6N1Tk9L472fY473jGI9byzgnxBxMmJDEb0ZQl54oVK+xM
oW4WUVVABbMfOKGtacwmtYjlrf8+ZkOasrItcpcYO5bUuaEiV2+RtLvtcdnjaTTWss4J8QcTKiQx
G9GUJWcWocNbaBUas0ktYy2a+m3KyrZIQottv8q5QUgaP+/tYHtc9ngajbWs9Yk/mFAhidmIpiw5
hZrUamXs2rXLVqAqbnRFK3wZv46UlW2RhBb7TZFzQ0WuJiRFYyDr5iUrziba9rjs8TQaa+2SoBGS
DhYSJwZZNqKpxDg4OGhbGJcuXbKTEKpZ3SpCMt4+7q0uGt0kJK1me1z2eBqNNYQEWkJIHKGNaMqS
U4OT/vLQTjZrnzGb1GYKScrKttGEljo3VOSJE5JWsz0uezyNxhpCApMuJDEb0ZQlp54ycU9pyddZ
FTJVAWM2qc0UkpSVbUhZ+93UuaEiF9t3J9oep46n2bGGkMCkC0nKRjRmyfn48WM76Kf1JAgatE9V
wJhNajOFRMSsbEPK2u+mzg0Vudi+O9X2OHY8zY41hARaqmurk5kIK1sqcmckEWKFGACExDIZVrZU
5PZMIsQKMQAISSaTYWVLRW7PJEKsEAOAkABCAsQfICSAkADxBwgJUJFJIkAMICRARSaJADEACAkg
JED8AUICCAkQf9BGQjIyMmIOHDhgn6XXf//qP9VlotOKwVXkP5wJeIQEiD+YYCHR9O9XrlypTaSo
+X/0D1l6dWsgIiScUyAGoISQZE15rVaK/jHLDwBNGa9Wi+YOkhubppHwiVmBpux1HUWse7PeN2IX
LAHdt2+fncdI8yzJfQ4hmbh9p65dIxa6Za2eU7GSOlZASLpWSDTZoiaR86e9zgoAGV+pEivxqrKp
O8yRsgJN2es6ilj3Zr1vxC74zJkztZlVNfPrunXrEJIJ3Hfs2jVqoVvW6jkVK7FjBYSkq4VEs++6
GXzlG33x4kU7q28YAP6d27dv3+omtUtZgabsdWPkOcH57xuxC9adqi+iKUteKnJz9x27do1a6Ja1
ek7FSuxYASHpaiFxqAtAd+fqWpKoDAwM1AVAWMH8LrGUFWgZV8Si1r3++0bsgss6KVKRm7vv2LVr
1EK3rENnKlZixwoICUIS8PLly7o7sVSFTFmBFhWSMta9WQJUxS44ZYtKRR7/feddu0YtdMsKSRH7
5LxjBYSkq4VEg+pZTX0NNvoBIBtex5cvX+zgtCNlBVrUXreMdW9eecraBa9Zs6au+0ROjwjJ5Ow7
69o1YqFb1uq5jH1yeKyAkHS1kOipGA1qyoJU6Gks2YRqkNIPAD0xo8FoVcIjR46Y7du315anrECL
2uuWse713zdiF6zBfbnjucH2jRs3IiQTuO/UtWvEQres1XMqVmLHCghJ13dt6SksVVA17TWYKXHx
7wS1rhL8vHnz7ICj/BrUKvGJWYEWtdctY93rv2/ELlhoPEjl1mOfenIHIZm4faeuXSMWumWtnlOx
kjpWQEi6WkgIACoySQSIAUBIACEB4g9aV0j8AU6gIpNEgBhASICKTBIBYgAQEkBIgPgDhAQQEiD+
ACEBKjJJBIgBhASoyCQRIAagk4RE83wBQgLEH7SRkISzneo/dvWfvb29vdbgaqKDiEeNERIg/qAN
hSREAqKZTeUcSLBRkbmuQAxAaSERmrTOnwFYxGxI3XK1ZjSjsJztylrjhq2jIvvNslMFhASIP2gB
IRG+kKRsSLVMrRg3i+7atWsrWeOGx5Pab5adKiAkQPzBJAuJpuSWW6I/lXzKhlS+HsPDw7XPoWVt
UWvc8HhS+82yUwWEBIg/mGAhCV89PT12+m61APxWRMyGNBwkDy1ri1rjhseZ2i/BiZAA8Qct1CJR
i2LLli11boiOspa1MSEReZal4e9S+yU4ERIg/qCFhESoFSJDn9u3b9d9n7IhlZuhxkYcz58/r2SN
G/4utV+Cs30qMteK2IMuERLXMtE4hDywHSkb0nCwXcuqWONOnz7djnk4h8bUfgnQ9qrMXC/iDrpE
SIT8rNevX1/3XcqyVt7nekxXYyx62sofNylqjasnsrSev25svwRp+1XorHE5Xp37gi4QkvFC3tjz
58/nzCMkwPkHhKQYc+bMsYPn7v899NSXP4gOJDLOP+cfEJIoDx48sP9Zru4n/Wf7oUOH6h4fBhIZ
55/zDwgJkMiA8w8ICZDIgPMPgJAAiYzzD4CQAImM8w+AkACJDDj/gJAAiQw4/wAICZDIOP8ACAmQ
yDj/AAgJkMiA8w8ICZDIgPMPgJAAiYzzD4CQAImM8w+AkACJDDj/0HkxTCCTxIBrANCwkBDMJDDg
OgA0LCQuoHlhdQoICUBlIaEiAxB/AAgJFRmIPwCEhIoMxB8AQkJFBiD+ACGhIgMQfwAICRUZiD8A
hISKDMQfAEJCRQYg/gAhoSIDEH8ACAkVGYg/AISEigzEHwBCQkUGIP4AIaEiAxB/AAgJFRmIPwCE
hIoMxB8AQkJFBuKPkwAICRUZgPgDhISKDED8ASAkVGQg/gAQEioyEH8ACEl7VmRevCbzBYCQAHfU
AICQACAkAICQAEICAAgJICQAgJAAQgIACAkAQgIACAkgJACAkABCAgAICSAkAICQACAkAICQAEIC
AAgJtJ6AMGcUAFDzASEBAIQEWkNMAAAhAUBIAAAhAYQEABASQEgAACGBbhMTAEBIABASAOh8IcHb
mxcvfOABIeGuF4A6AwgJFQIAMQFoIyGhIgBQhwAhoRIAUIcAIaESACAkAAgJAEICgJAAAHUIEBIq
AQB1CBASKkH38fLlS05Cm54H6hAgJIlKMDo6ahYvXvzL9yMjI2b37t1m2rRpZs6cOebgwYPmy5cv
ddsNX1OmTCFJ/Mvdu3fN1KlTzcqVK+1nncd2K4+/rWZtd6LOA0ICCMkEVYIfP36Y7du3Z/5m7969
5tSpU+bnz5/2dfbsWfvbPG7fvm2OHj1KkvgXici9e/cmPBmNl5B0c1JGSAAhiVSCDRs2mPfv32f+
RneOEhCH3s+cOTNzO1q2YsUK24qJHcfTp0/N3LlzzapVq2rfnzhxwsyaNcvMmDHDtnp8vn//bltF
06dPN0uWLDFDQ0N1y/v6+ux6Wq6yfPjwIbo/Hee+fftsOXp6esy1a9fqyu5aEWpZLV++3Dx69Ci3
PG/fvjXbtm2z+9Y6Or5bt27lttay5nCKlT3vfIXnPVaerOsaLh8cHLQtTh3D/v37bQs11SKJXZcy
56XIeShzTRASQEgmoRI8ePAg9zehkCh55HVLXLhwIdka0T6UqLTNjx8/1ta7fPmy/U6tIyVCtYIc
x44dMzdu3LDv79y5Y5YuXVpbdvr0aXPu3Llai0nbUnKL7e/MmTPm5MmT9rtPnz6ZdevW1ZXdb0Xc
v3/fLFq0KLc8Es6rV6/W9q9jUdLPO+/h51TZs44/JFWeIkKirjcJsLahhH7gwIGkkMSuS9nzkjoP
Za4JQgIIySRWgqzfKCmrO0sVXHepSjB5YyBKHu/evUvuw28xCCUxX6yEnyiUoMLljmXLlllx84VO
d9ax/enO3l/n2bNndWVXwnMJsgr++UkJSarsWccfkipPESHxWxPfvn0z8+fPTwpJ7LqUPS+p89Do
NUFIACGZRCHRwPrOnTvtHaEG43U3mNUief36tVm9enWlfWjbsQF7LS+SnLJ+n7e/sGvI/53K6O7S
jx8/niyTup50d75r1y4rbLEkHn5Olb3IdUuVp4iQhEk87xyGLbdmnZfUeSh7TRASQEhaSEhCXr16
ZfvhQ9Rq0VhFlX2knvKKJaysZakkmlrHJUF112zevNkcPnw4d/8aW9Cd+aVLl2wXobqfyghJquxV
hKTIOShzjqoISdnzUuRJv6LXBCEBhKTFheTmzZv2DjNET3KpklfZhwZPv379mruOWkJ5XShaN+za
8ltMWftbs2ZN3ToSx7yyv3jxInpeNMDtH7u69soISarsRa5JqjzhNrKOUeX0W6H+AxV524pdl7Ln
JXUeylwThAQQkhYTEt1VSjyEnsTR3aD64EPUn503GJzahwbM3WCxXvqsp68c6h5R14Z4+PDhL4Pt
bgxHr/Pnz9f9P0zW/jQI3N/fXxuc3rhx4y99/3pKSGiAN3bnvWDBgtrTSErg6t6LJUw9xaQxD5f4
U2Uvct1S5fEHqvV0np6mCo9R+9S62saRI0fqHvGODbbnXZfUeSl7HspcE4QEEJIWExKJhgZz3RhJ
3oCnlhcZeM07Dj3tpbtYtSaU6HxR0iD/jh077D7U1x4KmXv8Vy89HPDmzZvk/gYGBuygvB431RND
/u/UhaL9qLtF+3QJLIvHjx9bEdXvlOx0fmJCoieRVEa/1RQre9HkFSuPS7wqj66hyhMeo5L+vHnz
7KD2oUOHfvmn06z3seuSOi9lz0OZa4KQAEJCJQBig/MECAmVAEiQnCcAhAS6hnac94o6BAgJlQAA
IQFASAAQEgCEBACoQ4CQUAkAqEOAkFAJABASAIQEACEBQEio7ADEFiAkVAIqOxBbgJBMcCWoYn2r
dTQ9uOZ2mj17trl+/bqdZE/zJIUe5SLLCld2vDJP8i1dhSbx00ywRY4jZTELgJAAQjJBQlLW+lbr
7Nmzxy67ffu2TeR79+61n8OZWWNWuL29vXa5j2xjJR5FjiNlMQuAkABCMkFCUtb6NlxHn30vCX9f
MStcuSqqVeL2pb8LFy6sbTt1HCmLWQCEBBCSCRKSkLL2r7HPKSvc9evX21aHkK+Gpg8vehwpi1kA
hAQQkkkSkrL2r7HPKRtYuSouWbLEvtfYiGxZix5HEctcAIQEEJJJEJKy9q+xzykrXCE3PY13qFur
zHGUscwFQEgAIZlAISlr/xr7nLLCFRpA11NX/kB6keNIWcwCICSAkEySkIgy9q+pzzErXPH582e7
H4lBmeMQMYtZAIQEEBIqAQB1CBASKgEAQgKAkAAAdQgQEioBAHUIEBIqAQB1CBASKgEAQgKAkAAg
JAAICQBQhwAhoRIAUIcAIaESACAkAAgJAEICgJAAAHUIEBIqAQB1CBASKgEAdQgQEioBAEICgJAA
AHUIEBIqAgB1BxASKgQAdQYQkpauGLx48Sr2AkBIgDtfAEBIACEBAIQEACEBAIQEEBIAQEgAIQEA
hAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIAQEgAIQEAhAQQEgBASAAhAQCE
BAAhAQCEBBASAEBIACEBAIQEEBIAQEgAEBIAQEgAIQEAhAQQEgBASAAhAQCEBAAhAQCEBBASAEBI
ACEBAIQEEBIAQEgAEBIAQEgAIQEAhAQQEgBASAAhAQCEBBASAEBIACoJSPgCAIQEACEBAIQEJkdM
AAAhAUBIAAAhAYQEABASQEgAACGBbhMTAEBIABASAEBIWiGh8uqeFxD3xD1Cwl05cM05B9CEa04U
UJmAa0/ZoaFrTyRQmYAYoMzQUAwQDVQoIAYoMyAkVCggBigzICRUKCAGKDMgJJxMIAYoMyAkQIUC
YoAyA0JChQJigDIDQtJBFWp0dNQsXrz4l+9HRkbM7t27zbRp08ycOXPMwYMHzZcvX+q2G76mTJlC
wqGMbR33oq+vz8ycOdNMnz7d7NixwwwPD9eWffv2zfT29poZM2bYuqHlfr0gJhCSrqtQP378MNu3
b8/8zd69e82pU6fMz58/7evs2bP2t3ncvn3bHD16lApFGds67gcGBsy5c+dqcd/f3282bNhQW37g
wAFz/vz52nKJjsSEmEBIurZCqYK8f/8+8ze621JFcei97tKy0LIVK1bYVkzsOJ4+fWrmzp1rVq1a
Vfv+xIkTZtasWfYOT60en+/fv9tWke4MlyxZYoaGhn65c9R6Wq6yfPjwIbo/Hee+fftsOXp6esy1
a9fqyn737l0zdepU27Javny5efToEULSZXG/aNEi2+rwUUw4Zs+eXVcvJEqqK8Q9QtK1FerBgwe5
vwmFRMGdV2EuXLiQbI1oH/v377fb/PjxY229y5cv2+9UIRXgagU5jh07Zm7cuGHf37lzxyxdurS2
7PTp03V3jtqWKl9sf2fOnDEnT56033369MmsW7euruyqTPfu3bPv79+/b5MKQtJdce/z9etXm/B3
7dqV+xvVCyVt4h4h6fpujazfKDjVnaXgU3+ymvR5YyBqjbx79y65D//OSaxcubJOrNwdoUMVKFzu
WLZsma3EfoXWWE5sf7pD89d59uxZXdmVEFwFpmurO+PesXPnTnvXr9fz589zf3flyhWb+Il7hIQK
lfEbDSCqMuluRYOSulPJapG8fv3arF69utI+tO3YgL3fpRCSJWr+7/P2F3bJ+b9TGfVZFf348eMI
SRcLid+NpO6eLD5//mzriFoVxD1CQoUq8JtXr17Z/tUQtVpU2arsI/WUV6xCZS2rC5wCFSrrd+pf
VnfC5s2bzeHDhxGSLo97iURW3Oj733//3XYVEfcICRWq4G9u3ryZ2Vesp18UgFX2oTs99UPnoZZQ
XhNf64ZNfL/FlLW/NWvW1K0jccwr+4sXLzomASMkxX+jbh5fHMKuI9cS0SPAqe5c4h4h6foKpX5a
iYd4+/atvVNR32qI+nbdoF7ZfWjg0A0C6qXP/qOW6ntWs1s8fPjwl0FHN4ajlx7J9P8vIGt/V69e
tY9zukHHjRs31v1O29cTLEKDj7E7Q4SkM+NerWt177i4OnLkiH05njx5YtavX1/3vyXEPUJChcr5
jURDg3RujCRvME7L8+6eihyHnvbSY4m6q9q2bVudKGmQX8/oax8aZAyFzD0GqZceDnjz5k1yf/o/
Ad1h6tFLPfHi/07Ne+1HXQ/ap6tcCEn3xL26rPTUk+JRcRV2286fP7+UrTFxj5CQRIAYoMyAkAAV
ChASQEiACgXEAGUGhIQKBcQAZQaEhAoFxABlBoSEJALEAGUGhASoUEAMUGZASKhQQAw0XqYq/78B
CAmQRIAYqBOSvH8MJO4BISGJUO5xOBd5ybdTX+0Sa5O9PkICBBnlpkUyyS0ShAQh6dokErPXjFl9
VrEOTS3XNuUYt2DBgtp8P86xrcj6KStRYoAxkiKxJG8RTZLo15EtW7YUqhOx/frfFYlVYh0haZsk
ErPXjFl9VrEOTS3XNjVxnXN2C2cgTa2fshIlBnhqq0gsKZ5l0uZcQVUnZNxWpE4UFZJUrBLrCElb
VaiYvWbM6rOKdWhqedY2/eNOrZ+yEiUGEJKisaRErmSt5C176aJ1oqiQpGKVWEdI2qpCxew1Y34E
Va1DY8tTla+sNWloJUoMICRFY8klc025LgOrsnWiSCzHYpVYR0jaLonk2WuWFZKUdWhqearyVbEm
pXIhJFViUWzdutW2QCZCSIh1hKRjkkhorxmz+qxiHZpanqp8qfXLWIkSA91d5lQsyXFQYxSXLl2q
69oqWifC/cqO1/8uFavEOkLSVhUqZq8Zs/qsYh2aWp4SktT6KStRYgAhKRJLGmxfu3ZtXVL/+++/
S9UJ/yGW9+/f24dI/OWpWCXWEZK2qlAxe82Y1WcV69DU8pSQFNl+zEqUGEBIisSSYt5//FfvtbxM
nXA3ZapXasWoXoXHkopVYh0hIYkAMUCZASGhQgExQJkBIQEqFCAkQNwjJFQoIAYoMyAkVCggBigz
ICRUKCAGKDMgJJxMIAYoMyAkQIUCYoAyA0JChQJigDIDQkKFAmKAMgNCQoUCYoAyA0ICVCggBigz
ICRUKCAGKDMgJFQoIAYoMyAkVCggBigzICRAhQJigDIDQkKlAq49ZYdxuvZEApUKuOacA2jomhMF
TT7BvLrnBcQ9cY+QAHelANCMHMApAIQEABASQEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBI
AAAhAYQEABASAIQEABASQEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBIAAAhAYQEABASAIQE
ABASQEgAACEBhAQAEBJASAAAIQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQA
EBJASAAAIQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQAEBJASAAAIQGEBAAQ
EiCIEBIAhAQAIQEAhAQQEpi068+re14ICSAkwLWHpl9zogBIJsB1h4auPZEAJBTgmkNDMUA0AEkF
uOaAkABJBbjmgJAASQW45oCQAAEFXHNASABIKsA1B4QESCrANW8uL1++5KIjJEBSgYm45t++fTO9
vb1mxowZZtq0aWbHjh3my5cvteXDw8Pm//7v/+yy6dOn2+WfPn1q+fLqeMeLu3fvmqlTp5qVK1dW
OqdZ/30+ZcoUhAQQEmjPa37gwAFz/vx58/PnT/vq6+uzic+xceNGc/369dpyvd+0aVNXx7hE5N69
e7nLU+c05Pbt2+bo0aMICSAk0J7XfPbs2TbZOX78+FF3N6+kmZVIY/t5+vSpmTt3rlm1alXt+xMn
TphZs2bZu/SDBw/+ss7g4KCZM2eOXb5//34zOjpa9xslYy1Tq2jDhg3mw4cPufvMmmvKtSJ05798
+XLz6NGj6PnK21+ReaxS59RHv1uxYoUZGRlBSAAhgc645t+/f7cJOWyROG7cuGHWr18f3Y+EQAny
48eP9rsLFy6Yy5cv2++UVK9du2ZOnTpVt466iZSs9RuJju7qHadPnzbnzp2r3eFre7t3747uMyyv
34q4f/++WbRoUW4ZiuyvDOE59dG2J6I1gpAAQgITds2vXLlijh07Vvv8+vVre4ft7sD1Xt/F9uO3
FoREwr9DF34i1zpDQ0O1zxpjmD9/fu3zsmXLbDL2E7NaL7F9huVVIpcIFqHI/soQnlMftUbevXuH
kABCAp1xzT9//mx27txpWw2Obdu22Tt0d3c+MDBgtm/fXmo/ag3EBpf1ORQav/ssayDaX545u23w
nVohruVz/Pjx6Hmosr8y59QX6dWrV09KDJABACGBpl9zJbrff//9lyey1LfvJ3m917hBmf2knkjK
E5+s95lJsYCQCI2j3Llzx2zevNkcPnw493iq7K/MOXWcPXvWjsUgJICQQNtfc90163HVrC6WUDQk
JBqELrMfDW5//fo1us6LFy9qn/Wo7MyZM+vWD7ua/MHrokLi0L5iy6vsr8w5dahlJ2FDSAAhgba+
5k+ePLGD5/p/kSw0iH3p0iV7dy0ROXPmjNm3b1+p/ahr7OTJk7XuMX3Wk1D+OvqsO3ctP3LkSF33
mX6vu3e3vh6tXbx4cXSfEkCNmzhBWLp0qX1yS2jQPfbkWZX9lTmnDo0TuYcDEBJASKBtr7kGtWP2
rHoMV2KiO3K9JCLho7lF9qMnk9TK0DY07uInUK1z69YtM2/ePDsofujQobp/4BPucVy99ATVmzdv
ovvUU2HumIW6tTSIrm42iYgTlTzK7q/MOXXoOMKxIYQEEBLgmhOPbXGeOeNAxQWEBBASoOIC19wx
nvNiAUICCAlwzQEhAZIKcM0BIQGSCnDNASEBIKlwzYEYQEiApAJcc0BIgKQC7XPNsasd3/My0ecX
IQGEBCb8mjfjsdwqkx1WQbP7bt26tfY5ZYfbyHE263HliX7sGSEBhAQm/Jo3I04mKtYkGL5PSsoO
txEhaVaZJroeIiSAkMC4XPM8C9qseaJSs+xq3ijNxaU5tXp6eqwTYixBx+x3y1jjapJE30e+yrEX
FZK8+bPyyiIvkocPH9aVa8uWLYUsexESQEigLa55zII2XCeVjDUzsJvlVzP5rlu3LjdBp+x3y1jj
ypZXnu+xY22WkGQtj5VFk1PKvErLNNmlyuFaTrRIACGBjrjmMQvassl41apVdT4ez549y03QKfvd
Mta4StSvXr2aNCFJlUVCI5GVuPhe9AgJICTQEdc8ZkFbNhmHHh9KrnkJOmW/W8YaV94jYSKfSCFJ
lcWJjXzfZXiFkABCAh13zfMsaBsVkliCTtnvxo4rJGtbzRCSvHGMcFtFyqInymSuhZAAQgIdfc1D
C9pUMpaNrP/dmjVr6rq21N2Ut72U/W7suJrRIgmPvZEWSaoscljUGIqcJunaAoQEOu6axyxoQ7ta
fwD8/fv31unQ3+7Vq1dNf39/bbB948aNuQk6Zb9bxhpXYyQaj4mVN3XsZYQkPC+xsmiwfe3atXWi
8/fff2duByEBhATa8prHLGhDu1qX0PVbeZjrt+F2BwYG7FiAHoXVIHMsQcfsd8tY4+ouX/uKlTd1
7GWEJDwvsbLs2LGj7vFfvdfyvO0gJICQANd8EhgaGqprzQBCAiQV4JqXRk9FMTcYQgIkFeCaV0Zd
V7/99hsXGiEBkgpwzQEhAZIKcM0BIQGSCnDNASEBIKkA1xwQEiCpANccEBIgqUAHXnMes0VIABAS
rnlDhP+JXXTbzToG/We4/9/i7XIOW2l9MgAgJDCp17zqtpp1DDKGkvcJQoKQAEICLXDN3759a+/w
NYGg5qJasmSJuXXrVt16mvdKRlNK3ikbW01AuHv3brs9bUvTl+QdQyNWu7LWlcVujLL2t2WOv1Hb
4VT5i6yPkABCAi1xzVesWGFn7XUz1547d86Khr/e/v377TI3EWFsivZjx47VnA3lJaJZfLN+16jV
bjgle0hV+9uix9+o7XCq/Kn1ERJASKClr7lv1KT1NNV5bFv+ZyXe0Bsk63eNWu3K60RikEdV+9ui
x9+o7XDq+FLrIySAkEBLXXN1XelOfNeuXXbq9jIJM/wc8w1pptWukrC6hPKoan9b9PgbtR1OHV9q
fYQEEBJomWs+ODho78LVVfTgwQPb7TMRQtIMq93Yvqra346XkJQtf2p9hAQQEmiZa67BXN8mNmZB
W0RIZBpVpGuoUatdjSvEWiRV7W+LHn+jtsOp40utj5AAQgItc80XLFhQe0rLjTukhCS0iA0H29Ut
JfRkVN5gdaNWu8+fP4+OkVS1vy16/I3aDqfKn1ofIQGEBFrmmj9+/NgO8ioxKmlqgDslJKFFrP8b
PQUle1ltT+Mtvpd6M612L168GH1qK7b9mP1t0eNv1HY4Vf4i65etxwgJICTANffQ47ASm27mzz//
REiApAJc8yqoC05PXHU76oZDSICkAlzzCshSdzLm2uqkGCADAEkFuOaAkABJBbjmgJAASQW45oCQ
AAEFXHNASABIKsA1B4QESCrQLtccm12EBAAh4Zo3tG5Vm11ASICkAlzzzO0QSwgJEFDQxdd84cKF
tSnU3ey1f/31l/08PDxsl/vr5tnsnj171k7+6ObFcpMZ5h2Hb93riNnOpuyAU7a8fX19drtaXxMj
+kZdOh7NApx3/KltIyRAUoGuvua///67uXnzpn1//fp1222lyQHdZ3mX/5KAMlok8vVwyTlrpt7w
96F1b8p2NmUHHLPl1ay6+r1bV/ty5XLHI5HKO/6U5S9CAiQV6OprLlOr3t5e+14TAMohUS+xZ88e
m9CLCEnKijf1+5TtbBa+MVTMllcz+Pq+HnqvGXWLHn/K8hchAZIKdPU1f/36tb3bF+q2kYHU/Pnz
7Wd1H6m7q4iQlImvrGVFbHFjdsAxW94sJ0K/xZE6/pTlL0ICJBXo+ms+e/Zsa5zkBERjBZpd132e
CCFJ2c6m7ICd0GTZ8qYsa4scf8ryFyEBkgp09TXfvn27+eOPP2pdWq57y32eCCFJ2c6m7IB9Qlte
bTvs2vIfYS5z/FmWvwgJkFSg66+5nrjSmIE8zIWcB/V0kwa/s9aN2exWFZKU7WzKDjhmy6ttqYxu
2yqnHA2LCknK8hchAZIKdP01f/LkSd1jv7KW1WfnYR6uG7PZrSokImY7m7IDTtnyusd/9dITW2/e
vCksJKltIyRAUgGuOXRlDBANQFIBrjkgJEBSAa45ICRAUgGuOSAkQEAB1xwQEgCSCnDNASEBkgpw
zQEhAZIKcM0BIQGSCnDNOwHsgBESIKlAC13zyYqVRvaLHTBCAuMcSFkud4CQdHJZiXOEBBASGGch
kc2t5rnSlPJyEwxn+x0ZGbHTyo+Ojtatp4kbNbuuv508u9yUpW006ZVYt6odcOzYERKASEUDhEQJ
Wh4bmhlXviRr167NnDZeToqaSdfnzJkzNgGLlF1uytI2JSRV13WfY3bAqWNHSAAQEogIyZo1a8zw
8HDts5v9N1xPbopqlThLXP1duHBhLTmn7HKrWPI2Y90i61ex+kVIACFBSBCSfwkHppVQ84ys1q9f
X/MpuXr1qm0lOFJ2uY1MN9/oVPWp9YtY/SIkAAgJ1z3neoddRDEhkd2svNyFxkZke+tIJd5WFpJO
FA2EBCYtqUD3XXO5DWpsxPH8+fNoEteAtcZG1K3lk7LLbWUhSR07QgKAkIApPtgui9tYEtcgdE9P
zy+D0Sm73IkUkrJ2wKljR0ggeWJ5dc8LIcmmv7/fPvoqgdATTP64Sbje58+f7XK/FeOI2eVOpJBU
sQOOHTtCAtyVA9e8RNn1vyJ6Ogvo2gISCnDtC5V7zpw5dhDd/Q9FX1+f7eoChARIJEAMFCqznrxa
tWqV7dLRf7YfOnTICgogJEASAWKAuAeEhAoFxABlBoSECgXEAGUGhIQKBcQAZQaEBKhQgJAQ98Q9
QkKF8mmWleh4WJK2g80pQmI6oA505r4Qkg6oUPIh0BxCehRScxC9ePGitkxz8ZT5b+m7d+/aCfE0
RXXpi5yo9OGMrVVp1nZi2yyawCYy0SEk9Xz+bIy8nObO1SSOxixbproQrt9a5WlG6BYtU7ivyTgX
Y+nEXpuC6QQhmawK9ddff1lvhnfv3tl/ztI02UuXLq0t1z9t7dixo/B+Ug5wjQhJsxLheCTUdvAG
R0j+Y2TEmFWrNOeWHA9dXTBGczIODraukEzk8bRC2SUiJdIJQjJZFWrXrl1mYGAgdz3NRyS7zqL7
yLL7LCoeqTmIslpEeVahO3fuNA8fPqxrKW3ZsqVQy+rt27d23iFNgidh1BTit27dqjuWp0+fjt3J
zrX/1JYqtybR2717t92etjU0NJRb5pj1qWvtafpvzdz66NEjhKRimY8d06SFWTdW/wiMn0wV/gsW
aNr1XxPbWKgY2ZOMXVq7TLPNe6Fi1x8LFdvqcdtNrSNhGwsXu1zLXLhoW/7rv5gxYzFjxmLmnxZW
KAbh/v113R2/yib3YBdSWfvy18s7xtg28+jr++fYtS3NGem8uPLKi5C0YIXS9Nix/v3t27ebTZs2
2eSmyd00lUSZ/TRLSLKWx6xCNfmcuum0TPMoyflNbndF9rNixQrbMnOzosrPW6LhH8f+/fvtMjfJ
Xazcx8ay1o0bN2otPL/F5/8uZX3qt/bu379f2s0OIfkPXYL374vdlW/d+l9y0+n3rUzGQmUsVuRn
8s9rLFSMFyp2/bFQscvcfIipdSRy/4bLWLz8c6x5rYSxkLGtKm1H/5ivrjl/guKs/fvb8IVxLKSM
H1LhvvzPsWOMbTNEYq7yu3Oh8kigmtkqQkgmoEIpOSkp6U5Zd8zqxvry5Utt+bx588yVK1fseyW4
ixcv2sTYCkKSsgpVYpaHhJLxgQMHGkqooetdygLV/yzhCI8z63ep8kjMnCDRtdVo3Bfv3gkudTK5
+X5RWeun1lFSzgmXX/atsYPwt6EYxI5fApYXUjEhiR1jbJshGpdyXYuupTNnDkLSdhVK3/f29tpB
dSUxJV91d+Wh30hcWkFIiliFKjlrgj5NA14moarrSoKpc7FsLNrLTu8dWpoWKVOqPBJ8facyHT9+
HCFpoMzqRikqJKnv1HWkeytVGyVGf3neKY+tExO5cHv6bdgFFApZbBtqMeizBCkMqZiQxI4xts2Y
gGZtGyFpkwql7qrv3i2BhCL1VFPMorMZQpI3jhFuq4hV6NatW22LoIyQDA4O2nUuXbpkJ/dT99VE
CEmR8kjg1D22efPm0rPVIiT1XVIZ1iK2eygc44glYg3M6+58LFSMHHjVfZQSktQ6ZYQkFTJFhVDd
U2MhZfyQqioksW0WaRkWEWKEpMUqlAagwxbHdO92TXfzI3rEpdb0/F7zr64iJHo6rFktkpRV6Pnz
5+2YgwShTNeWxNXfbuyYi5R78eLFhbq2ylif6hHtssKAkPyH7pQ1thCiXty1a4sn4rFQMf4lGwuV
ZCJMrTMWLoW7tjSYHQuZIkLyX0zFj73oMca2GaLjD7u2/PtYhKRNKpT63PVyA8t6QkuD1A5Nr60n
idxyjTcoQZfpfnIDxO/fv7dPQ1UVktBKNGYVqlbEWi8jKEn//fffmdsJ0QMI7imtV69e2fOROs6Y
zam6yNQtJfQkWd5ge8r6VOvpyS2hczq1aEc/QvILGgZUl5JC+du3f5LizZvGzJ5tzOPHxROxnuZy
LZixUDGqOikhSa2jLq9/w8XowUN/IFv3eBrzcKGrweqxkKkNVuuz75abOn5t+9+Q+uVBgnBfRY8x
ts0QHa+einPHr+shkUJI2qxCCYmHBnKd3aZLuEJPPO3du7fm26BEV2Y/LuGp20Z35kqEVYUktBIV
eVahemjAf/xX77U8bzs+j8cyiQa5ddxK3hLa1HHGbE51DnU82p7GW549e5a7rZj1qbq1tL7Opbbl
RAUhqVZmPbX1++//PHqqLiI9HuuFTKFELNHR4LaSpRKoBplTQpJaZyxcjP51y/2TpBcu9okshZgf
umMhY1s5+k4h7rvlpo5fXVDah3u02Q+pcF9FjzG2zSzc47966YmtN28QkrasUEAMUGbohhggGqhQ
QAw0pczhU0682ueFkJBEgBigzECLhAoFxABlBoSEkwnEAGUGhASoUEAMUGZASKhQQAxQZkBIqFBA
DFBmQEioUEAMUOYup1MsdRESKtSklb2sNTAxQJnz99We6zfbvrf1XCUREpLIOJe9rDUwMUCZO01I
mjMNCS2Srq5QKVvZmL1ryvq1qm1sI9vVZIf79u2z81X19PRYl8GYF0vWdPVygdS2dU40aaJvYhXa
7JJU27fMeRa1O3fWz7mluaLcJNkxi9nUXbn/nSYoHAtTO0fWWJhaZ8NwnZiFbpH16+tbNUvdKsde
phxlbXkRkhatUClb2Zi9a2xZI7axjWxXjohuBt1Pnz6ZdevWJb3gfTTjrs6BOx/a327P+zPLZhch
ab8yxyxqdVk1I6+WaXJChd+/Ls2FbXBTyXgsTGuz9soXZSxM65anLHRT6//a8q5mqVvl2MuUo4wt
L0LSZknEN1iK2bvGljViG9vIdtVK8KeH10y7ZYREs+v66+v9HM/7M8tmFyFpvzKnLGqVAJUwlfQ8
K5vCNripZKzGrO9ioNlz/eWp40ut/2udqmapW+XYy5SjjC0vQtLiSSRmKxuzd40ta8Q2tpHthh4d
Ep0yQpLlUuhvs52TMUJSfyccs6h1SVD3EJ65ZmH3wlQyDrejZBsujx1fav2Qqpa6VY69TDnK2PIi
JC1coVK2sk5o8uxd85Y1ahtbdbtZZk9lhCS1PkLSGWUuEJ5m69Z/WiATISTh8tTxpdbPrm/lLXWr
HHuZcsSOCyFpowqVspX1idm7hsuaZRtbdrtr1qyp65qSw2EZIdH2w64t3wALIWm9MpW5vv9d57hF
rZz61LcvX3W/a6uoDW6429BOdyxM67qH5JToL08dX2r9eH0rbqlb5djLlCN2XAhJGyWRlK1szN41
tqwR29hGtqsHB/r7+2uD7Rs3biw92C7HSLd92Qov9rw/EZLWFJK8J/DyyhyzqNVgu+/brmToTENj
FrPhXbsbRJYTo5wL/eVjYToWp/8NWI+Fad3ylIVuav2QMpa6jR57mXKUseVFSFo4iaRsZWP2rinr
16q2sY1sVwwMDNgBcj0irKeuyt6xusd/9dITW288789OEJK85NuprzzyLGplIes//qv3/7o0Ry1m
/V25pKiuHd2HKITDQxkLUzsGo0djNbgfLo9Z6BZZP+w+Kmqp2+ixlylHWVtehIS7USAGWqZFAt0Z
90QDSQSIgVwhKVNmLGs711YXISGJADFAmYEWCRUKiAHKDAgJFQqIAcoMCAlQoYAYIO4BIaFCATFA
mQEhoUIBMUCZASGhQrUMLzvdD5QYmNAyE08ICUxgEqn6z11l1sv7rf9+WjP8QIkBylwxnsrEMCAk
JJFxqCBVBYiKipCMV5nLnguEBCEBk7IczbeujbUstJ7mvJo9e7Z1FYy1LGQGpXmrZF+7ZcsWazhV
tEUSTn8hV8cQuSXOnz/fjIyMcLFJdtEyZ02nkrKcLhPDqToFCEnHJZGUdW1ektc68glxs+yuXbs2
Kgia3n14eNj+/ubNm2bPnj2FhSR8rxl9Qx93Hc/evXu50AhJpRZJynK6TAyn6hQgJB1XoVLWtXnJ
3FUqR2hpG7737960P+23qpA4wysfWew+f/6cC42QVBKSLHwTtTIxnKpTgJB0XIVKWdcWHfwOLW1T
g+159rVFtyEfldevX9dETEICCEkjQhKznC4Tw6k6BQhJx1WoVIDnVaaUN3qqEua5Dhbdhsyrent7
7Xv1W1+8eJGLjJBUFpKU5XSZGEY0EJKuq1Ap69q8yiQnRY2NONStFBMB13oQsq/VwHgjQqJ9a9BT
3Wsa1ByV4xAgJBWFJGU5XSaGy9hMA0LSERUqZV1bdLBd68REYNOmTebz58/299pf2cF2iYaemvH9
1NUS+e2338z+/fu5wAhJqTKH8ZSynC4Tw6k6BQhJRyaRmHVtqntJrYGenh77pEqsu0rL9Vv9RhVS
lbiMkOipF63r72NoaMj+hv9SRkjKljmMp5TldJkYTtUpQEhIIjmoa8lv6k8Eqpy6kwSEhDIDQtKG
FWrOnDn2MVz3rHxfX5/t6pootF/d9R0/fpyLS1KlzICQtGOF0pMteuRWTXf9Z/uhQ4esoEwU6uNW
9wKD7CRVygwICRUKiAHKDAgJFQqIAcoMCAkVCogBygwICVChgBigzICQUKGAGKDMgJBQoYAYoMyA
kFChgBigzICQABUKiAHiHhASKhQQA5QZEBIqFBADlBkQEioUEAOUGRASoEIBQgIICVChgBigzICQ
UKmAa0/ZYbKuPZFApQKuOecAGrrmREGTTzCv7nkBcU/cIyTAXSkANCMHcAoAIQEAhAQQEgBASAAh
AQCEBBASAEBIABASAEBIACEBAIQEEBIAQEgAIQEAhAQAIQEAhAQQEgBASAAhAQCEBBASAEBIABAS
AEBIACEBAIQEEBIAQEgAIQEAhAQAIQEAhAQQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIA
QEgAIQEAhAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIAQEig5QQkfAEAQgKA
kAAAQgKTIyYAgJAAICQAgJAAQgIACAkgJACAkEC3iQkAICQACAkAICStkFB5dc8LABAS7sqBaw6A
kJBQgGsPgJCQSIAYAEBISCJADAAgJEASAWIAACEhiQAxAICQkESAGABASEgiQAwAICRAEsnh5cuX
XHSEBAAhmagk0tfXZ2bOnGmmT59uduzYYYaHh+vWC19Tpkxp+fJOmzZt3LZ99+5dM3XqVLNy5crM
5d++fTO9vb1mxowZ9jh0Tr98+VL4nCMkAAhJWwnJwMCAOXfunPn586d99ff3mw0bNuRu5/bt2+bo
0aNdffctEbl3717u8gMHDpjz58/XzqlEQ2JR9ZwjJAAISUsn1kWLFtk76DBRZqGkt2LFCjMyMhLd
z9OnT83cuXPNqlWrat+fOHHCzJo1y96lHzx48Jd1BgcHzZw5c+zy/fv3m9HR0V/u4LVMd/BKuh8+
fMjdZ9ZcU64VodbU8uXLzaNHj6LnK29/Reaxmj17tj1Xjh8/ftS1kMqcc4QEACFpqzv0r1+/2oS/
a9euzOUXLlxItka0HwmBEunHjx9r612+fNl+p6R67do1c+rUqbp11E2kZK3f6Bh0V+84ffp03R28
trd79+7oPsPy+q2I+/fv22SeR5H9leH79+9W5Kqcc4QEACFpGyHZuXOnvQPX6/nz55m/UWvk3bt3
yf34rQUhkfDv0N1dub/O0NBQ7bPu1ufPn1/7vGzZMpuM/cSs1ktsn2F5lchv3LhR6FwV2V8Zrly5
Yo4dO1bpnCMkAAhJW7VIXJeOun5CXr9+bVavXl1pP2oNxAbs9TkUGr+rJ2tw31+etc/wO7VCXMvn
+PHj0TJU2V8enz9/toKhlljZc46QACAkbSkkSnhZ/fVnz561Ca/KflJPeeWJT9b7rHWKCInQOMqd
O3fM5s2bzeHDh3OPp8r+8s7l77//bj59+lTpnCMkAAhJWwiJunz8RBd24zi2b99uk3CV/ehuW2MB
sXVevHhR+6xHZfVorL9+2NXkD14XFRKH9hVbXmV/WS0RPQKc1RVY9JwjJAAISVsIiVoZ6upxA8tH
jhyxrxCNabiB7LL70eD1yZMna/vQZ/9xV62jz0qu7hgkXP76ahG59fVo7eLFi6P71NNWGjdxgrB0
6VL75JbQoHusBVBlfz5Pnjwx69evz/3fkKLnHCEBQEjaQkjUraInnnTHrUHfvO4rJd5wHKPMfvS0
l1oZ2s+2bdvqREnr3Lp1y8ybN8/erR86dCjzH/jcwLSeoHrz5k10n3oqTPtyLQl1a2kQXd1sKosT
lTzK7s9HDwrELG+LnnOEBAAhaQsh4diIAQCEBBAS4DwDICTdnUTGc14sQEgAEBKSCBADAAgJSQSI
AQCEhCQCxAAAQkISAWIAACEBkggQAwAISfskEexqiQEAhAQaSiLNeCy3ymSHgJAAICQdkkSakXhI
XggJAELS4Ukkz4I2a56o1Cy7motr3759dk6tnp4e64QYa5HE7HeLWuMuXLjQzrQrNNOu9vHXX3/Z
z5o0UcuL7K+KRTBCAoCQICQmbkEbrpMSkjNnztRm+dVMvuvWrcsVkpT9blFrXPl93Lx5076/fv26
7Y7Ttt1nZ5FbxO63rEUwQgKAkCAkJm5BW1ZIdCfv+3g8e/YsV0hS9rtFrXEHBwet74f4888/rfe5
8z/fs2ePTf5F9lfFIhghAUBIEBITt6AtKyShx4eScJ6QpOx3i1rjygJYXvJCXWAyrXJ+70uWLKkZ
SxWx+81qrcXWQUgAEBKE5F/yLGgbFZJwuf++SEIuao07e/Zs25XmBGTBggXm1atXtc9F9lfFIhgh
AUBIEJKA0II2JSRucNuxZs2auq4tJfO87aXsd2PHFSI3xT/++KPWpeW6t9znIvurYhGMkAAgJAiJ
iVvQhna1/gD4+/fvrdOhv92rV6+a/v7+2mD7xo0bc4UkZb9bxhpXtrjyPJclrrh48aI9dg2UF91f
FYtghAQAIUFITNyCNrSrdQldv5WHuX4bbndgYMAmdT0yq6eeYi2cmP1uGWtceaT7j/26Qf6///67
8P6qWAQjJAAICUICxAAAQgIkESAGABASkggQAwAICUkEiAEAhIQkAsQAAEICJBEgBgAQEpIIEAMA
CAlJBIgBAISEJAKWTrIbJgYAIYFxSSLNSi6Nbmc8129k26HdcDsnY4QEEBJo6STSykLSzO0iJAAI
CUIS+V7vNdGhpmF3c1y5SRqFJm+U46AmRJTXx9DQUO52YvtJWfKKmMVtkfWrljFcL8tuWJNExtZv
VXtehAQQEpgQIdHEhM4pMJx199ixYzXXQvmEaIbeKkKSsuRNWdym1m+kjEVaJFu3bs1dv5XteRES
QEhgQoQktJv1l0s4QuvZKkKSsuRNWdym1m+kjEWEJLZ+K9vzIiSAkMCECElsedE790YteVMWt6n1
Gzm2IkKSKlur2vMiJICQQMcKSbg8lXhT60+mkLSyPS9CAggJTLqQyMyqStdWWUvelMVtav3JFJJW
tudFSAAhgUkXEg22379/375/+PBh7mB7o5a8KYvb1PrNFJLQbji1fivb8yIkgJDApAvJ6Oio2bFj
hxUK2eBqkDvrd41a8oqUxW1q/WYJSWg3XGT9VrXnRUgAIQGSCBADAAgJSQSIAQCEhCQCxAAAQkIS
AWIAACEBkggQAwAICUkEiAEAhIQkAsQAAEJCEgFiAAAhgbZLImUtbDvJ8pYYAEBISCIV9+u/Dy1s
U3SS5S1CAoCQkESasN+yx0MSREgAEJIWTiJ9fX12bqi5c+eawcHBUnNTvX371s4npckNNb+WLHhv
3boVbZFkWdjGtpNneTsyMmLmz59v5wDz0QSLmoXX0arWtwgJAELSEUlEtrVuJl1NLij3wTJCsmLF
Cjsbr5vt9ty5c1aQYkKStd0y2/E/9/b22hl2wzJJPEQrW98iJAAISUckEVnD+nf0Q0NDDc2WK3xz
p6JCUmY7/ufXr1/bVonzSdHfhQsX1uxwW9n6FiEBQEg6IomkbGuLCMnTp0+tV8muXbvs9PJFxCNr
u0W3E35ev369bXUItWrUReaXr1WtbxESAISkI4WkSML3v9OYigyuLl26ZB48eGC7x6oISZnthJ/v
3Lljx1SExka0flarhhigGgFCAuOQRNauXWu+fPlS+xza1qZsczVI71vLhsuLCkmZ7WR9XrBggR0b
UbeWTytb3yIkAAhJRySRmzdv2qe28mxrU7a5SuDu6SqJ0OrVqwuJR2hhm9pOyvJWA+g9PT2/DKS3
svUtQgKAkHRMEtGTTXpCat68eTaZl7HNffz4sR281m/UNXXjxo1CQhJa2Ka2k7K8/fz5s10mMQxp
VetbhAQAIenYJELCIQYAEBJASIDrCoCQTF4SKTsPFiAkAAgJSQSIAQCEBEgiQAwAICQkESAGABAS
kggQAwAICUkEiAEAhAQmO4lgjUsMACAkJJGGmEhrXBIk5wkAIenAJJKaZBEQEgCEpEOSiObOcnNp
aabcR48emTdv3ljHwhA5DMpESha32p48QDTZotb1J3fMs8Y9e/Zs5u8dMUvcrOPMKlvsd8QA1QgQ
EhiHJOIn9Pv379fcAzULcJiEJRx79+6tbU8TIDonQje5Y6xFsnXr1tzfpyxx844z3Ffsd8QA1QgQ
EhiHJKJZfzXTbojMojZv3lz3nfzcnz9/XtueE4WsfWQJSez3KUvcvOMMtxP7HTFANQKEBMYhieiu
XcuUyI8fP163TN1Q8kQXz549s0IS214ZI6qslkTMEjd2nP52Yr8jBqhGgJDAOCUReaW7Fsjhw4dr
3/f395ve3l77fvfu3ebixYvjJiRFLHHzjjPLQz7rd8QA1QgQEhjnJPLixYu638kkSs6Ew8PDdhB8
dHR03ISkjCVueJx5ZQt/RwxwLgAhgXFIInIj1JNOIhwAdy2R3377zezfv7+UMKSsccPvUpa4seP0
t5MqDzEAgJBAk5OIuoGWLVtWeyTXJWHH0NCQXTf8T/WUMKSscbO+i1nixo7T306qPMQAAEICE5xE
lMw16A4ICQBCQhIpvY66mNRK4OknhAQAIYFKSUTjHJs2baobZAeEBAAhIYkAMQCAkABJBIgBAISE
JALEAABCQhIBYgAAISGJADEAgJAASQSIAQCEhCQCxAAAQkISAWIAACEhiQAxAICQAEkEiAEAhIQk
AsQAAEJCEgFiAAAhIYkAMQCAkACJBLj2AAgJCQW45gAISeslFl7d8wIAhAS4MwcAhAQQEgBASAAh
AQCEBBASAEBIABASAEBIACEBAIQEEBIAQEgAIQEAhAQAIQEAhAQQEgBASAAhAQCEBBASAEBIABAS
AEBIACEBAIQEEBIAQEgAIQEAhAQAIQEAhAQQEgBASAAhAQCEBBASAEBIABASAIQEACEBAIQEEBIA
QEgAIQEAhAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIAQEgAIQEAhAQ6UkDC
FwAgJAAICQAgJDA5YgIACAkAQgIACAkgJACAkABCAgAICXSbmAAAQgKAkAAAQtIKCZVX97wAACHh
rhy45gAICQkFuPYACAmJBIgBAISEJALEAABCAiQRIAYAEBKSCBADAAgJSQSIAQCEhCQCxAAAQgIk
kRxevnzJRUdIABCSiUoifX19ZubMmWb69Olmx44dZnh4+JffjI6OmsWLF7dNeadNmzZu2757966Z
OnWqWblyZfR3eedsZGTE7N692x7jnDlzzMGDB82XL18QEgCEpD2FZGBgwJw7d878/PnTvvr7+82G
DRvqfvPjxw+zffv2tkpE43msEpF79+5FfxM7Z3v37jWnTp2qnfOzZ8/a3yIkAAhJWybWRYsWmW/f
vv2SKH0kLO/fvy+UiPSbp0+fmrlz55pVq1bVvj9x4oSZNWuWmTFjhr0DD9cZHBy0d+davn//fns3
H7aatEytJh3Phw8fcveZNdeUa0VMmTLFLF++3Dx69Chajrz9FZ3HKnbO1BKRgDj0Xi1ChAQAIWn7
O/SvX7/ahL9r16667x88eFB4G/qNhEDJ8ePHj/a7CxcumMuXL9vvdKd+7do1e0fur6NuIiVr/UbH
cODAgdry06dP17WatD11DcX2GR6r34q4f/++FdA8iuwvReychULy/fv3ce2KQ0gAEJIJSSI7d+60
d+B6PX/+vHIi0m/81oKQSPiJ07WE/HWGhoZqn9VCmj9/fu3zsmXLbLL1E69aL7F9hseq1sqNGzcK
nasi+2vkvEuU1J2lc6KWl0RTLSWEBAAhafsWievSUddPI0ISotZA2CXkJ059DoXG717LSrL+8qx9
ht+pFeJaPsePH4+Wocr+ypwPDaxLuLVNDcbr2GiRACAkHSMk6noKx0gaFZLU3Xae+GS9z1qniJAI
jaPcuXPHbN682Rw+fDj3eKrsr5Hz/urVK9PT04OQACAk7Skk6vL59OlT7XPYjdMMIVELR+MvsXVe
vHhRd8fuDz5r/bCryb+DLyokDu0rtrzK/hpJ3jdv3vxlXAohAUBI2kZI1JWlrh43sHzkyBH7aqaQ
aPD65MmTtX3os/+IsdbRZwmaOwb/cVj93o0p6HX+/Pm6/8/I2qeettK4iROEpUuX2ie3hAbd81pd
VfdX5nzoWCQe4u3bt7aF9OzZM4QEACFpTyFRV5aeeNIdtwbaJSyNJKK83xw9etS2MrSfbdu21Z6u
cuvcunXLzJs3z7aQDh069Ms/6LnHcfXSYPWbN2+i+9RTYdqXa0moW0uD6Opmk4g4Ucmj7P7KnA+J
hh5TdmMkRR8CQEgAEJKWFBKOjRgAQEgAIQHOMwBC0t1JZCIefQWEBIAaQBIBYgAAISGJADEAgJCQ
RIAYAEBISCJADAAgJEASAWIAACFp/SSCXS0xAICQQENJpBmP5Vad7BAQEgCEpAOSSDMSD8kLIQFA
SDo8ieRZ0GZZyqZm2dUEh/v27bNzamladDkhxlokMfvdota4CxcuNJ8/f7bv3717Z/fx119/2c/D
w8N2eZH9VbEIRkgAEBKExMQtaMN1UkJy5syZ2iy/msl33bp1uUKSst8tao37+++/12bSvX79uu2O
07bdZ2eRW8Tut6xFMEICgJAgJCZuQVtWSHQn7/t4aJbbPCFJ2e8WtcYdHBw0vb299v2ff/5pfT2c
t8eePXts8i+yvyoWwQgJAEKCkJi4BW1ZIQk9PpSE84QkZb9b1Br39evXZsWKFfa9usBkWuX83pcs
WWK7u4rsr4pFMEICgJAgJP+SZ0HbqJCEy/33RRJyUWvc2bNn2640JyALFiyw9rXuc5H9VbEIRkgA
EBKEJCC0oE0JiRvcdqxZs6aua0vJPG97Kfvd2HGFyE3xjz/+qHVpue4t3762iN1vSJljREgAEJKu
FZKYBW1oV+sPgL9//946HfrbvXr1qunv768Ntm/cuDFXSFL2u2WscWWLK595WeKKixcv2mPXQHnR
/VWxCEZIABAShMTELWhDu1qX0PVbWcTqt+F2BwYGbFLXI7N66inWwonZ75axxn3y5EndY79ukP/v
v/8uvL8qFsEICQBCgpAAMQCAkABJBIgBAISEJALEAABCQhIBYgAAISGJADEAgJAASQSIAQCEhCQC
xAAAQkISAWIAACEhiQAxAICQQJEk0qzk0uh2xnN9EijnAQAhaYMk0spCApwjAIRkglokeq+JDjUN
u5vjyk3SKDR5oxwHNSGivD6GhoZytxPbT8qSV8QsbousX7WMCAkAQgINCokmJnROgeGsu8eOHau5
FsonRDP0VhGSlCVvyuI2tX4jZURIABASaFBIQrtZf7mEI7SerSIkKUvelMVtav1GyoiQACAk0KCQ
xJbH7twb2U5oyZuyuE2t38ixISQACAm0oZCEy1MWt6n1ERKEBAAhaVEhkZlVla6tspa8KYvb1PoI
CUICgJC0qJBosP3+/fv2/cOHD3MH2xu15E1Z3KbWR0gQEgCEpEWFZHR01OzYscMKhWxwNcid9btG
LXlFyuI2tT5CgpAAICQkESAGABASkggQAwAICUkEiAEAhARIIkAMACAkJBEgBgAQEpIIEAMACAlJ
BIgBAISEJALEAABCAh2URF6+fFlpWTN+TwwAICTQAUlE/7med5zhska2BZwPAGpAhyaRZnqtkyg5
PwAIySQlkb6+Pjuv1dy5c83g4GCpuanevn1r58KS/a7m15IF761bt+p+m2dtG3qO+NvOWhbbV962
RkZGzPz58+08YT6aPVizDDti1r4ICQBCApEkIttaN5OuJkaU+2AZIVmxYoWdjdfN1Hvu3DkrSP5v
Y9a24fZj+y6yr6xt9fb22hmEw3JLPETK2hchAUBIIJJEZGvr360PDQ01PFuub0yVsrYtIyRF9pW1
rdevX9tWifNS0d+FCxfWjitl7YuQACAkEEkiKdvaIkLy9OlT61Wya9cuO718mfXLCkmZffmf169f
b1sdQq0atZL8cxCz9kVIABASKCEkRZK5/53GVGRwdenSJfPgwQPbPTZeQlJ2X/7nO3fu2DEVobER
rZ/VqunGGABASKChJLJ27Vrz5cuX2ufQtjZlm6tBet8WN1zeTCEpu6/wswb8NTaibi2flLUvQgKA
kEAkidy8edM+tZVnW5uyzVVydk9OSYRWr15dSkj0BJbGKpwHe2xZal+xbQkNoPf09PwykJ6y9kVI
ABASSCQRPbWkp5/mzZtnE3UZ29zHjx/bgWn9Rt1ON27cKCUkSur6R0L3z4SxZal9xbYlPn/+bJdJ
MENS1r4ICQBCwgkskURIOMQAAEICCAlwXQEQkslLImXnuAKEBAAhIYkAMQCAkABJBIgBAISEJALE
AABCQhIBYgAAISGJADEAgJDAZCcRbG+JAQCEhCTSEBNpe0uC5DwBICQdmERSEygCQgKAkHRIEtHc
WW4uLc2C++jRI/PmzRvrRhgi90AZRMm+toqF7tmzZzN/74jZ3WYdZ1bZYr8jBqhGgJDAOCQRP6Hf
v3+/5gyoWYDDJCzh2Lt3b217ZS10t27dmvv7lN1t3nGG+4r9jhigGgFCAuOQRDTrr2bRDZER1ObN
m+u+k5/78+fPa9sra6Eb+33K7jbvOMPtxH5HDFCNACGBcUgiumvXMiXy48eP1y1TN5T8zsWzZ8+s
kMS2V8ZkKqslEbO7jR2nv53Y74gBqhEgJDBOSUQ+6K4Fcvjw4dr3/f39pre3177fvXu3uXjx4rgJ
SRG727zjzPKQz/odMUA1AoQExjmJvHjxou53MoCS6+Dw8LAdBB8dHR03ISljdxseZ17Zwt8RA5wL
QEhgHJKInAb1pJMIB8BdS+S3334z+/fvLyUMKdvb8LuU3W3sOP3tpMpDDAAgJNDkJKJuoGXLltUe
yXVJ2DE0NGTXDf9TvREL3bxtxOxuY8fpbydVHmIAACGBCU4iSuYadAeEBAAhIYmUXkddTGol8PQT
QgKAkEClJKJxjk2bNtUNsgNCAoCQkESAGABASIAkAsQAAEJCEgFiAAAhIYkAMQCAkJBEgBgAQEig
lZMIlrvEAABC0gVJRDPmyitkPAgtdzs1wRbdhv5j/+HDhwgJAELSWUKiKdfddPHdmLwm8hh1nv3p
+BESAISk7YXkyZMn9p8Ow99eunTJzJkzx8yePdtcv37dTqKoebDKWORmWe6+ffvW3pXrnx21rSVL
lphbt25Fjz21Tsz2t+j6ReyFm2X3q/Ot846QACAkHSEkBw4cMIODg7/8ds+ePTaJ3r592wqILHb1
uaxFbrhfJeurV6/WZvk9d+6cdTWMkVonZftbZH2Rshdult2vRFrnHSEBQEg6QkhWr15tXr169ctv
fVtcffa9QspY5BZJXkVMrWLrpGx8i6wvUvbCzbL71fnWeUdIABCSjhASdfeEQpAypSpjkZu1X031
fuzYMbNr1y475XuRBBdbp8gU9UXXj9kLN8vuV+db3YAICQBC0hFCktUaKCMkqdZEuK660WQ+pe6d
Bw8e2Gnq3W+yxlRS6xQRkjLrx+yFnSA1w+53Mgy3EBJASKAlWyQpi9xwXY23+L9/9+5dMsGl1kkJ
SZn1Y/bCPo3Y/WosiRYJAELSMUKivnp14VQVkpRFbmi5q64j98SUGytIJbjUOikhKbt+nr1ws+x+
NebCGAkAQtIxQqKnh/TkVVUhETGL3NBy9/Hjx3YwXslVCVeD0qkEl1onJSRl18+zF26W3a+6y3hq
CwAh6RghUdL0WxAw/vbC69ats2KDkAAgJB0hJEJPFzEn1j+Mt72wutZ0vlstBgAQEmgoiagfX2MC
MP72wjrPzLUFgJB0nJAAMQCAkABJBIgBAISEJALEAABCQhIBYgAAISGJADEAgJAASQSIAQCEhCQC
xAAAQkISAWIAACEhiQAxAICQAEkEiAEAhIQkAsQAAEJCEgFiAAAhIYkAMQCAkJBIgGsPgJAACQW4
5gAIyaQnFl7d8wKAf/h/NXI5A/KmFOoAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-11-05 13:22:16 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAOwAAAPMCAIAAADO9cLoAAAq50lEQVR42u2dsW4cx7KGFzBgONhA
wT6Bn2EjY+HIjvxOVqiAgBnuWxh+BMG0QpqRM8M+IkEzYKDrk1G20LepvfBd73b3VPd09XTNfIUN
pNHq53Dmm5qa6u5/ViuCmEE4gjAbQEwAMUEAMUEAMQHEQEwAMUEAMUEAMQHEQEwAMTFrOLof1gVi
gIjurWQjEC8IXytAHPat+F+BeJ4E2wKCmpiY5xVITUxYAiK4w53fN4AYIICYAGIgBuLOa83+dxiI
AYLuBEEAMdE7HN0PNAIxQIjqeGpiCDYDBN0JYj7dCSAmzEPsGHYmjAJBd4IggJjo5qZhyLMPiAGC
TEwQQEz0DgcLRQlbQJwUQuktQLy4ytgEEEBMzAfik52knCDMAOEivRRabJTCtNiAmCCAmABiggBi
ggBiooenUiAGCJNr7MjEhDEggJiYD8SGdhuIAUJa/1ATUxAzYgfEBAHExMgbCBADBJPigXheT3UL
nxRf95IGYiBuus8aL0QDYrJaO2WlF6IBseGa2NxrHqmJiRZZrfHOUxMTioTpDdBU9wgFYttAOF7z
CMSzKSqqOx/rPYwCMd0JdYgbrNCu+0I0IG7alOi/vrTyaAjEfXUSuspqhjMFnBHpa091GIWaeOlA
WK/jqYmX/mDn1Jag0p0grGa1xOVR/WgAse02RbdANL6qGXYmrEJMd4JQzGrBu4fDZJswBIRqjlea
SQLE3PTN7zMQk9WAmJh1D8HEwicgNg+E3Us6sQWIuTx6RA2IiXaotZlPXH+HoaFNmrQ4w6H/owHE
s0rGzCcmyPHhH+EYsSMcI3ZAPJs7PiN2QAzE7DMQA8SIslu1oAdit2Qg7F7SZGJCJasBMWEeCNd8
xA6ITZbF3dKQEFddnk1NvPQHO6XTx4tniEYQW5yVAcRAPNkjY7fKQNwUCEMEt3wYpSbm8lj6ax6B
uPUJq1tl8oY8IG5dSKQ3LgRiamJu+nOAmO4EoXt5NBixA2JiguK1YvHDiB1h9fGLTEw0ymoNIKY7
QVBtA3EfQCxwhoPeHgKxydNmsYdATQzErZU17h50J+CYHQbingribs35LN49gHhuCX6BHAMxELe+
e1ATz6SiMKFMTUw0uulzNIAYiDPu+xqFBOUEEGuZxuq9+pzuBDVxCjWnME1HT5lygrAHMeUE0RRi
Z8d6C4hbQNbmzRq02AjCat8DiM13J6yXQCzZt5dyOu+5WqzjgXiaTMzRAGKiNW3V53tUVAZik48y
QWWnOWLnWLIPwXUfZRqgpjTYoVF0AbHJKtCusoa9IhADsQg4nOIJ3YckRuyAmABiYtwDTe9wYO1K
aHOsPdesekcFiC3f7zS92Gw9MgIxMZO+B7PYiBaomShUgLh1ReF0eq6GniCZAES+5GgA8Vwg1nvN
Y5slVRULFSA2nIlVX/Nor1SDs2Y1McPO+E4Qhi88fCcI2/myug4QT5zVLL7jiBE7sprt3Vat4ykn
Fg2xRr7UNgNgxA6OG6HW4FAw2GG7IO72IQmICSKbY8oJwl7fg+6EedSckVfNATGhWwW2gbj6hceI
HRA35bjZPlMTk4kNr96rxTEQT/P4RQkExITtCw8bK6JF34PuBCF6Ku/88QuIieHn8Yor7frvIQDx
fAg+3tIzxMwnJhpB7PTfGg3ERAq1zo98g+6EY7CDMH1fYiomEW19ADFhu9ru//IAYqIRxC0vD2pi
OF6Zg5juhO3K1fW9/N0ix0Bs8lGmTTnR4FW+TIoHYturncnEQGyVYyA2XxNr35e7venrcQzEhOju
gRcbQQlEOTEjJlzfy9+BmJCeNnNrRauXE0AMxPN5xqUmXnp3wuHFBsT0EGZweQAxPYRGj1969yUg
nqwQXCzEOADN5MFugT0EIAbiGd49gBiObd89qInNpzSNaTpuqZPjgJjuhHmOgRiIp7l7VLxUgLh1
RaGULA25YvJgR77UfUhqUEsAMRDPoUFBdwKIm9Y/zJ0gdG/6zo4VNuUE0QiI9tmd+cRArAixlUdG
IDZfX+IUD8Szeuo3keMpJ+B4btU2LTYgduYKlepHA4inqYl7zujteQBiMrqKZkvTWMoJOF414IwR
OzjTspxqYGNl5vDCWct8ufDZP44JQPO44y+ZY+ZOALFuVpukUAFik2XxknM8EBMzKVSoiYmmhYoz
McMTGprlHqfsXVn98uh/NQoQN82XFtckAzEBxEAMxDllsYlCBYjN18S02Ko/IQAx3Qnz9yUgJseb
73sA8QTphzV2QMyDnflChRE7IJ6AY7oTQDwTL7ZaibNujgfipkwYSsOGLgwgniEZ1TNl3coYGytC
F4jz+0Z6IzUx0SnEGj2EoLJjxI5wlt+QR5+YiD4qATFh4/FrBrcOIOaOP59LmpqYx6+lJ3ggts1x
YytsWmzcQA0YkcSkqtSvjNiRhltn4uCWDmkBYmpiICbm26AIXh5VfhG6E3MoiOkTV7zCgdg2CqZH
7ICYmOAGotr3AGKT9aWt7oRqcTXmsACxyRuo01w+ZO5JFIitQtwANStgALFtiFsWxN2+BRWIbdfE
zuAkT9bYEWEg+vdzB2JCBLGrtxpZu5wAYqtVhF4PwZy3EDWx7We76nno+FxSThB0J+x1oIEYiKe8
ewCx4eK4f9QaL3wCYnK8CmpW7h5ADMQT3D2AeA7lxAJR09tnIJ4mX3I0Kh4fIAbi1ncPIIbjRuWE
IZsBIJ4mpfXfQzBkMwDE1JfmqyAgBuLWdw8gnk9F0XlN3Ozao5wwli8NTV03dPcA4gkgdt3PYrP1
MArEViHWnjDZsriinLDHMQecBzui9TMo3QkC1IZ3HohtnLCKjzIz606Qic2csOOnftULpu6F1/+s
DCBuCrHq+8Q1WmDN1j4BsaVMrMRuA/Ng1tgBse6CYUMQ050AYvOZGIittiZUG2HVa2KlfeZljES7
7oTJTMHpJ4CYIICYIICYAGKCAOKFH0FCP4BYEWKUp1UGYoAAYiAGNSAGYpSBGIiBGIgBAoiBOP2F
d3+9e/X21e5m9+KnF6vXq/XVenu9ffn7y8f3jyOVP3x49z//8+rhYXd7++I//1m9fbv+44/tu3cv
P3x47Haf/3r37u2rVze73U8vXrxera7W6+vt9veXL98/PgJxpxDv7/ebNxvPwfnH83F5d1ms/N//
7m9vN57d849n+s8/Lzvc5/v9/s1mExJeeabvLi+BuDuIfeoKonD88d8pUPbpNojv8cd/p6t99ul2
SHjlvwPEHUHs89kgDYdPLLfFlH0OHiT48Inl4/b77HOwTHgVy8e9QFx9mcCYL8fsIIQb07vha8rY
HTl4j354ehAq+zr4uIr48cfVl1+uPvvs+fPNN6uffz6tK/7++2HyffZ1cKyKCNYVTw8PXUPc5kk2
+EvGfnTQ5C+9cfC38E9FQhoSN+igsn+SO8b088+ff7Ufflh9//3zH774QlRUNN5n/ySXIxwuKnqH
OEHPuQ9f7H/FfpHgOkptiP1zfeDkHCJ03vyzv1D54WEXrBx+/fVZ+9NPT7f/8cd28n2+2e2yIL7e
bucDcdARNW2TKrzpa0N86EzJgVhfrYXKh27ayeeXX1ZfffWs/d13p//09u168n0+dNPkn6v1umuI
gzVxFj11IR68VMpq4jAKx3F26oTKwTT89dfPkt9+G368m3yfzzHdDAiv5pOJ9SAO1ieSoqXPTPzJ
J8/Cv/0WIJhMPGeIhWhaqYljH2ri1hAHb+4Wa+Jm3YnD5xDyIQ+6Eyp94vR9fEx3Yt594jTE9ImN
jZAxYseIXe/gduvlz9wJoTJzJ6zeGXxuCz/1f7wjX9xeFCt/nMX2Ij6L7aLDffb5ONap8NtvLwqV
gVi9vInNzQ3WlFnKsfnEwTq4k32OzScO1sFAbL5GRxmIgRiICVADYiBGGYiBGGUgBmIgJoQHl8AV
k0yMMpkYiIEYiAECiIEYZSAGYpSBGIiBGIgVT5uew6RFZVwx7UGs5zBpURlXTHsQ662SsKjMyg57
EOutV7OojCvm2GeIkQubu1rtbFEZV8yaP7TAYqI33wmLyrhijnXFzP2JVSDWc9OxqIwrpmijMLs3
g1jP18yiMq6Yw18QQjzmJ/bjimlRGVfMiSEmE5OJe4F4Nk7x1MS9Q6zkihl0E6Q7QXeicp9YzxUz
UYjTJ6ZP3NcIGSN2jNj1Di6umNaVmTth9c6g5zBpURlXTKvljZ7DpEVlXDGXVaOjDMRADMQEqAEx
EKMMxECMMhADMRATwoNL4IpJJkaZTAzEQAzEAAHEQIwyEAMxykAMxEAMxIqnLfYG5g8fHrtV1vCu
1FMGYl2I//vf/e3txhN2/vHk/fnnZYfKSt6VDldMixD7pBiE7Pjjv9OVst76C1Z22IPYZ8pBzg6f
WNZsr6y3Eg5XzLHPEFlrmINbclc7+2r1+F7/44+rL79cffbZ8+ebb1Y//3x69//774fJlfXWJOOK
WfOHCh2rBv/74G/hn7eOYfr882fZH35Yff/98x+++EJ062+srOcOgStma1fMKhA/POyC9/dff33e
yU8/Pd3+xx/byZX1fHpwxRRtFGZ3yX+pAvGh53Xy+eWX1VdfPe//d9+d/tPbt+vJlfUc03DFHP5C
LUPBihAHk+XXXz//1t9+G34Im1xZz7sSV0yTEAfz5SefPB/q334LcDYyE1dRJhP3DrEcTdWaOPYZ
XxOPV6YmrgPxtK6YFSE+6SEcPoeQD0w0VqY7MbZP3IkrplKfOI3amD5xRWX6xNOPkDFix4hd7+Ba
dMVk7kQbZeZO6N4ZPs41exGfa3bRobKSd6XDFdNueROb9RusVjtR1vCu1FMG4n5rdJSBGIiBmAA1
IAZilIEYiFEGYiAGYkJ4cAlcMcnEKJOJgRiIgRgggBiIUQZiIEYZiIEYiIFY8bTpeVfG3sD8+L5f
v00gtgexnnfl/n6/ebMJzi33TF/e9ei3CcT2INZbf+HT7eBCH/+drvYZiO1BrLcSzudg4brhWD5u
v8/zgdioK6YTe7Ic15RK3pW+Do5VEcG64uFper/NuUHc5heO/ZQCV8zYxvRvoedd6Z/kVjkmDsGi
ovE+LwLi/l0xcyHW867c3ewCsMYszV6vttfT+20uGuIeXDHLygk978pDN00O8fpqer/NRdTEPRsK
lkGs510ZxjdpMTn5Pi+9nDAKsZ53ZeNMXGWfgbgOxMWumGUQ63lXtq+Jx+/zsiDu0BWzDGI978pm
3YmK+7yUPnHPrpjj+8QVvSub9Ykr7vOsINb+ZbraH0bsgDiaTQ1dVMydAOI53Bn0vCt9Pg53Kj5W
ERe3PfptArHV8kbPuzI2nzhYB3eyz0C8rBodZSAGYiAmQA2IgRhlIAZilIEYiIGYEB5cAldMMjHK
ZGIgBmIgBgggBmKUgRiIUQZiIAZiIFY8bRa9K2NvYH7/2KOTJxDrQmzRu/J+v3+z2QSn2num7y67
c/IEYkWILa6/8Ol2cN2T/05XRwOItSC2uBLO52DhMupYPm5/NPIgjq1SbglK2Y+Tu2Jm+Wcmdsmi
d6Wvg2NVRLCueHqYfoV2HsRC+5wOIZY7s2R5uKQ3WvSu9E9yObscLioaH40MiBPmDP94QQxmr/Q3
Jf/XDXlNyB0stSG26F15s9tlQXy9nd61aBTEQQTHmPcISZL/iGkhtuhdeeimyT9X6+n946pBLDzH
g4hUgXhMRZR23s6qiS16V57jtBnY5emdPHUhPp8GKoc48X/bQ2wiE1fxrlxcJq51X861QiuGWOKK
abomHu9dOfOaWNidKHO5rFsT516E1rsTFb0rZ96dEPaJg29wKXjXy8juhKQ+mU2fuKJ35fz7xAQj
dnMYsSNyDy5zJ9ocDSBWhNjZ9K70+TjWqfDbby+6c/IEYl2InU3vyth84mAdPPnRAGJ1iFHWVgZi
gABiIAY1IAZilIEYiIEYiAECiIGYwBWTTIwymRiIgRiIAQKIgRhlIAZilIEYiIEYiBVPm553JcpA
3AJiPe9KlIG4BcR66y9QBuIWEOuthEN5eogHRxHP93v8HiZcWoT7lrXaWc+7EuXpIc5y1KwFsdBp
ILFvuUv29bwrUZ4Y4kETkzK7CUkGbQyxnnclyt1BLKRqpEnPSIjTjrGNvStRNg9xcbERgzhmWzgS
Yj3vSpTnALHck0ryYOfE7lvjM3EV70qU+62Jx5QTxT0EYZpPz8tu7F2Jcr/diVyIB/02K9bEBZeH
nnclyl33ibO6Ey7HzH3yPnFF70qUGbFjxI4ROyLn4DLDoY0yECtC7DS9K1EG4kYQO03vSpSBuBHE
KGsrAzFAADEQgxoQAzHKQAzEQAzEAAHEQEzgikkmRplMDMRADMQAAcRAjDIQAzHKQAzEQAzEiqct
9jbjx/dLdMWMvTX6/SOumL1CvL/fb95sYu+Vv7xblivm/X7/ZrMJHYyVZ/ruElfM/iD26TaI7/HH
f6dA2eL6C59uhw7Gyn8HiDuC2OfgQYIPn1g+ntNKOJ+DZQdjFcvH6hAXGF02fm4Ys9q5wHfC18Gx
KiJYVzw8zdm70tfBsSoiWFc8PTRf7VxmdNkS4pGumOkfGvxX/yQnJDhRVMzGu9I/yeUcjHBRoQhx
sdFl4l9PjFHSXxi8FYx0xSy7LHc3u8DJOUTovG2v5+xdebPbZUF8vd1ODLEQlNi/yq3+2jgADc6i
Cm4/dNPkEK+v5uxdeeimyT9X67VtiEcmy1yI5ZeKy3F/C+N7HGenTqhs0bvyHNPNwMFYAXHGg50T
eGQVQNw4E3fuXWkvE+caXU4FcUl+FW9sXxP37F3Ze03sRhtd5kLcviYugLhZd8KEd2Xv3Yl0c6Cs
OzGIVFZ3omKfWJ7Im/WJTXhXGugTM2LHiN0cRuyAOBjMnTgO5k6YhPiQj8Odio9VxMXtslwxfT6O
dSr89tsLXDG7hNjF5xMH6+AsZYuumLH5xME6GIh7gRhlbWUgBgggBmJQA2IgRhmIgRiIgRgggBiI
CVwxycQok4mBGIiBGCCAGIhRBmIgRhmIgRiIgVjxtOGKqX00gFgXYlwxGxwNIFaEmJUdbY4GEGtB
zBq7NkejI4jTnm7jxeVrmFf59jPByg9XzAZHo2uI6xJ8/ue0i0DwGGVBjCtmm6PRL8TplJm2/RP+
lLSpxfl/yYUYV8w2R6NTiAeteiRbyiCuWE7gitnmaPQIcRaCY2jThhhXzDZHozuIY2iezyiNuVnK
i9eZZeLOXTGXlYmFfz6BuJahYEWIccVcdE0cK14l1oPyd8NoQ4wr5tK7EzE0BzsYg9VI2pPTYp/Y
hCvmUvrEtcbJGLFjxA6Ca+4McyfaHA3mTuheUbhiNjgaQKx+W8AVU/toAHG/tQ3KQAzEQEyAGhAD
McpADMQoAzEQAzEhPLgErphkYpTJxEAMxEAMEEAMxCgDMRCjDMRADMRArHjaLHpX4ooJxP8fFr0r
ccUE4qOsY3D9BSs7gPhf+czcSriFrrFTdbOsqJxYBV22Mb1XFr0rl+uKGVwH3xvEQS7P/5zln5ne
aNG7crmumGmIE4ktneokPA1aZR7/tTHEFr0rl+uKeYyIxF0q8YeC/+vExpiNIbboXblcV8wExME9
GGO9KlHO9WKT3zqyamKL3pXLdcVMQxwztIw9Y2UlxUGrTMmDXctM3Ll35XJdMYvLiTF3drnPu/AQ
NKuJe/auXK4rpqTYDaZY+deE/8Xl2P417k6Y8K5crivmYJqM1RjpO7vkdp/1roNp+8QmvCtxxex6
8IwRO0bsILjw5zJ34jiYO2H14rHoXYkrJhAHak1z3pW4YgIxyk2VgRgggBiIQQ2IgRhlIAZiIAZi
gABiICZwxSQTo0wmBmIgBmKAAGIgRhmIgRhlIAZiIAZixdOm4QN5CFwxgbgFxEo+kA5XTCBuA7He
WgZWdgBxC4j1VpWxxq4E4lzry/QS6Ek4G7OwuWC1s976XlwxyyHOsr7shN3zfRhjAOdyfCf0nBZw
xVSB+NxO6nzeRpnfmXDjPz9CfkupyGtjzxtcMUeVE1WsLzXy4qDXW3uI9dzHcMWsD7GwFC6wyhzc
KIcv/TWhyXFWTaznA4krpgrECU9LoaFlbuXQHuLOMzGumNOXE3JQiiEuNhS0UhPjipn9PDTG+jJd
yLZpIMymO4ErZgWIXcS+8qRjILTKHNOdSPA6poDpvE+MKyYjdozYLWbEjiiA2DF3otXRAGJFiJ2a
D6TDFROIm0HsdHwg/6liccUE4hYQo6ytDMQAAcRADGpADMQoAzEQAzEQAwQQAzGBKyaZGGUyMRAD
MRADBBADMcpADMQoAzEQAzEQK542i96Vf7179/bVq5vd7qcXL16vVlfr9fV2+/vLl+8fe1QGYl2I
LXpX3u/3bzab4LR1T97dZXfKQKwIscX1Fz4pDq4h8t/pShmItSC2uBLOZ0rhkuRY1myv7HDFVFrt
bNG70lersXt98O7/9DC9ch7EuGK6HN8Ji96V/nkrxxwifOtvrFwN4nm7YpZBbNG78ma3y0Lteju9
cnY5sUxXzDKILXpXHnpe8s/VenrlOhALS2G7rpjBS2VwPy16V57DtBmwrpxeuRrEs3fFDBZFBfmy
c+/K5WZiXDFn4125iJrY4YpZ2p0w4V05/+7EYHngcMWMd3NNeFfOvE9MMGJnfsSOKIDYMXeilTIQ
K0LsbHpX+qwZ6yf47bcX3SkDsS7EzqZ3ZWzWb7BanVwZiNUhRllbGYgBAoiBGNSAGIhRBmIgBmIg
BgggBmICV0wyMcpkYiAGYiAGCCAGYpSBGIhRBmIgBmIgVjxtFl0xbfltArEuxBZdMc35bQKxIsQW
V3ZYXDMCxFoQW1xjZ3H13pQQJ5bRj/EjlK9Jli+lTo98zsYV06Lf5vQQDzpt1tqxIKyJi8eNNk+x
6Ipp0W+zX4jT5lcnv1XCg+LkayMhzvKdsOiKadFvs4tyIm2NVWCGqWRjJbR4+ycsumJa9Nu0BHG6
dB4DscQWqABii66YFv02jUGc8N4sgNhF3LdUM3HnrpgW/TbnUE6MgVheTgiNuyX1Zc+umBb9Nntp
sel5adaqiQsgtuiKadFv0xLE8rt/9T5xGcQWXTEt+m0yYseIHSN2xNDBZe7EcTB3wiTEzqYrpjm/
TSDWhdjZdMW05bcJxOoQo6ytDMQAAcRADGpADMQoAzEQAzEQAwQQAzGBKyaZGGUyMRADMRADBBAD
McpADMQoAzEQAzEQK542XDGP491f7169fbW72b346cXq9Wp9td5eb1/+/vLxPa6YvUKMK+Zx7O/3
mzeb4Hx4z/TlHa6Y/UHMyo7j8Ol2cHGS/w4QdwQxa+xOcrBwrXMsH/cCcZYTZtlexUyD5Aubs9wv
Ha6YAmVfB8eqiGBd8fD00DXEcifMWhCXGa8E4ZZDjCvmcfgnuVWO8USwqDAAcbEl5omU0CNCG2Jc
MY9jd7MLwBqzYXu92l5vu4bY5VtXZVliakCcvjxwxRxUPnTT5BCvr9Zzg1hOoRM7/2lDjCvmvzYG
8U3aYs4QYqElpgbEZVaFuGKSicfe+gcPQRbEBe/swBVz5jWx07TEFHKm/boDXDHn3J0o+IMbssRM
dydiqbRln3jhrpiz6hMzYseInfkRu0VB7Jg78e9g7oRJiB2umGf5ONyp+FhFXNziitklxA5XzLP6
ODifOFgHA3EvEKOsrQzEAAHEQAxqQAzEKAMxEAMxEAMEEAMxgSsmmRhlMjEQAzEQAwQQAzHKQAzE
KAMxEAMxECueNg0fSG3l2BuY3z/2qAzEuhAr+UCqKt/v9282m+C0dU/e3WV3ykCsCLHeWgY9ZZ8U
B9cQ+e90pQzEWhDrrSrTU/aZUrgkOZY12yvXh3hwhLD4OaDAnyq9V7FdTayXlu+Y3vpePWVfrcbu
9cG7/9PD9Mr1IRY68ahCLNyrhPeKxGZl8EfrOS3oKfvnrRzh8K2/sXJliGMpLTiHI2gTkciXTmaS
6Wq4YlaBWM/zRk/5ZrfLQu16O71yI4gTAEkcfQq+WQzx4F/lEOu5j+kpH3pe8s/Venrl6SHW2DjG
ULAixHo+kHrK5zBtBoSnV24KscSRUmh9mf5mJxCTieeWiXMdKcd8c4wrZkWIqYlN1sQFqa5ZTSy/
S9SCmO6Eye5Eom8wbXciyxWTPvHS+8SM2DFiN4cROyA+DuZOtFEGYkWInZoPpKqyz5qxfoLffnvR
nTIQ60LsdHwgtZVjs36D1erkykCsDjHK2spADBBADMSgBsRAjDIQAzEQAzFAADEQE7hikolRJhMD
MRADMUAAMRCjDMRAjDIQAzEQA7HiaYu9J/nDh0eUqygDsS7EH99Yv4m/sf4S5fHKQKwIsU8wwRN2
/PHfQXmkMhBrQeyzzuA5O3xiGQhlkxALhxlz72JyV8ws/8zEj/aV3/F988cfV19+ufrss+fPN9+s
fv759E76998PKBcodwpx2aNuFVfMLP/M9Eb/7HJ8Yj7//Pkg//DD6vvvn//wxRei2yjKc4M45jUR
dKUY1K/Ia3Cjf/oO3it//fX5V/j009Pt/gkd5QJlSxAnTNkS35wQ4kP/6OTzyy+rr7563ufvvjv9
p7dv1ygXKFutiRPMyY24CyDOqomDiefrr59/qW+/DT/QoFygbCATx/iWFBvTQhzMPZ988ryHv/0W
OGcjs9pilS1BXPYcJq+2ByEWPjgOVoGxz/j6cpnKJiGW22OmZXNf5JG7zyfP44fPIeRNfpTnWU4U
MJfliil09cztjKZP25ie68KVGbFjxI4RO2Lo4DLDoY0yECtC7P5v3taL+LytC5THKwOxLsQuPoM2
WPmhDMQ9Qoxym4d+IAYIIAZilIEYiFEGYiAGYgIggHjJEBO4YpKJUSYTAzEQAzFAADEQowzEQIwy
EAMxEAOx4mmz6F0ZewPz+8celYFYF2KL3pX3+/2bzcYTdv7x5N1ddqcMxIoQW1wl4ZNiELLjj/9O
V8pArAWxxfVqPlMOcnb4xLJme+XWEGeZXlbcK1wxJcq+Wo3d64N3/6eH6ZWngViOaa29whVTqOyf
t4ScJW79jZX7gvjcoirxV3dmvpab3bUhtugwebPbZaF2vZ1euSOI0/TILTGdgitmGcQWHSYPPS/5
52o9vXJHNXEZxLmFR5mhYPCyGTy4Fh0mz2Ha/Pt8nX9hcuXpM3Ea7vNSIZZ9nbIr5rmDVlm+7Nxh
kkw8FmLhrb9Myo12xaxVE/fsMElNXA3ikeVEdVfMKt0JEw6TdCfGDm7F7CjT3QlJOTHSFbNKn9iE
wyR9YkbsGLFbxojdoiB2zJ1opQzEihA7m96VPmvG+gl+++1Fd8pArAuxs+ldGZv1G6xWJ1cGYnWI
UW7UFYBFgABiIEYZiIEYZSAGYiAmAAKIFwwxgSsmmRhlMjEQAzEQAwQQAzHKQAzEKAMxEAMxECue
NouumHrK7/569+rtq93N7sVPL1avV+ur9fZ6+/L3l4/vccXsFWKLrph6yvv7/ebNJjgf3jN9eYcr
Zn8QW1zZoafs0+3g4iT/HSDuCGKLa+z0lH0OFq51juXjTiGWO2QGf5m0McXgIcAVs5myr4NjVUSw
rnh4MrLaOcshU0hz+peM/ThcMbWV/ZPcKsd4IlhUWIL4H8OomAna8ReO3aXSXmlVIJZnYouumHrK
u5tdANaYDdvr1fZ6axLiYNaMWbOd/2GQuZEQ55YTFl0x9ZQP3TQ5xOurtQ2IYzVxgVumxCEzkfgH
r4oCVziLrph6ymF8k7aYJrsTcpO1KhC7iNfl+caK/sSdu2LqKc82E2cZbmtALESzrlN8z66YespL
qYkbQ4wrZkvl2XYnqtTEwXqgwz6xCVdMPeXZ9okZsWPEbg4jdvOG2DF34t/B3AmTEDubrph6yj4f
hzsVH6uIi1tcMbuE2Nl0xdRTjs0nDtbBQNwLxChrKwMxQAAxEIMaEAMxykAMxEAMxAABxEBM4IpJ
JkaZTAzEQAzEAAHEQIwyEAMxykAMxEAMxIqnDVfM44i92/n9I66YvUKMK+Zx3O/3bzab4IR4z/Td
Ja6Y/UHMyo7j8Ol2cHWS/w4QdwQxa+xOcrBwsXMsH/cOcZk9ZoF+xY3pg4sr5kkdHKsignXF04O1
1c7j7THl+gUWE7hijlf2T3I5thPhosIqxDFXiliyHLwGRkIsz8S4Yh7HzW6XBfH1dmsb4sEMKrTH
rAsxrphjlA/dNPnnar02BrHLsQIqu+OnvzYojivmSOVzTDcDppg2XTFVy9aREBfUxLhiLisTZzkL
FkPc2FAQV8xF18RjIE6/8aAlxLhiLqs7kegTZ3lmxroTsSUuuGI2U55/n7hNr4MRO0bsegdXdcCv
+LJh7sRxMHfCau7HFfMkH8c6FX777QWumL0WMLhintTHwfnEwToYiM1X4SgDMRADMQFqQAzEKAMx
EKMMxEAMxITw4BK4YpKJUSYTAzEQAzFAADEQowzEQIwyEAMxEAOx4mnDFfM4Yu92fnyPK2avEOOK
eRz7+/3mzSY4H94zfXmHK2Z/ELOy4zh8uh1cnOS/A8QdQcwau5McLFzrHMvHKhBPu7IttjNlG53M
xE2+ZB9XzJM6OFZFBOuKh6cmq521rSyLd6bMREJo4oYrZpmyf5Jb5RhPBIuKphBnOUicOJ0Fv5DO
oLEdK7AMTN9tslI4rpjHsbvZBWCN2bC9Xm2vtxNAXJYUB70uc93W3Ag7n0ETN1wxi5UP3TQ5xOur
Vl5sSlaW8i8IL6FJIMYV818bg/gmbTEn6E5UdAHsCuLicgJXTAOZWM/KshjiYt9LiazwyhmsL5fp
immjJp4c4jG+lxoQ44ppoDvhcqwsXaa/ZQyyhHPrSN/L6hDjimmgT0wwYjeHETti8OAyd+I4mDth
EmKHK+ZZPg53Kj5WERe3uGJ2CbHDFfOsPg7OJw7WwUDcC8QoaysDMUAAMRCDGhADMcpADMRADMQA
AcRATOCKSSZGmUwMxEAMxAABxECMMhADMcpADMRADMSKpw1XTG1lINaFGFfMBspArAgxKzvaKAOx
FsSssWujPBnEwrHEWs8KIz0z07uKK+aEypNBnOuoOXL3RlphFFheOFwxWyn3BXHaD9NN55k5eBxx
xZxQuReIYwB15ZmZuxFXzDbK3dXEwQTsZP5Awl+1oMYYVMYVc0LlXroTMbPrLIiznhQbQIwrZhvl
7h7siiGe0DPT4Yo5qXKP3YnxnQQNz0xhnZ14Hl+4K6aeco994jKIj/EN8jrGM3NwhQyumBMqM2LH
iB0jdsTQwWWGQxtlIFaE2OGK2UQZiHUhdrhi6isDsTrEKGsrAzFAADEQgxoQAzHKQAzEQAzEAAHE
QEzgikkmRplMDMRADMQAAcRAjDIQAzHKQAzEQAzEiqct9jbjx/f9elfa2mcg1oV4f7/fvNnE3it/
edejd6W5fQZiRYh96gqicPzx3ylQ1lslYXGfgVgLYp/PBmk4fGK5rf16NYv77KZasi+0TquIVGIV
tHyjfLWzryljd+TgPfrhaXqHSYv7PA3EuZaYFS+b2M/V8J3wT0VCGhI36MYOkxb3uSOIg/M8EmZt
CexiPim1DC6EB9c/1wdO/CFCQPhnf6GynsOkxX3uAuLYvw4a/AwawsrvAJIfmmuyfehMyYFYX03v
MGlxn3usiYtNsHPdMiv6xoY3BlE4jjMmhMp6DpMW97mL7oSkDNWA2EWcrxJ2WFkbG2e1Kg6TFve5
rwe7kTVrLd/iWhvb15fjHSYt7vNMIHbK1q5l5USzJ/2KDpMW97mjmjirO1EFYqf89qRmPdeKDpMW
93k+I3adON0zYudwxbRIsGPuRAf7zNwJ3avI57bwU//HO/LFbY/eleb2GYjVbwWxubnBmjJLWc+7
0tY+A3G/9QzKQAzEQEyAGhADMcpADMQoAzEQAzEhPLgErphkYpTJxEAMxEAMEEAMxCgDMRCjDMRA
DMRArHjaLHpX2lIGYl2ILXpXmlMGYkWILa6/sKgMxFoQW1wJZ1F5MojTtoLV92fkwuaC1c4WvSst
KvcCccxVTe9nOX3fCYvelRaVO4X43FQqbYx5/E032rAwvVGeiS16V1pUnrgmHvShEhpjxv61LsS5
5YRF70qLyl1ALPRmHXnHT3+t4LIZPLgWvSstKhuAOOht1R7igprYonclmbg+xBU5c80NBS16V1IT
1+mwZt3Q5TWx/AcpdSdMeFfSnagPcbDnkCgJEu/sCC5xadknNuFdSZ+49/EzRuwYsesdXL0X4425
bJg70UaZuRO6ud+id6U5ZSBWL2AselfaUgbifqtwlIEYiIGYADUgBmKUgRiIUQZiIAZiQnhwCVwx
ycQok4mBGIiBGCCAGIhRBmIgRhmIgRiIgVjxtOm5YqIMxC0g1nPFRBmIW0Cst7IDZSBuAbHeGjuU
u4NY4pA5fg8Tq6DLNqYPrp4rJsq9Q6zkkBnk8vzPJlwxUTYGsdAqM50sg7m8Iq+NXTFR7rQmljtk
trexKoNYzxUT5a4hzk3JaSKFEMe8YmNeRMKDq+eKibJ5iF3EeXtw1mnswc6J7bBcH66YKM8B4nQZ
UNZlrL5RzxUT5X77xKrGla65taueKybK5iEua+VO3ieu6IqJMiN2jNgxYkfkHFxmOLRRBmJFiJ2m
KybKQNwIYqfpiokyEDeCGGVtZSAGCCAGYlADYiBGGYiBGIiBGCCAGIgJXDEJokYe4UAQQEwQQEwQ
QEwAMUEAMUEAMUGMgpggTMf/AqOY+ncirIJEAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-11-05 13:22:16 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAAC1CAMAAAC6VA/0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-05-08 10:08:36 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-05-08 10:08:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-08 10:08:31 +0100" MODIFIED_BY="[Empty name]">Literature search by authors for the previous version of this review</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-08 10:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>The following searches were conducted by the review authors:<I>
<BR/>
</I>
</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to September 2004), PREMEDLINE, and Dissertation Abstracts were searched.</LI>
</UL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;31 reports of 19 studies were included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;37 reports of 23 studies were included in the qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;65 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;197 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;197 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;197 records identified through searching the Specialised Register&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;132 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;28 reports of 27 studies (full-text articles) excluded, with reasons given in the &lt;a link_type=&quot;SECTION&quot; href=&quot;CHARACTERISTICS_OF_EXCLUDED_STUDIES&quot; protected=&quot;true&quot;&gt;Characteristics of excluded studies&lt;/a&gt; table&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>